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Thesis summary 
 
Pre-mRNA (precursor messenger RNA) splicing is a fundamental process in eukaryotic gene expres-
sion. In order to catalyse the excision of the intervening intronic sequence between two exons, the 
spliceosome is assembled stepwise on the pre-mRNA substrate. This ribonucleoprotein machine is 
extremely dynamic: both its activation and the progression through the catalytic stages require ex-
tensive compositional and structural remodelling.  
The first part of this thesis aims at understanding how the spliceosome is activated after assembly. 
When this work was started, the GTPase Snu114 was thought to activate the helicase Brr2 to un-
wind the U4/U6 snRNA duplex, which ultimately leads to the formation of the spliceosome active 
site. To explore the role of Snu114, a complex built from Snu114 and a part of Prp8 was expressed 
and analysed in its natural context, bound to U5 snRNA. However, before I was able to obtain highly 
diffracting crystals, the structure of Snu114 was determined in the context of a larger spliceosomal 
complex by electron cryo-microscopy by competitors. Regardless, the role of Snu114 in spliceo-
some activation remains elusive. In a short section of this thesis, genetic and biochemical analysis 
suggest Snu114 to be a pseudo-GTPase, precluding a role for Snu114-catalyzed GTP hydrolysis in 
activation.  
The second and larger part of the thesis describes the development of a novel, biochemical method 
to analyse spliceosome remodelling events that are caused by the eight spliceosomal helicases. 
Purified spliceosomes assembled on a defined RNA substrate are analysed by UV crosslinking and 
next-generation sequencing, which allows for the determination of the RNA helicase binding profile 
at nucleotide resolution. In vitro spliceosome iCLIP (individual-nucleotide resolution UV crosslinking 
and immunoprecipitation) was initially developed targeting the helicase Prp16 bound to spliceoso-
mal complex C. The obtained binding profile shows that Prp16 contacts the intron, about 15 nucle-
otides downstream of the branch in the intron-lariat intermediate. Our finding supports the model 
of Prp16 acting at a distance to remodel the RNA and protein interactions in the catalytic core and 
thereby it promotes the transition towards a conformation of the spliceosome competent for sec-
ond step catalysis. Control experiments, which locate SmB protein binding to known Sm sites in the 
spliceosomal snRNAs, validated the method. Preliminary results show that in vitro spliceosome 
iCLIP can be adapted to analyse additional spliceosomal helicases such as Prp22. Finally, I performed 
initial experiments that give promising directions towards time-resolved translocation profiles of 
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1.1 Introducing the spliceosome, a dynamic RNP enzyme 
Pre-mRNA splicing is a crucial step in eukaryotic gene expression. Most eukaryotic genes are tran-
scribed as precursors that contain intronic sequences (introns) interrupting the coding regions (ex-
ons) in a mosaic structure. In higher eukaryotes, pre-mRNA splicing enables cell-type specific ex-
pression of many proteins and enhances proteomic diversity via alternative splicing (Roberts and 
Smith 2002; Hallegger, Llorian, and Smith 2010). In addition to expanding the proteome from single 
genes, splicing has been reported to be crucial for: efficient transcription (Furger et al. 2002), mRNA 
export (Valencia, Dias, and Reed 2008), RNA localisation (Le Hir et al. 2001), transcript stability and 
efficient translation (Moore and Proudfoot 2009). Furthermore, the excised introns are involved in 
the biogenesis of noncoding RNAs (Pawlicki and Steitz 2010). 
 
 
Figure 1-1:  Two step splicing mechanism and consensus sequences. (A) Introns are excised in two consecutive 
transesterification reactions. Step 1 or branching generates the intron lariat-intermediate and a free 5’ exon. 
Step 2 or exon ligation results in the joined exons and the excised intron lariat. The nucleophilic attacks are 
indicated with red arrows. (B) Consensus sequences of the three reactive groups in Saccharomyces cerevisiae 
(S. cerevisiae) (top) and human (bottom). The 5’SS is located at the 5’-end of the intron and the 3’SS at the 3’-
end of the intron, while the branch point sequence (BPS) is found 18-40 nucleotides upstream of the 3’SS (Reed 
1989; Spingola et al. 1999; Sheth et al. 2006). Strictly conserved residues are coloured in red, including the brA 
within the BPS. N represents any nucleotide, R any purine, and Y any pyrimidine. Most human introns contain 
a stretch of 15 – 20 pyrimidines (polypyrimidine tract).  
 
An intron that separates two exons is excised from the pre-mRNA by two consecutive SN2-type 
trans-esterification reactions (Figure 1-1 A) (Sharp 1987). In the first reaction, named branching, 
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the oxygen that forms the 2’-hydroxyl group of a conserved adenosine (branchpoint adenosine, or 
brA) serves as a nucleophile to attack the phosphate at the 5’ splice site (5’SS). A branched intron-
lariat intermediate is formed, while the 5’-exon leaves with a free 3’-hydroxyl group. In the second 
reaction, named exon ligation, this newly generated hydroxyl group conducts a subsequent nucle-
ophilic attack to form a bond with the phosphate at the 3’ splice site (3’SS). The spliced RNA is 
formed, and the branched intron-lariat remains as the leaving group. All three reacting nucleotides 
are located in conserved regions of the intron. The human sequences are less conserved compared 
to yeast (Figure 1-1 B). 
 
Although the splicing mechanism is rather simple from the chemical point of view, a plethora (~150) 
of proteins and several RNA components are required to interact in a highly ordered manner with 
the substrate pre-mRNA to perform the reactions in living cells (Zhou, Licklider, et al. 2002). The 
formed multi-megadalton ribonucleoprotein (RNP) machinery, called the spliceosome, is built from 
highly conserved components across eukaryotes (Wahl, Will, and Luhrmann 2009).  
Most of our current knowledge about the spliceosome’s composition and the splicing mechanism 
is derived from studies in budding yeast Saccharomyces cerevisiae (S. cerevisiae) or human HeLa 
cell. Since the work in this thesis was exclusively performed with yeast components, the following 
introduction focuses on the yeast spliceosome.  
 
Pre-mRNA splicing happens co-transcriptionally in the nucleus (Wallace and Beggs 2017). The 
spliceosome forms de novo on each pre-mRNA substrate by sequential joining of the so-called U 
snRNPs (small nuclear RNP), which are the main building blocks of the spliceosome (Lerner and 
Steitz 1979; Bindereif and Green 1987; Tardiff and Rosbash 2006). Each U snRNP consist of a unique 
small nuclear RNA (snRNA) bound by Sm or LSm proteins and several specific proteins. Transacting 
factors are recruited to remodel the spliceosome, which leads to activation (1) and to the catalytic 
stages during which the two splicing reactions occur (2). After release of the ligated exons, the 
spliceosome is disassembled (3) and remaining building blocks can be recycled for a new round of 
splicing  (Wahl, Will, and Luhrmann 2009) (Figure 1-2).  
 
(1) First, the U1 snRNP assembles onto the pre-mRNA substrate as the 5’ region of U1 snRNA 
forms specific contacts by base pairing to the 5’SS (Bindereif and Green 1987; Siliciano and 
Guthrie 1988), while the branch point binding protein (BBP) recognises the branch point 
sequence (BPS). Prp5-mediated remodelling subsequently replaces the BBP with U2 snRNP 
whose RNA component forms base pairs with the BPS (Perriman and Ares 2010). This step 
requires additional remodelling by Sub2 (Fleckner et al. 1997). Overall, the association of 
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U1 and U2 snRNP with the pre-mRNA substrate leads to the formation of the pre-spliceo-
somal complex A. Next, U4/U6.U5 tri-snRNP, in which U4 and U6 snRNA are extensively 
base-paired, is recruited as a pre-assembled complex to form the complex pre-B (Bai et al. 
2018). 5’SS transfer from U1 snRNA to U6 snRNA is mediated by Prp28 (Staley and Guthrie 
1999), generating the pre-catalytic complex B (Plaschka, Lin, and Nagai 2017). Spliceosome 
activation happens through the release of U4 snRNP and U6 proteins, which allows the 
spliceosomal RNA components to fold into the catalytic core (Madhani and Guthrie 1992; 
Newman and Norman 1992; Sun and Manley 1995). This rearrangement comes along with 
the association of the nineteen and nineteen related complexes (NTC, NTR) (Chan et al. 
2003) and is initiated by Brr2, which unwinds the U4/U6 snRNA duplex (Raghunathan and 
Guthrie 1998; Laggerbauer, Achsel, and Luhrmann 1998). For the purpose of this thesis, 
spliceosome activation will be defined as the transition between complex B and complex 
Bact (Yan et al. 2016a). The time point when U1 snRNP is completely released from the 
spliceosome is unclear and might happen during activation or earlier (compare dashed out-
line in Figure 1-2). The literature has suggested a role for Snu114 in the activation step, 
which will be discussed in detail in the introductory section 1.2.  
(2) To allow the first step of splicing, Prp2 initiates a remodelling event that brings the 5’SS and 
the brA into close proximity (Warkocki et al. 2009). Binding sites for the branching factors 
Cwc25 and Yju2 are generated, while SF3a/b complexes that are part of U2 snRNP are re-
leased (Chiu et al. 2009; Schneider et al. 2015). After the reaction, spliceosomal complex C 
is formed, harbouring the cleaved 5’-exon and the intron-lariat-3’-exon intermediate (Wan 
et al. 2016; Galej et al. 2016). Prp16 joins the complex, promotes release of the branching 
factors and binding of the exon ligation factors Slu7 and Prp18, which in turn leads to dock-
ing of the 3’SS into the active site of the spliceosome (complex C* (Yan et al. 2016b; Fica et 
al. 2017)).  
(3) After the second step of splicing, yielding complex P (Bai et al. 2017; Liu et al. 2017; 
Wilkinson et al. 2017), Prp22 mediates the release of the ligated exons. Subsequently, the 
intron-lariat-spliceosome (ILS) (Wan et al. 2017) is disassembled into free U2, U5, and U6 
snRNPs by Prp43 and Brr2 and the excised intron-lariat is released (Makarov et al. 2002). 
This allows the snRNPs to assemble anew on another pre-mRNA substrate.  
 
During the past three years, an increased knowledge about the spliceosome’s architecture and 
structure was achieved by electron cryo-microscopy (cryoEM). Both catalytic reactions were con-
firmed to be catalysed by the same active site formed of RNA (Fica et al. 2013; Fica et al. 2014). We 
can learn a lot from the snapshots of the spliceosome taken during assembly, activation, catalysis 
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and disassembly, however, due to the dynamic nature of the spliceosomes, most processes which 
happen between the stable intermediates remain poorly characterised. Only recently, the dynamics 
of the spliceosome became a focus for single molecule studies (DeHaven, Norden, and Hoskins 
2016; Hoskins et al. 2016; Semlow et al. 2016; Larson and Hoskins 2017; van der Feltz and Hoskins 
2017; van der Feltz, DeHaven, and Hoskins 2018). 
Most of the remodelling steps between spliceosome intermediates require energy, which is utilised 
through hydrolysis of nucleoside triphosphate (NTP). The next paragraphs will focus on the remod-
elling steps and the enzymes that initiate the rearrangements. 
 
 
Figure 1-2: The general mechanism of pre-mRNA splicing by the spliceosome. Schematic presentation of the 
spliceosome intermediates which are formed during the reaction; adapted from (Wilkinson et al. 2018). Con-
tours are based on available cryoEM structures. The pre-mRNA is depicted as: exon 1 – white box; intron – 
black line; exon 2 – black box. See text for description of the different stages and abbreviations. Snu114 is not 
indicated in the figure but discussed in the text.  
 
1.2 Snu114 – the only spliceosomal GTPase 
Snu114 stands out among all the proteins required for splicing as the only GTPase. Snu114 is an 
integral part of U5 snRNP and interacts with the U5 snRNA internal loop 1 (Dix et al. 1998). The 
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protein joins the spliceosome as part of tri-snRNP and stays associated with U5 snRNP throughout 
the splicing cycle.  
Snu114 is homologous (26% identity, 46% similarity (Fabrizio et al. 1997; Brenner and Guthrie 2005)) 
to elongation factor EF-2 (EF-G in bacteria), a GTPase that catalyses the rearrangement of the ribo-
some after peptide-bond formation (Tourigny et al. 2013). A fold resembling that of EF-2 was also 
observed for Snu114 in the early spliceosomal structures solved by cryoEM (Nguyen et al. 2015). 
Snu114 possesses five GTPase motifs in domain I (Figure 1-3 A). The G’’-domain is an insertion 
unique to Snu114 and EF-2 GTPases. In contrast to most GTPases, both Snu114 (Fabrizio et al. 1997) 
and EF-2 possess a histidine instead of the usual catalytic glutamine in switch II. In contrast to EF-2, 
Snu114 has an extended N-terminus. Normally, GTPases are assisted by GTPase activating proteins 
(GAP); interaction with these factors enables the placement of a water molecule into the active 
loop in switch II, close to the gamma-phosphate of the guanosine triphosphate (GTP) molecule to 
facilitate catalysis (Vetter and Wittinghofer 2001; Wittinghofer and Vetter 2011). After GTP hydrol-
ysis, the GDP is generally exchanged for GTP by another protein called GTP exchange factor (GEF). 
The GAP of EF-2 is thought to be the rotated-state of the ribosome but it appears to have no GEF 
(Lin et al. 2015). Neither GEF nor GAP are known for Snu114.  
 
 
Figure 1-3: The protein Snu114 and its suggested role in spliceosome activation. (A) Snu114 has five common 
domains with EF-2 in addition to its unique N-terminus. Five GTPase motifs locate to the G-domain and are 
conserved between Snu114 and EF-2. The domain organisation for S. cerevisiae Snu114 was adopted from 
(Brenner and Guthrie 2005) and overlaid to the protein sequence of human EF-2 as in (Fabrizio et al. 1997). (B) 
Topology diagram of a general G-domain showing the location of the five GTPase motifs. The so-called ‘switch-
regions’ are indicated in purple and blue. α-helices are depicted in red and β-strands in green (Wittinghofer 
and Vetter 2011). (C) Snu114 was supposed to give the initial signal for Brr2-mediated unwinding during 
spliceosome activation. Unwinding of the U4/U6 snRNA duplex leads to the release of U4 snRNP and the U6 
proteins, while it allows U6 snRNA to leave its inhibited position and participate in the formation of the active 
site. The rearrangement also involves the association of the NTC/NTR proteins.  
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Indeed, Snu114 was found to be essential for splicing. Deletion of the Snu114-specific N-terminal 
domain causes a temperature sensitive phenotype in yeast and accumulation of stalled spliceo-
somes (Bartels et al. 2002). A similar effect was seen for mutants with an altered GTP-binding site 
(Bartels et al. 2003). Snu114 was proposed to play a role in spliceosome activation as the combina-
tion of mutations in the N-terminus and in Prp8 or Brr2 lead to a lethal phenotype (Brenner and 
Guthrie 2005). In a proposed model, Snu114 GTPase transfers an activation signal via Prp8 to the 
helicase Brr2 (Bartels et al. 2002). As described above, Brr2 catalyses the unwinding of the U4/U6 
duplex to allow formation of the catalytic centre during the complex B to Bact transition (Brr2 hel-
icase function is described in detail in 1.3.3). Prp8, likewise an integral part of U5 snRNP, is the 
largest spliceosomal protein forming the active site cavity and indeed contacts Snu114 (Grainger et 
al. 2009; Galej et al. 2013; Nguyen et al. 2015). On the other hand, Prp8 interacts with Brr2 and its 
C-terminus was shown to have an inhibitory function for Brr2 unwinding (Mozaffari-Jovin et al. 
2013).  
The many similarities between Snu114 and EF-2 led to the speculation of Snu114 acting as the ac-
tivating GTPase in splicing, for which the correctly assembled complex B could serve as a GAP in a 
similar way as the rotated state of the ribosome activates EF-2 for GTP hydrolysis. 
Two independent studies tried to understand the role of Snu114 in a more mechanistic way. In the 
first one, Snu114 was claimed to activate Brr2 helicase activity through GTP hydrolysis (Bartels et 
al. 2002; Bartels et al. 2003) acting like its homologue EF-2. The second study, however, showed 
that nucleotide binding and not hydrolysis is the activating signal for Brr2, which implies Snu114 to 
be similar to a small switch-like GTPase (Small et al. 2006). A third hypothesis is drawn from struc-
tural analysis of Snu114-containing spliceosomal complexes, and ascribes a solely structural role for 
the GTP molecule during splicing (Nguyen et al. 2016). 
Whatever the role of Snu114 in spliceosome activation, the way in which the major rearrangement 
between complex B and Bact is initiated and accomplished on a mechanistic level remains elusive.  
 
1.3 Remodelling of spliceosomal complexes by RNA helicases drives the 
splicing reaction 
This introductory section will focus on the spliceosomal helicases, which have multiple roles during 
the splicing process. The first paragraph (1.3.1) will give a general overview about the function and 
architecture of nucleic acid helicases, before each spliceosomal helicase is discussed in more detail 
(1.3.2, 1.3.3, 1.3.4). In general, the directionality of the splicing reaction is coupled to the sequential 
action of the eight spliceosomal helicases. The last paragraph (1.3.5) will discuss splicing fidelity 
which is enhanced by the proofreading activity of spliceosomal helicases preventing the progres-
sion of splicing for defective pre-mRNA substrates.   
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1.3.1 Helicases are involved in all aspects of nucleic acid biology 
Nucleic acid helicases are a group of enzymes that are involved in all areas of nucleic acid metabo-
lism. Their activity is essential for DNA replication, recombination and repair as well as for transcrip-
tion, pre-mRNA splicing, RNA degradation, ribosome biogenesis and translation (Wu and Spies 
2013).  
Helicases use the energy derived from NTP hydrolysis for various functions. In the classical view, 
the enzyme couples NTP hydrolysis to separate double stranded nucleic acids into single strands, 
meaning it unwinds a helix (Pyle 2008). Others translocate along single or double stranded nucleic 
acid, often referred to as ‘translocases’ (Fischer and Lohman 2004). NTP-hydrolysis-coupled trans-
location often coincides with removal of proteins bound to the target strand (‘RNPase activity’) 
(Jankowsky et al. 2001). Some helicases are understood to be NTP-dependent switches, which nei-
ther unwind a helix nor move directionally, but couple NTP-hydrolysis to a conformational change 
to induce downstream effects (Singleton, Dillingham, and Wigley 2007).  
Some helicases have a preference for their target, which can be DNA, RNA or even hybrid duplexes, 
while others can act on any nucleic acid (Pang et al. 2002). The helicase core is generally sequence 
unspecific, however helicases exist that recognise their substrate through additional domains in a 
sequence specific manner.  
 
Helicases are defined by their conserved nucleotide hydrolysis core engine, which is composed of 
short amino acid patterns, so-called helicase motifs (Caruthers and McKay 2002). Based on the con-
servation and organisation of their motifs, helicases are grouped into families. Enzymes of the SF1 
and SF2 superfamilies are usually monomeric and comprise at least seven conserved motifs (ex-
plained in Figure 1-4 for SF2), whereas members of the SF3, SF4, and SF5 superfamilies assemble 
into ring-shaped hexamers (Singleton, Dillingham, and Wigley 2007). 
Here we focus on the SF2 family, to which all spliceosomal helicases belong. These monomeric hel-
icases arrange into helicase domain 1 and 2 (HD1 and HD2), both of which resemble a RecA-like 
fold, and are connected by a linker region (Figure 1-4 A) (Fairman-Williams, Guenther, and 
Jankowsky 2010).  
Motif I and II have similarity to the Walker A and B motifs in other ATPases and are sandwiched 
between the two domains (Figure 1-4 B). Motif I (Walker A) with the consensus sequence AxxGxGKT 
forms a phosphate binding loop. The residues ‘GKT’ interact with Mg2+ and the phosphate region 
of the nucleotide; the glycine in the triad is required to keep the loop flexible (Walker et al. 1982). 
Motif II (Walker B), reading DExx, is directly involved in NTP hydrolysis. While the aspartic acid co-
ordinates Mg2+, the glutamic acid activates the attacking water molecule. Motif VI is involved in 
nucleotide binding and hydrolysis, too (Hall and Matson 1999). Motif Q can provide specificity for 
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adenosine triphosphate (ATP) by coordinating the adenine base but is not present in all SF2-type 
helicases (Tanner 2003). Motifs Q, I, II, III, Va and VI compose the nucleotide binding pocket located 
on both helicase domains. Domain closure is induced upon nucleotide binding (Figure 1-4 C). Motifs 
Ia, Ib, IV, IVa, and V contact the phosphodiester backbone of the nucleic acid target (Singleton and 




Figure 1-4: The SF2 helicase family. (A) Domain organization of the SF2-type helicase core shows the consensus 
sequence found in helicase motifs. Letters in brackets represent highly but not completely conserved residues. 
The length of and the distance between the blocks are not depicted to scale. Motifs Q to III are located in 
helicase domain 1, whereas motifs IV to VI are found in helicase domain 2. Motif IVa is not highly conserved in 
SF2-type helicases but frequently marked as QxxR. Both C- and N-terminal domains vary between members 
(Fairman-Williams, Guenther, and Jankowsky 2010). (B) Schematic view giving the rough location of the hel-
icase motifs. Both the bound ATP (dark red) and the nucleic acid (NA, black) are indicated. (A) and (B) show the 
helicase motifs coloured according to their function. Red: ATP binding and hydrolysis. Blue: Coordination be-
tween nucleotide binding and interaction with the nucleic acid. Cyan: nucleic acid binding. (C) Upon ATP bind-
ing, the helicase domains come into proximity. ATP hydrolysis, generating ADP (adenosine diphosphate) and 
Pi, causes the helicase domains to swing apart (ATP, ADP and Pi are schematically depicted). 
 
Helicases are often part of large molecular complexes, such as in pre-mRNA splicing where the eight 
RNA helicases act within the spliceosome. The energy that is required for pre-mRNA splicing is uti-
lised by the spliceosomal helicases to drive the conformational and compositional remodelling of 
the RNP machinery during the splicing process. RNA duplex unwinding and protein-replacement 
have been reported as two required helicase functions for splicing (Staley and Guthrie 1998), while 
translocation on RNA targets and molecular switches were suggested as well. All spliceosomal hel-
icases belong to one of the following sub-classes of SF-2 type helicases:  
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DEAD-box, Ski2-like, and DEAH-box. Except for the Ski2-like helicase Brr2, which is an integral part 
of U5 snRNP (Lauber et al. 1996), spliceosomal helicases interact only transiently with the spliceo-
some.  
 
1.3.2 DEAD-box helicases are involved in spliceosome assembly 
DEAD-box helicases derived their name from the single letter code of the four amino acids in mo-
tif II. Not all helicases in that family, such as the spliceosomal helicase Sub2, however, read this 
pattern as D-E-A-D (Zhang and Green 2001). The DEAD-box helicase family is defined by a total of 
13 characteristic and conserved sequence motifs, including all helicase motifs of the SF2 superfam-
ily (Linder 2006). Three of the additional motifs are involved in NTP binding and two in the coordi-
nation between NTP binding and interaction with the target RNA (Figure 1-5 A). DEAD-box helicases 
make up the largest proportion of the SF2 family and are exclusively RNA helicases. Having the 
Q-motif (Figure 1-4 A and Figure 1-5 B), DEAD-box helicases specifically utilise ATP, while most have 
an enhanced ATPase activity upon RNA binding (Kim et al. 1992; Jacewicz et al. 2014).  
Although DEAD-box helicases have been shown to separate RNA duplexes in vitro and in vivo, they 
are rather inefficient unwinders (Gilman, Tijerina, and Russell 2017). Instead of translocating on one 
of the nucleic acid strands for duplex unwinding, DEAD-box helicases directly load onto helical re-
gions and then locally force the strands to open (Cordin et al. 2006). In addition, structured regions 
of single-stranded RNA can similarly be destabilised upon simultaneous ATP and target RNA bind-
ing. Subsequent ATP hydrolysis releases the enzyme from the RNA (Gilman, Tijerina, and Russell 
2017). Some DEAD-box helicases have shown to possess RNA annealing activity (Yang and 
Jankowsky 2005).  
 
Sub2, Prp5 and Prp28, which are the three spliceosomal DEAD-box helicases, share high conversa-
tion in their core domains but vary in their C- and N-terminal extensions (Figure 1-5 A (Cordin and 
Beggs 2013)). All three are essential for the assembly phase, indicating they are needed for correct 
splice site recognition (Figure 1-5 B). Most functions for the helicases were deduced by comparing 
mutants or the absence of the protein to an intact wild-type (WT) system.  
In spliceosomal complex E, U1 is the first snRNP to be bound to the pre-mRNA substrate at the 5’SS, 
while the branchpoint binding protein (BBP) binds to the branch site to bridge the brA and 5′SS by 
interacting with U1 snRNP specific proteins (Berglund et al. 1997). The BBP itself is thought to recruit 
the DEAD-box helicase Sub2, whose activity is essential for U2 snRNP to recognise the branch se-
quence by remodelling the U2 snRNA (Fleckner et al. 1997). Prp5 functions as well in the formation 
of the pre-spliceosomal complex A and is involved in proofreading the branch site sequence (Liang 
and Cheng 2015). Its direct RNA target was proposed to be U2 snRNA (O'Day, Dalbadie-McFarland, 
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and Abelson 1996). Following Prp5 function, U2 snRNP replaces the BBP. Prp5 has long been 
thought to be an integral part of the spliceosome as it was found during most of the splicing cycle 
(Kosowski et al. 2009). Later, however, it was shown that tri-snRNP association is blocked until the 
release of Prp5 (Liang and Cheng 2015) showing that Prp5 is a transient factor. Just after tri-snRNP 
has joined the spliceosome, the role of Prp28 is to act in the complex pre-B, where it mediates the 
transfer of 5’SS pairing with U1 to U6 snRNA (Staley and Guthrie 1999), tethering the 5’SS to U6 
snRNA for later transfer into the active site of the spliceosome.  
 
 
Figure 1-5: Spliceosomal DEAD-box helicases and their role in spliceosome assembly. (A) Sequence alignment of 
S. cerevisiae spliceosomal DEAD-box helicases adapted from (Cordin and Beggs 2013). Nine of the thirteen 
conserved sequence motifs are depicted. The helicase motifs are coloured according to their function. Red: 
ATP binding and hydrolysis. Blue: Coordination between nucleotide binding and interaction with the RNA. 
Cyan: RNA binding. (B) After formation of the spliceosomal complex E, Prp5 mediates a remodelling event 
which replaces the BBP with U2 snRNP whose RNA component forms base pairs with the BPS. This step requires 
additional remodelling by Sub2. Prp28 is required for the 5’SS transfer from U1 to U6 snRNA to promote the 
complex pre-B to B transition.  
 
The function of DEAD-box helicases is essential for normal growth of S. cerevisiae. Knocking out 
some of the spliceosomal components, which are normally destabilised by the acting helicase and 
which are thought to stabilise certain RNA structures, however, could bypass the function of the 
corresponding helicase (Kistler and Guthrie 2001). Therefore, a rather passive role was ascribed to 
spliceosomal DEAD-box helicases (Cordin and Beggs 2013) in agreement with an ATP-induced mo-
lecular switch without active RNPase or unwinding activity.  
How the three helicases act in molecular detail on their target RNA, and how their activity is regu-
lated in the context of the spliceosome remain unclear.  
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1.3.3 The Ski2-like helicase Brr2 is essential for spliceosome activation 
The helicase Brr2 belongs to the Ski2-like ATPase subfamily of SF2 helicases. Ski2-like helicases uti-
lise exclusively ATP for their function, determined by their possession of the Q-motif. Between hel-
icase motif V and VI, Ski2-like helicases contain a characteristic β-hairpin (Jankowsky 2011). Studies 
on Ski2-like family members found a correlation with the 3’ to 5’ unwinding polarity and suggested 
a function for the hairpin in duplex separation (Buttner, Nehring, and Hopfner 2007). Brr2 is an 
unusual Ski2-like helicase in possessing two helicase modules of which only the N-terminal module 
is active (Figure 1-6 A); it was shown to interact with RNA in vivo without the C-terminal part of the 
protein and has both ATPase and unwinding activity (Kim and Rossi 1999).  
 
 
Figure 1-6: The Ski2-like spliceosomal helicase Brr2 and its role in spliceosome activation. (A) Sequence align-
ment of the two helicase cassettes of S. cerevisiae Brr2 adapted from (Cordin and Beggs 2013) showing the 
rough location of the helicase motifs. The motifs are coloured according to their function. Red: ATP binding 
and hydrolysis. Blue: Coordination between nucleotide binding and interaction with the RNA. Cyan: RNA bind-
ing. The triangle between domain V and VI indicates the β-hairpin characteristic for Ski2-like helicases. The C-
terminal Sec63 domain is connected through a winged helix (WH) domain and consists of the following subdo-
mains: a ratchet domain, a short α-helical domain (α) and a fibronectin-like domain (Fn-like). (B) After for-
mation of the pre-catalytic complex B, spliceosome activation happens through the release of U4 snRNP and 
U6 proteins, which allows the spliceosomal RNA components to fold into the catalytic core (Madhani and 
Guthrie 1992; Newman and Norman 1992; Sun and Manley 1995). This rearrangement comes along with the 
association of the nineteen and nineteen related complexes (NTC, NTR) (Chan et al. 2003) and is initiated by 
the helicase Brr2, which unwinds the U4/U6 snRNA duplex (Raghunathan and Guthrie 1998; Laggerbauer, 
Achsel, and Luhrmann 1998). The time point when U1 snRNP is completely released from the spliceosome is 
unclear and might happen during activation or earlier (compare dashed outline).  
 
Brr2 is the only spliceosomal helicase that is an integral part of the spliceosome, belonging to the 
U5 snRNP specific proteins. It is already pre-loaded on U4 snRNA in the context of tri-snRNP when 
it gets recruited to the spliceosome (Nguyen et al. 2016). In complex B, Brr2 still locates to the same 
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position where it is bound by complex B specific proteins (Plaschka, Lin, and Nagai 2017), ready to 
unwind the U4/U6 snRNA duplex in a 3’ to 5’ direction (Laggerbauer, Achsel, and Luhrmann 1998; 
Raghunathan and Guthrie 1998; Santos et al. 2012) to dissociate U4/U6 snRNP proteins and the U4 
snRNA (Figure 1-6 B). The liberated U6 snRNA, can refold leading to base pairing with U2 snRNA 
and the formation of the active site of the spliceosome. So far, the mechanism of Brr2-mediated 
unwinding has mainly been studied in minimal systems using purified material but lacking the nat-
ural context of a complete spliceosome (Mozaffari-Jovin et al. 2012).  
 
The architecture of spliceosomal complex Bact locates Brr2 at the periphery of the complex (Yan et 
al. 2016a). Brr2 has changed location in complex C (Galej et al. 2016), while its location could not 
be determined in the structures of some spliceosomal complexes (Yan et al. 2015; Fica et al. 2017). 
This raises the question, how stable Brr2 is integrated into the spliceosome.  
In yeast two hybrid experiments, Brr2 helicase was shown to interact with the DEAH-box helicases 
Prp2 and Prp16 (van Nues and Beggs 2001; Chen et al. 2013), and this interaction could be verified 
for Prp16 shown in the cryoEM structure of complex C (Galej et al. 2016) (spliceosomal DEAH-box 
helicases are discussed in 1.3.4). Questions such as the following remain open: Does Brr2 have a 
function after spliceosome activation, when it interacts with other helicases or is the helicase stored 
there for later activity? One study, for example, found Brr2 to be involved in in the rearrangement 
of the spliceosome towards a second step conformation (Hahn et al. 2012) in line with the Brr2-
Prp16 interaction. In addition to its genuine role in unwinding the U4/U6 snRNA duplex during ac-
tivation, Brr2 was proposed to be involved in disassembly of the ILS together with the DEAH-box 
helicase Prp43 (Small et al. 2006; Fourmann et al. 2013).  
 
1.3.4 DEAH-box helicases remodel the spliceosome during catalysis and disassembly 
Helicases of the DEAH-box family fold into a structure similar to that of the DEAD-box helicases. 
Their barely conserved N-terminal domain is thought to be involved in target recognition and re-
cruitment (Fairman-Williams, Guenther, and Jankowsky 2010). The C-terminus is well conserved and 
consists of structured domains (Figure 1-7 A), which stabilise the helicase core (He, Andersen, and 
Nielsen 2010). In contrast to DEAD- and Ski2-like helicases, the Q-motif coordinating the adenine 
nucleobase is absent in DEAH-box helicases, making them unspecific for the energy-delivering NTP 
(Tanaka and Schwer 2005). Similar to Brr2, DEAH-box helicases translocate along the RNA strand in 
order to unwind duplex regions with a preferred 3’ to 5’ directionality. In vitro experiments have 
shown that DEAH-box helicases cannot load onto structured RNA regions directly, but require a 
single stranded overhang for initial binding (Tanaka and Schwer 2005). In addition, opening of the 
two helicase domains was shown to be required for proper loading.  
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It is thought that a pair of extended β-hairpin motifs, unique to DEAH-box helicases, trap a stretch 
of the RNA between each other and operate the translocation by incorporating an additional base 
on the 5’-end while excluding one on the 3‘-end (He et al. 2017). During this directional transloca-
tion, the complementary strand is displaced (Pyle 2008).  
 
 
Figure 1-7: Spliceosomal DEAH-box helicases and their role during the catalytic stages and disassembly. (A) Se-
quence alignment of S. cerevisiae Prp2, Prp16, Prp22, and Prp43 adapted from (Cordin and Beggs 2013) show-
ing the rough location of the helicase motifs. The motifs are coloured according to their function. Red: NTP 
binding and hydrolysis. Blue: Coordination between nucleotide binding and interaction with the RNA. Cyan: 
RNA binding. The triangle between domain V and VI indicates the 5’-β-hairpin insertions, while the 3’-β-hairpin 
was proposed to be motif Ib (He et al. 2017). The C-terminal domain is composed of a winged-helix (WH), a 
ratchet domain, and an OB-like fold. (B) Schematic view for DEAH-box helicase action during splicing. Prp2 
initiates a remodelling event that brings the 5’SS and the brA into proximity to allow the first step of splicing. 
Binding sites for the branching factors Cwc25 and Yju2 are generated, while SF3a/b complexes, which are part 
of U2 snRNP, are released. After the reaction spliceosomal complex C is formed, containing the cleaved 5’-
exon and the intron-lariat-3’-exon intermediate. Prp16 joins the complex, promoting release of the branching 
factors and binding of the exon ligation factors Slu7 and Prp18, which in turn leads to docking of the 3’SS into 
the active site of the spliceosome (complex C*). After the second step of splicing, yielding complex P, Prp22 
mediates the release of the ligated exons. Subsequently, the intron-lariat-spliceosome (ILS) is disassembled 
into free U2, U5, and U6 snRNPs by Prp43 (and Brr2) for recycling, while the excised intron-lariat is released. 
Helicases are depicted at the position where they are proposed to have their main function. Neither the stage 
when they join nor when they leave the complex is indicated.   
 
Four DEAH-box helicases are involved in pre-mRNA splicing: Prp2, Prp16, Prp22, and Prp43 (Figure 
1-7). The helicase Prp2 is involved in remodelling the spliceosome prior to the first catalytic step 
(Kim and Lin 1996). It acts on spliceosomal complex Bact and promotes juxta positioning of the 5’SS 
and the branch point adenosine for the branching reaction (Warkocki et al. 2009). In addition, Prp2’s 
action is also needed to promote binding of the branching factors Yju2 and Cwc25 (Chiu et al. 2009; 
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Krishnan et al. 2013). The CryoEM structure of complex Bact shows that the branch helix is held by 
the SF3b complex (Yan et al. 2016a). If Prp2 translocates from its binding position downstream of 
the branch helix towards the brA on the intron, the SF3a and SF3b complex (part of U2 snRNP) 
would likely dissociate, which in turn would allow the branch helix to move into the active site of 
the spliceosome (Lardelli et al. 2010). Unfortunately, the resolution around Prp2 was not high 
enough in the complex Bact reconstruction to model the complete RNA path of the intron (Yan et al. 
2016a).  
After branching, the helicase Prp16 is required to reposition the substrate in a way that allows the 
3’SS to reach the active site. In addition, Prp16 remodelling also causes branching factors to be 
released. At the same time, binding sites for exon ligation factors Slu7 and Prp18 are generated 
which allows the complete transition towards catalytically active complex C* (Ohrt et al. 2013).  
After Prp16 is released from the spliceosome, the helicase Prp22 binds at a similar location on the 
particle (Galej et al. 2016; Fica et al. 2017). The exons will be ligated during the second catalytic step 
and Prp22 is the helicase required to release the spliced RNA from the spliceosome (Company, 
Arenas, and Abelson 1991). In parallel, exon ligation factors are released. Prp22 was demonstrated 
to unwind duplex RNA in vitro (Schwer and Gross 1998). The helicase was proposed to open con-
tacts between the spliced RNA formed with spliceosomal proteins and U5 snRNA by translocating 
along the second exon in a 3′ to 5′ direction, and thereby releasing the ligated exons from the 
spliceosome (Schwer 2008). In additional studies, Prp22 was found to bind on the intron close to 
the 3’SS before exon ligation (McPheeters, Schwer, and Muhlenkamp 2000).  
These two binding locations for Prp22 imply repositioning of the helicase on the RNA substrate, 
however, the mechanism remains elusive.  
Prp43 plays a major role in disassembly of the resulting intron-lariat spliceosome (ILS) (Mayas et al. 
2010). As described above, Brr2 was found to be involved in the disassembly process, too (Small et 
al. 2006). Despite both Prp43 and Brr2 being extensive targets for structural analysis (He et al. 2017; 
Tauchert et al. 2017), their precise RNA target and their function in the context of spliceosome 
disassembly, however, remain quite unknown (Fourmann et al. 2013). Prp43, for example, was pro-
posed to disrupt base pairing between U2 snRNP and the branch sequence, which would lead to 
the release of the three snRNPs and the excised intron-lariat (Fourmann et al. 2016), but the hel-
icase was also suggested to act on U6 snRNA to disrupt protein-RNA and RNA-RNA interactions 
(Wan et al. 2017). 
 
Taken together, the biochemical properties of the helicases and most in vitro experiments propose 
a model in which DEAH-box helicases actively unwind RNA duplexes. However, RNA-RNA interac-
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tions targeted by spliceosomal helicases are buried within the large body of the spliceosome, mak-
ing them inaccessible for the transiently, surface bound helicases. Recent experiments with both 
Prp16 and Prp22 suggest a novel and exciting model, in which the DEAH-box helicase acts from a 
distance and induces an unwinding effect without actively translocating through the structured 
RNA parts (Semlow et al. 2016). One of the key observations was that the substitution of RNA by 
DNA nucleotides, which are located close to the remodelled regions but apart from the initial hel-
icase loading region, did not interfere with helicase activity, despite spliceosomal DEAH-box hel-
icase activity is only stimulated by RNA not DNA (Schwer and Guthrie 1991; Semlow et al. 2016). 
The result led to the hypothesis that as soon as the helicase is physically stopped from translocating 
by an obstacle like the spliceosome body, the translocation movement is transferred into a pulling 
action, which disrupts RNA structures located in the usual translocation direction in a process which 
the authors named ‘winching’ (Semlow et al. 2016).  
This model remains to be tested to completely unravel the molecular mechanism of ‘winching’ 
within the spliceosome and to determine whether this model is universal for all spliceosomal DEAH-
box helicases as well as DEAH-box helicases involved in other biological systems.  
 
1.3.5 Spliceosomal DEAD/H-box helicases have proofreading activity to increase 
splicing fidelity 
In general, the directionality of the splicing reaction is coupled to the sequential action of these 
eight spliceosomal helicases. However, promotion of the splicing reaction is not always favourable. 
Errors in spliced products, which can potentially lead to dysfunctional or toxic protein products, 
have to be prevented. To ensure error-free splicing, the spliceosome needs to master the challenge 
of recognising the minimal sequence elements at the 5’SS, BPS, and 3’SS with high accuracy. Both 
steps of the splicing reaction are reversible themselves, offering the potential to reject suboptimal 
pre-mRNA substrates from completing splicing and potentially allow subsequent recognition 
rounds for sequence elements that had difficulties pairing appropriately with the RNA components 
of the spliceosome (Tseng and Cheng 2008). 
Another mechanism to increase splicing fidelity is mediated during the splicing process by the 
DEAD/H-box helicases, which were proposed to promote the backwards reaction in case a subop-
timal splice site was recognised. Several of the spliceosomal DEAD/H-box helicases have been re-
ported to possess this proofreading activity.  
A first indication for proofreading arose from genetic studies, in which a mutation in Prp16 allowed 
splicing of pre-mRNA substrates carrying branch point mutations and this implied that Prp16 is ad-
ditionally involved in the discard of abnormal splicing products (Burgess and Guthrie 1993). As dis-
cussed above, Prp16’s helicase activity normally promotes the rearrangement towards the second 
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step conformation, which is essential for exon ligation of optimal pre-mRNA substrates (Schwer and 
Guthrie 1992a). Thus, Prp16 was implicated in proofreading the branching step by promoting a 
faster splicing process for optimal substrates, while rejecting suboptimal substrates from exon liga-
tion; both of which in an ATP-dependent manner (Koodathingal et al. 2010). Subsequent to the 
rejection by Prp16, the spliceosome might be disassembled by Prp43 in a discard pathway, which 
was deduced from an increased frequency of splicing errors in the absence of Prp43 (Mayas et al. 
2010). In another study, Prp16 was proposed to shift the equilibrium between competing spliceo-
somal conformations towards optimal and away from suboptimal substrates (Query and Konarska 
2004).  
Taken together, two proofreading models were proposed: (1) A kinetic mechanism – The fidelity of 
the splicing process is enhanced by the Prp16 NTPase activity that acts similar to a timer. Hydrolysis 
promotes either the productive (exon-ligation) pathway for correct substrates or the discard path-
way for suboptimal substrates (Semlow and Staley 2012). (2) A thermodynamic mechanism – Splic-
ing fidelity is enhanced through the stability of competing spliceosome conformations (Semlow and 
Staley 2012). 
 
In a similar fashion, Prp5, Prp28, Prp2, and Prp22 have been proposed to increase splicing fidelity 
through proofreading. The DEAD-box helicase Prp5 was indicated in branch site selection, meaning 
proofreading of the interaction between U2 snRNA and the BPS of the pre-mRNA substrate during 
spliceosome assembly (Xu and Query 2007). In this study, proofreading activity was determined to 
be proportional to the ATPase activity of the helicase, supporting the kinetic model. However an 
alternative ATP-independent role for Prp5 was proposed independently by (Liang and Cheng 2015). 
The DEAD-box helicase Prp28 was proposed to proofread selection of the 5’SS on the basis of a 
genetic screen. Proofreading was shown to be dependent on the 5'SS:U6 snRNA duplex stability 
(Yang et al. 2013). 
The DEAH-box helicase Prp2 was found to proofread the catalytic RNA core of the spliceosome 
(Wlodaver and Staley 2014). By destabilising the RNA active site, Prp2 might promote proper repo-
sitioning of the branch helix.  
The DEAH-box helicase Prp22 is proposed to proofread 3’SS selection prior to exon ligation (Schwer 
and Gross 1998; Mayas, Maita, and Staley 2006) and to lead suboptimal substrates towards the 
Prp43-mediated discard pathway (Semlow et al. 2016).  
In summary, all the above-mentioned studies propose a proofreading mechanism at various steps 
along the splicing pathway to increase fidelity. The precise mechanism in how each helicase recog-
nises suboptimal substrates and how the reaction is promoted backwards or into a discard pathway 
in the event of an abnormal substrate remains unknown.  
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Overall many open questions remain regarding the working mechanism of spliceosomal helicases, 
in particular: How and when is target recognition and loading onto the RNA initiated? How is the 
order of subsequently acting helicases maintained and regulated? Do auxiliary factors exist, which 
regulate the helicase activity? Which parts of the remodelling events are actively promoted by 
spliceosomal helicases and which are simply a consequence of loosened RNA or RNA-protein inter-
actions? 
 
1.4 Stalling the splicing reaction at specific stages is an indispensable tool 
for spliceosome research  
To study spliceosome biology, no complete in vitro system is available, however, spliceosomes can 
be assembled on synthetic pre-mRNA from yeast whole cell extract in vitro (Lin et al. 1985; Newman 
et al. 1985). With this system in hand and the possibility to stall the splicing reaction at various 
steps, step specific spliceosomes could be generated. This was essential to gain many of the bio-
chemical and structural insights into the spliceosome and builds the foundation for studying the 
mechanism of spliceosomal helicases in their natural context.  
 
There are different ways to interfere with the splicing reaction in order to obtain a stall. First, the 
general concept is listed, before some examples are explained in detail. 
(1)  The pre-mRNA substrate can be modified in a way to inhibit one of the catalytic steps 
(Newman et al. 1985; Vijayraghavan et al. 1986; Moore and Sharp 1992).  
(2) DEAD/H-box helicase mutants that act in a dominant negative (DN) manner and therefore 
fail in promoting the transition towards the next spliceosomal conformation can be used to 
halt the reaction (Plumpton, McGarvey, and Beggs 1994; Schneider, Hotz, and Schwer 2002). 
When temperature sensitive-mutants exist, yeast cells can be grown under the permissive 
temperature as usual, while the in vitro splicing reaction will halt due to the defective hel-
icase when performed under the restrictive temperature (Schwer and Guthrie 1992b; Kim 
and Lin 1996). Removal of the helicase through e.g. antibody-assisted depletion or heat 
inactivation of temperature sensitive mutants has a similar effect.  
(3) ATP or Mg2+ which are essential for helicase activity, will halt the reaction when used in 
limiting amounts (Fabrizio et al. 2009).  
Finally, the blocked splicing reaction will lead to the accumulation of spliceosomes at the stages 
prior to the stall. Purification via step specific factors can separate those further. The following par-
agraph gives examples of stalling methods used at various points in the splicing process.   
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The activity of the helicase Prp28, for instance, is needed to remodel the spliceosomal complex 
pre-B into B. Based on the RNA composition, the two complexes are equal, both bind pre-mRNA, 
which excludes a stall at the complex pre-B stage via the splicing substrate. However, a dominant 
negative mutant of Prp28, in which the DEAD-motif is altered to AAAD leading to impaired ATP 
binding and hydrolysis, was reported to stall splicing at the complex pre-B stage (Boesler et al. 
2015). In general, a dominant negative helicase mutant is characterised by its ability to strongly 
associate with the spliceosome in a way that prohibits the WT protein from associating with the 
complex. To ensure normal growth, which includes functional splicing, yeast cells usually require 
the WT copy of the protein. Sometimes, the dominant negative helicase can be co-expressed, oth-
erwise it can be added to the splicing reaction from a recombinant source and will then block the 
function of the WT helicase.  
Limiting the ATP concentration can halt the reaction at the complex B stage by impeding Brr2 hel-
icase activity. A minimal but requisite amount of ATP will still allow assembly of the spliceosome, 
as long as the upstream acting DEAD-box helicases are not impaired by the low ATP level. This strat-
egy was used for instance to determine the cryoEM structure of the pre-catalytic complex B (Chan 
and Cheng 2005; Plaschka, Lin, and Nagai 2017).  
Stalling splicing with a temperature-sensitive mutant of Prp2 (PRP2-1) leads to accumulation of 
spliceosomal complex Bact. Temperature-sensitive mutant strains usually grow normally at the per-
missive temperatures but show a growth defect at higher temperature, indicating the mutated hel-
icase protein is less stable compared to the WT. This property can be used to deplete Prp2-1 from 
splicing extract. Heat inactivation leads to a defective protein and the helicase cannot associate 
with the spliceosome but spliceosomal complex Bact ΔPrp2 will assemble (Kim and Lin 1996). After 
the splicing reaction, a dominant negative version of the protein such as Prp2-S378L can be added 
(Plumpton, McGarvey, and Beggs 1994). The mutation in the SAT residues of motif III (altered to 
LAT) impairs coupling of NTP-hydrolysis to helicase activity, so that the splicing reaction cannot 
proceed further.  
Acting on spliceosomal complex C, the helicase Prp16 is involved directly after branching to remodel 
the spliceosome towards a conformation in which the 3’SS is placed into the active site for the 
second reaction. One way to stall splicing at the complex C stage utilises a dominant negative ver-
sion of Prp16 such as Prp16-G378A whose alteration of the GKT residues in motif I leads to an NTP 
binding or hydrolysis defect. Secondly, the RNA substrate can be modified to prohibit the second 
step of splicing. Substitution of the conserved AG at the 3’SS with e.g. AC impairs with the second 
catalytic reaction. Similarly, a pre-mRNA substrate that terminates just before the AG-dinucleotide 
will not proceed further than the complex C stage until an AG-3’-exon is supplied in trans (Bessonov 
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et al. 2008). Depletion of Prp16 from the splicing extract, by e.g. antibody binding and removal, will 
lead to ΔPrp16 spliceosomes that stall at the same stage (Semlow et al. 2016). 
Spliceosomal complex C* represents a stage before exon ligation but after Prp16 remodelling. 
Equally 3’SS alteration can lead to the C* conformation. For structure determination of the yeast 
complex, the ribose backbone of the conserved G at the 3’SS was modified to have a 2’-H group 
instead of the natural 2’-OH group. An additional incubation step with ATP stimulated the remod-
elling from the complex C towards the C* stage (Fica et al. 2017). 
Several dominant negative versions of the helicase Prp22 were discovered, which block mRNA re-
lease and thereby stall the splicing reaction at the complex P stage (Tanaka and Schwer 2005). Both 
Prp22-K512A and Prp22-S635A with an alteration in the GKT residues of motif I minimising ATP 
hydrolysis and in the SAT residues of motif III which uncouples ATPase from helicase activity, re-
spectively, were used to purify complex P for structural analysis (Liu et al. 2017; Wilkinson et al. 
2017). 
 
1.5 Questions to be addressed in this project 
As described above, the spliceosome is an extremely dynamic particle. Although major milestones 
were achieved in recent years determining both the composition and architecture of the spliceo-
some at various stages throughout the splicing process, much is still unknown about how transitions 
between the snapshots are enforced and regulated.  
This thesis aims at providing a platform to increase our molecular and mechanistic understanding 
of spliceosome remodelling in the future. For all experiments in this work, the model organism 
budding yeast (S. cerevisiae) was used.  
 
1.5.1 Structural and biochemical analysis of Snu114  
The first part of the thesis (chapter 2) was initiated to increase the understanding of the role of 
Snu114 GTPase in spliceosome activation and was aimed to answer the following questions: 
(1) What is the overall structure of Snu114 and does the structure imply a function similar to 
EF-2? 
(2) At which stage does Snu114 hydrolyse GTP during the splicing process, and how is GTP 
hydrolysis triggered?  
(3) How does Snu114 influence U4/U6 snRNA unwinding by Brr2? 
 
1.5.2 Analysis of RNA-helicase interactions during spliceosome remodelling 
The second part spanning three results chapters focuses on improving the understanding of spliceo-
somal remodelling event that are mediated by RNA helicases.  
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Along with an increased interest for structural studies on the spliceosome, stalling and purification 
approaches leading to compositionally (and structurally) defined complexes moved into the focus 
of spliceosome research. Simultaneously, next-generation sequencing (NGS) based approaches 
emerged that enable one to precisely localise an RNA binding protein (RBP) on its target RNA. Com-
bining both offers the opportunity to analyse helicases within a fully assembled RNP and will in turn 
greatly improve our understanding of their function. Recently, the ambition to address mechanistic 
questions with NGS approaches rose in the pre-mRNA splicing community (Burke et al. 2018; Chen 
et al. 2018; Briese et al. 2018), however, an in vitro system based on NGS and fully assembled 
spliceosomes will bridge the gap between structural snapshots and genome wide data of the splic-
ing mechanism.  
To address the following objectives, I have conducted experiments in both the laboratory of Dr 
Kiyoshi Nagai and Prof Jernej Ule in the MRC LMB and Francis Crick Institute, respectively: 
(1) Development of iCLIP (individual nucleotide resolution UV cross-linking and immunopre-
cipitation; UV: ultraviolet) for in vitro purified spliceosomes concentrating on Prp16 in 
spliceosomal complex C 
(2) Adaptation of the method to analyse additional spliceosomal helicases  
(3) Modification of the method towards the development of a time-resolved translocation pro-
file of a helicase during remodelling 
In the thesis, objective (1) is divided into a method development section, which shows the genera-
tion of binding profiles for Prp16 helicase and the control spliceosomal protein SmB (chapter 3), 
while data interpretation and fine-tuning of the method for Prp16 is discussed separately (chapter 
4). Objectives (2) and (3) give an indication towards the feasibility of investigating additional hel-
icases by in vitro spliceosome iCLIP and may ultimately lead to monitor remodelling over time 
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2 Snu114 is apparently a pseudo GTPase 
 
The present chapter aims at understanding the role of Snu114 GTPase in spliceosome activation. 
When the project was started, we knew about the significant sequence similarity between Snu114 
and EF-2 (EF-G in bacteria) (Fabrizio et al. 1997; Brenner and Guthrie 2005) and we thought that 
detailed structural information on Snu114 would greatly increase our mechanistic understanding 
of the GTPase in pre-mRNA splicing.  
Around the same time, the structure of tri-snRNP was determined to ~6 Å resolution revealing its 
overall architecture and also showing how the RNA and proteins of the U5 snRNP are organised 
within tri-snRNP (Figure 2-1 A, here shown in high resolution) (Nguyen et al. 2015). Snu114 interacts 
with the N-terminal domain of Prp8 (Prp8-N), which is in agreement with yeast two hybrid experi-
ments (Grainger et al. 2009) (Figure 2-1 B). The architecture of tri-snRNP further revealed that 
Snu114, the N-terminal domain of Prp8, and U5 snRNA form a discrete substructure within the U5 
snRNP (Figure 2-1 A). The structure of tri-snRNP itself, however, provided little insight into the func-
tion of Snu114 in spliceosome activation.  
 
Since determining high resolution cryoEM structures was considered as an enormous challenge 
during that time, I aimed to produce a complex built from Snu114, Prp8-N and U5 snRNA for high 
resolution structural analysis by crystallography in order to reveal a detailed picture of Snu114 in 
its natural context, bound to Prp8 and U5 snRNA. Determining the structure of the RNP built from 
Snu114, Prp8-N, and U5 snRNA in different nucleotide states, such as before and after GTP hydrol-
ysis, was of particular interest. These structures should have helped to understand the molecular 













Figure 2-1: Spatial organisation of the Snu114:Prp8-N:U5 snRNA substructure. (A) CryoEM structure giving the 
spatial location of Snu114 (red), the N-terminus of Prp8 (purple) and the 5’ stem loop of U5 snRNA (navy) in 
tri-snRNP as an overview (left) and enlarged (right) (Nguyen et al. 2015); the coordinates used to produce this 
figure derived from the later, higher resolution structure of (Nguyen et al. 2016). (B) Domain organisation of 
Prp8, Snu114 and U5 snRNA. The N-terminal part of Prp8 is composed of a proline rich region (PRR), a nuclear 
localisation sequence (NLS), and was predicted to have two structured domains. The three-dimensional struc-
ture of the larger part of Prp8, containing RT finger/palm, thumb, linker, endonuclease, RNaseH-like and 
Jab1/MPN domain, was determined before (Galej et al. 2013). The interaction site with Snu114 locates to the 
N-terminal domain residues 420-464 (indicated in red). Snu114 possesses five GTPase motifs in domain I. The 
G”-domain is an insertion unique to Snu114 and EF-2 GTPases. Domains II to V show sequence similarities to 
other GTPases. The extended N-terminus is unique to Snu114. Snu114 binds to the internal loop 1 (IL 1) 
whereas Prp8 makes contacts mainly with loop 1 of U5 snRNA (Dix et al. 1998). Grey parts of U5 snRNA were 
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2.1 A structural approach to understand the function of Snu114 
For the work described in subchapter 2.1, I collaborated with C. Oubridge. Experimental planning, 
conduction, and interpretation were therefore done in collaboration.  
 
2.1.1 Production of the protein complex between Snu114 and Prp8 N-terminal domain 
In a first step towards structural investigation, we established a recombinant expression system for 
the S. cerevisiae proteins Snu114 and Prp8-N. Domain organisation in Prp8-N formed the basis for 
initial construct design (Figure 2-1). The approximate boundary between domain I and II as de-
scribed in (Boon et al. 2006) was analysed by secondary structure prediction, and constructs coding 




Figure 2-2: Snu114:Prp8-N can be expressed and purified from yeast. (A) After calmodulin (lane 1) and nickel 
nitrilotriacetic acid (Ni-NTA) affinity purification (lane 2) affinity tags are removed by TEV-protease cleavage 
(lane 3). Snu114, Prp8-N and TEV protease migration locations are indicated on the SDS-PAGE (sodium dodecyl 
sulphate polyacrylamide gel electrophoresis). (B) Gel filtration of the Snu114:Prp8-N using a Superdex 200 
column yields a homogenous sample in the major peak. The constructs for this representative Snu114:Prp8-N 
purification are indicated with a * in Table 8-1.  
 
Initially, expression systems in both bacteria and yeast were planned. Despite the suitable length 
of constructs for Escherichia coli (E. coli) protein production and testing of various strains and con-
ditions, Prp8-N constructs could not be expressed, or the overall yield remained too low (Table 8-1 
lists the tested constructs). Recombinant expression of Prp8-N domain I also failed in BCY123 yeast 
cells (Table 8-1). Since the interaction between Snu114 and Prp8 was predicted to be strong (Bartels 
et al. 2002), co-expression of the two proteins was considered to increase solubility and stability, 
while preventing aggregation. Constructs of Prp8-N including the predicted binding site for Snu114 
(Grainger et al. 2009) were finally successfully co-expressed with Snu114 in yeast (Figure 2-2), using 
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the pRS42x co-expression system in which the coding sequence is under the GAL-GAP promoter 
(MultiSac system). Our constructs were designed for a two-step affinity purification via CBP- and 
polyhistidine-tags. After optimisation we obtained a clean and stochiometric complex of 
Snu114:Prp8-N (Figure 2-2, lanes 1 and 2) (7.3.1 Materials and methods, Appendix Table 8-1 for 
successful expression of different constructs). TEV (tobacco etch virus) protease cleavage (Polayes 
et al. 1998) efficiently removed the CBP-His-tag from the N-terminus of Prp8-N (Figure 2-2, lane 3). 
Subsequent gel filtration for additional purification, removal of the TEV-protease and released af-
finity tags shows that most of the protein complex elutes as one soluble population (Figure 2-2 B, 
main peak); only a small fraction eluted in the void volume where aggregations are found normally 
(Figure 2-2 B, peak at 7.5 mL). 
In total, an overall yield of about 0.15 mg protein complex per 1 L yeast culture could be produced 
from the yeast expression system, sufficient for reconstitution with U5 snRNA and subsequent crys-
tallisation trials. Co-expression of the two proteins, yielding to a stoichiometric complex, is benefi-
cial for subsequent reconstitution with U5 snRNA.  
 
2.1.2 RNA binding studies show that a complex can be formed from the recombinant 
protein dimer and in vitro transcribed RNA 
In the living cell, Prp8, Snu114 and several other proteins assemble with U5 snRNA to form the U5 
snRNP, a building block of the spliceosome (Nancollis et al. 2013). As described before, structure 
determination of Snu114 was attempted in a natural context, meaning bound to Prp8-N and U5 
snRNA, in order to learn most about its biological function. Snu114 binds to the internal loop 1 (IL 
1) whereas Prp8 makes contacts with loop 1 of U5 snRNA (Dix et al. 1998). 
For crystallographic sample preparation, a U5 snRNA fragment should be generated by in vitro tran-
scription. The shorter version of U5 snRNA, containing the binding sites for Snu114 and Prp8, was 
designed based on the architectural information from tri-snRNP with the intention to produce a 
distinct and compact particle suitable for crystallography. Thus, a truncated U5 snRNA, consisting 
of only an apical region of the 5’ stem-loop but lacking the Sm-binding site was constructed (Figure 
2-1 B and Figure 2-3 A for U5 snRNA A). 
In addition, the truncated U5 snRNA A was extended by the four-nucleotide motif CGCG or CATG 
on the 3’-end (Figure 2-3 A, U5 snRNA B and C) to allow helix formation by base-pairing of the 
overhang between two molecules and thus to lead to a two-fold symmetry of particles later in crys-
tallography. After in vitro transcription, the homogeneity of all three RNA constructs was analysed 
by denaturing polyacrylamide gel electrophoresis (PAGE) and mass spectrometry (Figure 2-3 B 
shows denaturing PAGE).  
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Reconstitution of the protein dimer with the RNA was achieved by mixing the protein in high salt 
and the RNA in low salt in such volumes as reached a final concentration of 0.2 M KCl. Electropho-
retic mobility shift assays (EMSA), in which the protein concentration was increased, were used to 
find the optimal protein:RNA ratio (Figure 2-3 C). In later reconstitutions, a ratio of 1.25:1 pro-
tein:RNA was used, which leads to nearly complete complex formation (Figure 2-3 C, lane 6).  
 
 
Figure 2-3: U5 snRNA forms a complex with Snu114:Prp8-N. (A) U5 snRNA constructs used in this study. U5 
snRNA A is formed of nucleotides 28-125 of U5 snRNA. U5 snRNA B is extended with the 4-nucleotide motif 
CGCG at the 3’-end. U5 snRNA C was similarly extended with the motif CATG (not depicted). (B) Migration 
profile of in vitro transcribed U5 snRNA A on a denaturing PAGE (polyacrylamide gel electrophoresis). (C) EMSA 
of U5 snRNA A with increasing protein concentration (Snu114-His8:Prp8_122-770). The numbers give the molar 
ratio of protein-dimer compared to 0.6 μM U5 snRNA (final concentration). 
 
Initially, concentrating the complex led to a loss of sample which could be improved by increasing 
the salt concentration while decreasing the volume. Homogeneity of the complete RNP was tested 
by MALS (multi-angle light scattering), a method that determines the molecular mass and hydrody-
namic radius. A homogenous behaviour of complexes formed from Snu114:Prp8-N with the differ-
ent U5 snRNA constructs (compare Figure 2-3 A) could be verified by MALS (data not shown).  
 
In summary, the protein-RNA complex could be reconstituted and produced in sufficient amounts 
for crystallisation trials. Consequently, crystal plates covering 1248 conditions for three different 
constructs (Snu114-His8:Prp8_122-770:U5 snRNA A, Snu114-His8:Prp8_1-770:U5 snRNA A, 
Snu114:Prp8_122-770: U5 snRNA A) were set up. Promising protein-RNA complex-containing crys-
tals were not found. However, the behaviour of the complex in different conditions reveals some 
trends. Most screens showed precipitate in about half of the wells, whereas the other half con-
tained clear droplets or droplets with phase separation indicating a suitable concentration of the 
target complex in general. Complexes reconstituted with U5 snRNA B or C could potentially crystal-
lise due to the forced pseudosymmetry but have not been tested to date.  
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The overall set up for producing the Snu114:Prp8-N:U5 snRNA RNP is quite versatile as the three 
complex components can easily be altered individually. Thus, in parallel to modifying the RNA con-
struct, we targeted the protein components for optimisation. Limited proteolysis performed on the 
reconstituted protein-RNA complex was used to identify disordered or unstructured regions in the 
protein components that could hinder crystal formation. Prp8-N was digested with trypsin, chymo-
trypsin or subtilisin into stable fragments. Trypsin, for instance, cuts Prp8-N at the positions 122 
and 318 (Figure 2-4 A). Glu-C and Asp-N did not generate distinct fragments.  
 
 
Figure 2-4: Prp8-N cannot be subdivided into two distinct domains. (A) SDS-PAGE after limited proteolysis with 
trypsin of protein and protein:RNA complexes. The used constructs are indicated in the figure. Major cleavage 
fragments are labelled indicating the aa position, which we interpreted as the cleavage site. (B) SDS-PAGE 
showing unsuccessful separation of cleaved fragments (lanes 2 and 3) after TEV protease cleavage of the pro-
tein:RNA complex. (C) Close-up view of the location of introduced TEV cleavage sites (labelled Leu318, Tyr328, 
Arg380) and the lasso region (all light cyan) in tri-snRNP (Nguyen et al. 2016). The lasso region was transferred 
from the S. pombe structure (Yan et al. 2015) by sequence alignment and locates to residues 413–474 in 
S. cerevisiae Prp8. Unmodeled parts in the lasso region are connected with a dashed line.  
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New constructs were designed based on masses of the proteolytic fragments, taking into account 
the amino acid preferences of the protease and ensuring the binding site of Snu114 on Prp8 (resi-
dues 420-464) was included. To ensure proper formation of the Snu114:Prp8-N dimer, a TEV-pro-
tease cleavage sites for trimming after expression were included instead of shortening the expres-
sion construct directly. For Snu114, a construct was designed placing a TEV-protease cleavage site 
near its N-terminus. Three constructs with TEV-protease cleavage sites at position 318, 328 and 380 
were designed for Prp8; all three sites locate to the predicted boundary between domain I and II. 
All constructs could be expressed; however, the protease sites at positions 328 and 380 in Prp8 
became accessible to TEV protease only after insertion of a spacer sequence upstream (Figure 
2-4 B, lane 3 for cleavage at position 328). Reconstitution with RNA was still successful after TEV 
protease cleavage. The N-terminal region of Prp8 to be cleaved by TEV protease includes the pol-
yhistidine-tag, hence the fragment should be separated from the protein dimer in a subsequent 
nickel nitrilotriacetic acid (Ni-NTA) affinity step. Despite incubation in chaotropic and denaturing 
conditions or high salt (high concentrations of KSCN, 2 M urea, 2 M KCl) prior to Ni-NTA affinity 
purification, the cleaved fragment stayed tightly bound to the rest of the complex (Figure 2-4 B, 
lanes 2 and 3). 
Thus, we interpreted that the tight binding of the cleaved fragment must have an important role in 
maintaining the Prp8 structure itself or the interactions with Snu114.  
 
2.1.3 Concluding remarks for the crystallisation attempts of Snu114:Prp8-N:U5 snRNA  
Before this project yielded any structural results, near atomic-resolution information on the 
Snu114:Prp8-N:U5 snRNA subcomplex became available in the context of the intron-lariat spliceo-
some, whose structure was obtained by cryoEM (Hang et al. 2015; Yan et al. 2015). It became clear 
why Snu114 and Prp8 could be only expressed together (Figure 2-2) and why the cleaved Prp8-N 
fragments were impossible to separate (Figure 2-4 B). An extended unstructured loop of Prp8, 
named lasso for the S. pombe protein equivalent (Yan et al. 2015), emerges from the body of the 
protein and wraps around Snu114 (Figure 2-4 C). The domain boundary proposed by (Boon et al. 
2006) indeed identifies unstructured protein, namely the lasso region. The flanking regions, 
however, do not organise into two distinct domains but form one rigid body. By lying on the 
surface of the protein it becomes clear that the introduced TEV-protease cleavage sites were 
accessible during limited proteolysis without dividing the protein into subdomains.   
At about the same time when the structure of intron-lariat spliceosome from Saccharomyces 
pombe was published, the resolution of tri-snRNP improved until molecular interactions within the 
relevant region of U5 snRNP could be observed (Nguyen et al. 2016). Based on the density in tri-
snRNP, the authors concluded that Snu114 binds a GTP molecule that is firmly coordinated by side 
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chains of the GTPase (Figure 2-5). The authors claimed that a different nucleotide state would not 
fit well into the conformation of the binding pocket, while also suggesting that Snu114 must rather 
accommodate a GTP than a GDP molecule in the intron-lariat spliceosome structure.  
 
 
Figure 2-5: Snu114 binds to GTP in tri-snRNP. Zoom into the GTP-binding pocket of Snu114. Snu114 is shown in 
red, Prp8 in purple and the GTP molecule in cyan. Residues which were described to coordinate the GTP 
(Nguyen et al. 2016) are labelled with their residue number and shown as sticks. His218 is indicated in the 
figure since the equivalent residue has catalytic activity in EF-2.  
 
Although both particles reveal the structure of the subcomplex formed by Snu114:Prp8-N and U5 
snRNA and although the nucleotide state of Snu114 GTPase is structurally determined in both static 
spliceosomal complexes, neither of them can explain the role of Snu114 for spliceosome activation. 
In addition, there is no indication if GTP is exchanged or hydrolysed to GDP at a different stage 
during pre-mRNA splicing.  
 
2.2 Snu114 binds GTP throughout the splicing cycle 
The lack of explanation for the role of Snu114 in activation inspired us to initiate genetic and bio-
chemical analysis of the GTPase. The following two open questions were aimed to be addressed: 
(1) Does Snu114 hydrolyse GTP during splicing and, if so, at which stage does this happen? (2) How 
does Snu114 influence U4/U6 snRNA unwinding by Brr2? 
As mentioned in the introductory subsection 1.2, two independent studies aimed at understanding 
the role of Snu114 through biochemical experiments (Bartels et al. 2003; Small et al. 2006). For their 
analysis, both studies made use of the mutant Snu114-D271N, in which the nucleotide binding spec-
ificity is altered for xanthine instead of guanine nucleotides. This modification is commonly used to 
conduct GTPase experiments in an orthogonal system. Working with xanthine triphosphate (XTP), 
which does not normally occur naturally, allows one to exclude effects derived from endogenous 
GTP in the system (Bishop et al. 2000).  
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(Bartels et al. 2002; Bartels et al. 2003) claim that Snu114 activates the helicase activity of Brr2, and 
this requires GTP hydrolysis. The experiments which led to their conclusion were set up with early 
spliceosomes, captured under limiting ATP concentrations which causes splicing to stall at the com-
plex B stage. After incubation with different nucleotides, the amount of released U4 snRNA was 
determined as a measure for spliceosome activation. The highest amount of U4 snRNA release 
could be obtained with a mixture of hydrolysable XTP/GTP and ATP. Non-hydrolysable XTP/GTP, 
however, did not promote U4 snRNA release. This finding would imply Snu114 to act in a similar 
way to large GTPases involved in translation which change their conformation upon GTP hydrolysis 
leading to a downstream effect. 
In a second study, contradictory results showed that binding of the nucleotide but not hydrolysis 
affects spliceosome activation (Small et al. 2006). In this study, tri-snRNP particles were purified by 
affinity capture via Prp28, and the RNA was extracted after incubation with different nucleotides.  
Activation was measured as the proportion of U4/U6 snRNA duplex versus free U4 and U6 snRNA 
on native PAGE. Similar results were obtained from experiments with a non-hydrolysable form of 
XTP/GTP. This finding proposes that Snu114 acts as a switch-like small GTPase, likely to be active in 
the GTP-bound form (Cherfils and Zeghouf 2013).  
A third hypothesis derives from the structural information on tri-snRNP. The GTP nucleotide could 
have solely a stabilising effect on the fold of Snu114 and might not be subjected to hydrolysis or 
exchange during splicing.  
 
2.2.1 Recombinant Snu114 binds GTP and has no intrinsic GTPase activity 
In order to determine the nucleotide state of isolated Snu114, the bound nucleotide can be ana-
lysed from recombinantly expressed Snu114:Prp8-N by HPLC (high-performance liquid chromatog-
raphy; for expression compare subchapter 2.1). The nucleotide bound in this particle might reflect 
the initial situation before activation, when Snu114 is bound in U5 snRNP but not assembled into a 
spliceosome yet.  
The nucleotides, which were released by heat denaturation from the protein dimer, clearly co-elute 
with a GTP but not GDP nucleotide standard (Figure 2-6, GTP navy, released nucleotide grey). Native 
mass spectrometry confirmed the finding, identifying all Snu114:Prp8-N particles are bound to a 
molecule with the mass of a GTP nucleotide (in collaboration with J. Gault). Since no GDP-bound 
form nor the apo-form of Snu114 was found, which should be present if Snu114 would be able to 
hydrolyse GTP by itself, these results suggest that Snu114 lacks an intrinsic GTPase activity. Of 
course, it remains possible that an additional factor or a different spliceosome conformation can 




Figure 2-6: Snu114:Prp8-N binds GTP and nucleotide binding is required for yeast viability. (A) Released nucleo-
tides from the dimer (Snu114:Prp8-N) coelute with the retention volume of GTP but not GDP standards in HPLC 
analysis. (B) Yeast viability assays. The Snu114-gene is replaced by a plasmid coding for Snu114 in the indicated 
form, grown at 30 °C on 5-FOA containing plates (7.1.5 Materials and methods). (C) Colonies were further 
grown on YEPD plates at the indicated temperature. (B) and (C) depict one out of three replicates. 
 
2.2.2 Mutations of Snu114’s catalytic residue have no effect on viability 
For this subsection, I repeated yeast viability assays with Snu114 mutants, harbouring an alteration 
in their GTP binding pocket, to draw directly comparisons under the same experimental conditions.  
The translation factor EF-2, homologous to Snu114, coordinates the water molecule for GTP hydrol-
ysis with a histidine residue and Snu114 also possesses a histidine at this position (Figure 2-5, 
His218). To analyse if the histidine has catalytic activity, meaning it can activate the water molecule 
necessary for hydrolysis, mutants with alterations at this position were compared in yeast viability 
assays. Altering His218 to an alanine or arginine, two amino acids that are not able to activate a 
water molecule, resulted in hardly any  growth defect, and  the mutants are barely temperature 
sensitive (Figure 2-6 B and C, this was also shown in (Nguyen et al. 2016)). In contrast, G145 which 
is located in the GTPase motif 1 and necessary to bind the nucleotide, is a lethal mutation when 
replaced by a long side chain such as arginine (Figure 2-6 B, and shown in (Fabrizio et al. 1997)).  
Taken together, this suggests that nucleotide binding by Snu114 is indeed essential for viability in-
cluding splicing, but hydrolysis might not be.  
 
In addition, Snu114-D271N (xanthine nucleotide-binding) was tested for viability. In my hands, the 
mutant did not show any growth defect at 30 °C but was mildly delayed at 14 °C  (Figure 2-6 C last 
panel; compare (Bartels et al. 2003) in which a slow growth defect is noticed). Assuming that Snu114 
requires a bound GTP for proper function in splicing, the normal phenotype of Snu114-D271N either 
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suggests that the level of endogenous XTP is high enough to saturate the minimally required 
amount of functional Snu114 molecules, or that the mutation itself is not completely specific and 
other nucleotides can replace the xanthine nucleotide in the binding pocket. 
 
2.2.3 Spliceosomal complexes solved by cryoEM show Snu114 bound to GTP 
Recently, structures of spliceosomal complexes which were captured at various states of splicing 
have been determined by cryoEM. Following Snu114, it joins the spliceosome bound in tri-snRNP 
to form complex pre-B (Bai et al. 2018), which transforms to the precatalytic complex B (Plaschka, 
Lin, and Nagai 2017) to then remodel to catalytically active complex Bact (Yan et al. 2016a) to accom-
plish the catalytic steps of splicing. In all these structures, the bound nucleotide of Snu114 is iden-
tified as GTP, casting another doubt for Snu114-mediated GTP hydrolysis in activation.  
Nevertheless, it remains elusive what happens between these structural snapshots. 
 
2.3 Spliceosome activation might happen independently of Snu114 
Taken together, all these findings support the model of a constantly bound GTP molecule by 
Snu114, precluding a role for Snu114-catalyzed GTP hydrolysis in activation.  
To prove the hypothesis and exclude the requirement of GTP hydrolysis during splicing, several 
experiments were planned, however, the project was discontinued in favour of in vitro spliceosome 
iCLIP (chapters 3, 4 and 5) before clear results were obtained. Some of the experimental ap-
proaches and their theoretical implications are discussed below: 
We planned to take advantage of the orthogonal system, modifying the nucleotide binding site of 
Snu114 to perform experiments with xanthine nucleotides (XNP). To ensure specific and exclusive 
XNP-binding of the mutant, the nucleotide state of Snu114-D271N:Prp8-N should be analysed and 
binding to XNP tested. I was able to express the protein dimer with a 2.5-fold lower yield than the 
WT protein, indicating a less stable protein complex. Unfortunately, HPLC analysis of released nu-
cleotides was not obviously interpretable. Binding of exogenous XTP to the complex could not be 
achieved either.  
With the system in hand, nucleotide effects on unwinding were to be tested on purified spliceoso-
mal complex B. In a first step towards this set up, Snu114-D271N-Strep was expressed from a low 
copy number plasmid in a strain expressing endogenous Brr2-proteinA for split tandem affinity pu-
rification. Incorporation for Snu114-D271N into Brr2 containing particles, however, is decreased 
resulting in a low yield. A yeast strain expressing Snu114-D271N endogenously might have offered 
an improvement.  
To go further and examine if GTP is hydrolysed during splicing, a pseudo-haploid yeast strain ex-
pressing both Snu114-WT and Snu114-D271N-tag was generated. The WT copy allows the cells to 
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grow normally. Snu114-D271N containing extract was reported to have a temperature-dependent 
splicing defect (Bartels et al. 2003). This system would allow to test the effect of different nucleo-
tides and to compare splicing efficiencies of the Snu114 WT and mutant proteins. After an in vitro 
splicing reaction, spliceosomes bound by the two different Snu114 copies can be separated by af-
finity capture to analyse their splicing phenotype on the basis of resulting RNA species. In addition, 
one should perform the experiment with suboptimal splicing substrates to investigate if Snu114 is 
required to maintain splicing fidelity.  
In addition, incorporation of exogenous GTP/XTP into spliceosomes could be tested to reveal if nu-
cleotide exchange happens during splicing (GDP release). Excluding GTP hydrolysis/exchange in all 
the listed experiments, would strongly lead to the conclusion that Snu114 is a pseudo GTPase. The 
bound GTP, which might be essential to maintain Snu114’s three-dimensional structure, might re-
main from a time when the common ancestor of Snu114 and its homologue EF-2 was an active 
GTPase. Snu114 might have become part of the spliceosome due to its three-dimensional structure 
and lost its redundant GTPase activity. 
At the end of this chapter, the question remains what the activating factor for Brr2 is, if Snu114 
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3 Establishing iCLIP for helicases in stalled and purified 
spliceosomes 
 
As described in 1.5 Questions to be addressed in this project, crosslinking and sequencing ap-
proaches are powerful techniques to identify the direct RNA targets of spliceosomal helicases. Even 
transient interactions with an RNA can be captured through the covalent tethering by UV crosslink-
ing. To obtain a mechanistic understanding of the spliceosomal helicases, a defined system is 
needed. Therefore, I developed an iCLIP (individual nucleotide resolution UV cross-linking and im-
munoprecipitation) technique suitable for purified and stalled spliceosomal complexes. This chap-
ter leads though the modifications and optimisations for in vitro spliceosomal iCLIP.  
iCLIP was established to determine the interaction of an RBP and its RNA targets at nucleotide res-
olution in a genome-wide manner (Konig et al. 2010; Huppertz et al. 2014). The pipeline established 
by the J. Ule laboratory is shown in Figure 3-1. Living cells or extracted tissue are irradiated with 
254 nm ultraviolet (UV) light to stimulate the intrinsic crosslinking activity of RNA resulting in cova-
lently connected RNA-RBP complexes. After cell lysis, a controlled RNA digestion is performed to 
obtain crosslinked RNA fragments of lengths compatible with next-generation sequencing (NGS). 
The RNA-RBP complex is captured by immunoprecipitation using a protein-specific antibody cou-
pled to beads while stringent washes remove non-covalent interactions. Depending on the RNase 
used, the 3’-end of the RNA may need to be dephosphorylated to allow ligation to a universal DNA 
adapter (IR-L3 adapter, compare Figure 3-1), which provides the annealing sequence for later re-
verse transcription. In addition, the adapter is conjugated to an infrared (IR) fluorophore facilitating 
visualisation of the RNA-RBP complex when blotted onto nitrocellulose membrane after separation 
by SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) (Zarnegar et al. 2016). 
With the correct RNase concentration, a smear starting strongly around the size of the protein fad-
ing towards higher molecular weight is produced. Too high RNase concentrations will lead to a dis-
tinct band around the size of the protein. On the other side, concentrations lower than the optimum 
will result in long RNA species which cannot enter the gel and result in a diffuse signal. When mul-
tiple RBPs bind the same RNA as the target protein, proper RNase digestion and size-selection by 
SDS-PAGE will help to separate these. The RNA-RBP complexes are subsequently extracted by pro-
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teinase K digestion leaving a peptide at the crosslinked site. Library preparation for sequencing be-
gins with reverse transcription (RT) using primers, which anneal to the IR-L3 adapter and contain 
the P3 Solexa sequence. In reverse order, a hexa-ethyleneglycol spacer separates the P5 Solexa 
sequence, and a unique identifier (barcode) at the 5’-end of the phosphorylated primer. P3 and P5 
Solexa sequences are the flow cell attachment site in Illumina NGS. In addition, each RT primer 
introduces a randomised sequence component to identify PCR (polymerase chain reaction) dupli-
cates during later analysis. The RT reaction will truncate just prior to the crosslinked site. The re-
sulting cDNAs are circularised such that the truncation site is directly linked to the RT-primer bar-
code sequence. After amplification with P3 and P5 Solexa primers, the linear cDNA is gel purified 
and quantified before loading onto the Illumina platform for NGS. 
 
 
Figure 3-1: Workflow of the conventional iCLIP protocol (revised by Ule lab from (Huppertz et al. 2014)). Cells 
are irradiated with 254 nm UV light to obtain covalent crosslinks between RBPs and their target RNAs. After 
cell lysis, fragmentation of the RNA generates suitable lengths for Illumina sequencing. While capturing the 
protein of interest by immunoprecipitation, the RNA 3’-end is dephosphorylated to allow IR-L3 adapter liga-
tion. The covalently linked RNA-RBP complexes are separated by SDS-PAGE, blotted onto nitrocellulose mem-
brane, and extracted by proteinase K digestion. Reverse transcription truncates at the crosslink site occupied 
by the remaining protein peptide. Barcoded primers will identify reads from different experiments and the 
random sequence allows for later identification of reads derived from PCR duplicates. The cDNA is circularised, 
and the RNA template digested. After further purification of the cDNA, it is amplified directly with P3 and P5 
Solexa primers. The resulting library is purified on a 6 % TBE (Tris-borate-ethylenediaminetetraacetic acid) 
PAGE to separate cDNA from free IR-L3 adapter and primer artefacts. After gel extraction and quantification, 
the libraries from different experiments are multiplexed and loaded onto the Illumina HiSeq 2500 system for 
single-read sequencing.   
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The main advantage of iCLIP is that the precise truncation event occurs at the crosslink site in about 
80-100 % of reverse transcription reactions; this allows for identification of the interaction site with 
nucleotide resolution (Haberman et al. 2017). Other CLIP-based methods such as 
HITS-CLIP/CLIP-Seq (high-throughput sequencing of RNA isolated by crosslinking immunoprecipita-
tion) and PAR-CLIP (photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipita-
tion), in which crosslinking events are identified from read-through events, lose information and 
accuracy during the library preparation step due to a more laborious adapter configuration. iCLIP is 
constantly being modified and developed further, for example by isolating the RNA-RBP complex 
without its visualisation by SDS-PAGE in eCLIP (enhanced CLIP), therefore saving time and experi-
mental steps (Van Nostrand et al. 2016).  
 
By providing the precise location of where an RNA-binding protein binds on its target RNA, iCLIP 
was considered to be an ideal starting point for the development of in vitro spliceosomal helicase 
iCLIP. In addition to adjusting RNase amounts to obtain suitable lengths for next-generation se-
quencing, most other steps had to be optimised and adapted to an in vitro system. In contrast to 
irradiated human cells, were the UV dose is held constant throughout the protocols, purified 
spliceosomes derived from in vitro splicing reactions in yeast are the starting material here. This 
set-up allows for variation of the pre-mRNA substrate, the addition of dominant negative mutant 
helicases, or the depletion of specific spliceosomal factors. Basically, incubation of pre-mRNA sub-
strate in yeast extract under splicing conditions will lead to assembled spliceosomes (Figure 3-2 A). 
The assembled complexes can then be purified using size selection methods, or affinity strategies 
on either the RNA substrate (MS2-stem loops shown in Figure 3-2) or spliceosomal proteins. As 
described in the introductory section 1.4 using modified pre-mRNA substrates or dominant nega-
tive proteins, which stall the splicing process at a specific step in combination with capture via step-
specific factors, produces homogeneous spliceosome species. As a flexible alternative to using pro-
tein specific antibodies for immunoprecipitation during the iCLIP procedure, we chose to add 
epitope tags to the target protein via homologous recombination.  
Initially, Prp16 helicase in spliceosomal complex C served as the first target protein to develop the 
method. In addition, we decided that the RNA contacts of SmB protein should be determined in 
complex C, serving as a positive control. In a second step, additional spliceosomal helicases will be 
targeted by transferring and adjusting the method (compare chapter 5).  
 
There are several possible ways to stall an in vitro splicing reaction at the complex C stage (intro-
ductory section 1.4), for example by the addition of dominant negative Prp16 protein (Prp16-DN) 
(Schneider, Hotz, and Schwer 2002) or a pre-mRNA substrate with a 3’SS mutation that causes a 
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second step defect (Vijayraghavan et al. 1986) (Figure 3-2 B and C). In the following chapters 3 and 
4, a complete permutation of these two strategies obtains a full dataset for comparison: WT protein 
and mutant substrate, mutant protein and mutant substrate, mutant protein and WT substrate.  
 
 
Figure 3-2: Schematic description of in vitro splicing. (A) Splicing extract contains pre-assembled snRNPs and 
other essential spliceosomal proteins. Incubation with a pre-mRNA substrate (carrying three MS2-stem loops 
at the 5’-end and a fluorophore at the 3’-end which is indicated with a *) starts assembly of spliceosomes. (B) 
An in vitro splicing reaction can be stalled at the complex C stage by either the addition of (a) dominant negative 
Prp16 (Prp16-DN) or (b) pre-mRNA with a mutation at the 3’SS whereby AG is replaced by AC. (C) 10 % dena-
turing PAGE shows a time course of a splicing reaction for UBC4_AC accumulating intron-lariat intermediate. 
Spliced RNA would migrate between pre-mRNA and intron-lariat intermediate.  
 
Establishing an iCLIP method for Prp16 in complex C will allow us to better understand the Prp16 
RNA remodelling mechanism and will serve as a starting point for adapting the approach to the 
analysis of other spliceosomal helicases. Going one step further, it is essential to collect data points 
for the position of Prp16 at the stalled complex C step before the system can be altered to conduct 
time-resolved studies which will follow the helicase binding path on its substrate over time.  
 
3.1 Purified spliceosomal complex C is the starting material for in vitro 
spliceosome iCLIP 
To obtain the stalled and homogenous starting material for the iCLIP method, spliceosomal com-
plex C was purified from a 1.5 mL in vitro splicing reaction. The UBC4-derived pre-mRNA substrate 
was adapted from cryo-EM studies (Galej et al. 2016) to facilitate comparisons to the three-dimen-
sional structure. The sequence of the last 25 nt of exon 1, the 95 nt intron and the first 25 nt of the 
second exon were extended by three MS2 stem loops on the 5’-end (referred to as 
3xMS2_UBC4_short). The mutated version, in which AG|AG is altered to AC|AC (where | indicates 
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the 3’SS), stalls spliceosomes at the complex C step (referred to as 3xMS2_UBC4_AC_short) (Figure 
3-3 A). Since another AG directly follows the 3’SS in the UBC4 gene, the AC|AC mutation was nec-
essary to avoid redirecting splicing to this second site. Prp16-G378A was previously described as a 
mutant with an impaired ATPase activity and strong dominant negative effect (Schneider, Hotz, and 
Schwer 2002). Since it is unclear whether spliceosomes stalled by the substrate arrest in the same 
way as by the ATPase-deficient helicases, Prp16-G378A was included in the study. A calmodulin-
binding peptide (CBP) and octa histidine-tagged version (rPrp16-G378A) was purified recombi-
nantly from yeast, which replaces the wildtype protein when added in excess to the splicing extract 
before the reaction.  
 
 
Figure 3-3: Spliceosome purification. (A) Schematic presentation of the strategies for spliceosomal complex C 
purification. The splicing reaction can either be stalled by adding dominant negative Prp16 (in this study: 
Prp16-G378A) or by using a pre-mRNA substrate with the 3’SS mutation AC (in this study: 3xMS2_UBC4_AC). 
The latter strategy can be combined with either Prp16-WT or Prp16-DN. (B) RNA species are visualised by the 
3’-Cy5-label on a 10 % denaturing PAGE: before splicing (lanes 1 and 7) after 30 min incubation (lanes 2 and 
8), top (lanes 3 and 9) and cushion (lanes 4 and 10) after centrifugation through the glycerol cushion, flow-
through (lanes 5 and 11) and elution (lanes 6 and 12) of the amylose capture. The RNA band migrating between 
pre-mRNA and intron-lariat intermediate derives most likely from a splicing event using a cryptic site. Left: 
extract containing Prp16-WT, right: extract supplemented with dominant negative rPrp16-G378A. (C) Repre-
sentative amounts of purified spliceosomes compared to input pre-mRNA measured by fluorescence of the 
Cy5-labelled RNA substrate. (D) Silver stained PAGE showing protein composition in the amylose eluate. Prp8, 
Brr2, and MS2-MBP can be identified from their migration pattern. The region, in which several other com-
plex C proteins migrate, is roughly indicated but cannot be assigned with certainty due to a mixture of spliceo-
somes before and at the first catalytic step. 
 
After spliceosome assembly, a glycerol cushion separated free pre-mRNA and small particles in the 
top from the spliceosomes, which accumulate in the higher-viscosity cushion (Figure 3-3 B, com-
pare lane 3 to 4, and lane 9 to 10). After amylose capture of the assembled spliceosome via the 
MS2-MBP (maltose-binding protein) system, about a third of the starting pre-mRNA substrate could 
be eluted as a mixture of assembled spliceosomes before and at the first catalytic stage  bound to 
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pre-mRNA and intron-lariat intermediate, respectively (Figure 3-3 B lanes 6, 12, C and D). Introduc-
ing an ATP-depletion step by adding glucose after the splicing reaction increased the purification 
efficiency of the spliceosome (representative gel in Figure 3-3 B). Addition of glucose results in the 
depletion of ATP in the extract as the glucose is phosphorylated by hexokinases utilizing ATP. Re-
moving the ATP from the extract might have increased the accumulation of stalled complexes that 
otherwise would have been subject to disassembly. Although leading to a mixture of spliceosomes 
as indicated by the presence of pre-mRNA and intron-lariat-intermediate (Figure 3-3 B lanes 6, 12 
and D), this two-step purification was considered as sufficient at this stage. The subsequent capture 
on Prp16, a step 1 specific splicing factor, during the iCLIP procedure, ensures a homogenous pop-
ulation representing the spliceosomal complex C stage (chapter 3.2). 
The data in this chapter is derived from spliceosomes purified from extract containing either en-
dogenous Prp16-WT or supplementary rPrp16-G378G assembled on 3xMS2_UBC4_AC_short. In 
chapter 4 spliceosomes containing rPrp16-G378A assembled on 3xMS2_UBC4_WT were purified to 
use in in vitro spliceosome iCLIP.  
 
3.2 Helicases are captured and can be monitored by an affinity tag 
3.2.1 Polyhistidine-tags have advantageous properties but produce high background 
signal 
In the conventional iCLIP protocol, the target protein is captured by a protein-specific antibody. The 
spliceosomes containing the target protein for in vitro spliceosome iCLIP, however, originate from 
yeast which can be genetically modified to introduce C-terminal affinity tags by simple homologous 
recombination (7.1.4 Materials and methods). Affinity tags exhibit various properties such as sus-
taining binding capacity under stringent conditions like the commonly used polyhistidine-tag. These 
properties seemed beneficial to capture solely the crosslinked RNA-RBP complex under denaturing 
conditions and reducing unspecific background. The Prp16-His8 allele supported normal growth of 
the yeast strain. As the only copy of the essential PRP16 gene, this directly demonstrates intact 
function of the modified protein. rPrp16-G378A was similarly expressed with a C-terminal octa his-
tidine-tag.  
Ideally, the target protein can be monitored via its affinity tag during the multi-step procedure of 
in vitro spliceosome iCLIP, however, a high background signal was obtained when probing for the 
polyhistidine-tag by western blot in whole cell extract and even after capture with TALON™ beads. 
Only the purified rPrp16-G378A-His showed a distinct signal (data not shown). For this yeast-de-
rived system, the polyhistidine-tag was unsuitable to ensure protein detection throughout the iCLIP 
preparation.  
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3.2.2 3xFLAG-tag enables helicase monitoring throughout the iCLIP procedure 
As described before, visualisation of the protein during the immunoprecipitation would facilitate 
optimisation and troubleshooting of the iCLIP procedure. In a second approach, antiserum against 
Prp16 was explored for western blot detection. Although this serum was successfully used in im-
munoprecipitations by (Schwer and Guthrie 1992a), the background was comparably high as prob-
ing with anti-His antibody in western blot. Detection and visualisation of the genetically introduced 
C-terminal single FLAG-tag by anti-FLAG antibody in western blot was also ineffective (data not 
shown). Finally, a 3xFLAG-tag, introduced by homologous recombination at the C-terminus of 
Prp16, produced a clean and distinct signal in western blot for both endogenous Prp16-3xFLAG-His 




Figure 3-4: Troubleshooting benefits from 3xFLAG-tag. (A) Western blot probing with anti-FLAG antibody for 
Prp16-3xFLAG-His in whole protein extract (left; a 10-fold excess of total protein amount was loaded) and for 
Prp16-G378A-CBP-3xFLAG-His in extract made from yeast cells overexpressing the protein (right: cells were 
induced with galactose and harvested at a similar OD compared to the cells used for the left lane; the used 
plasmid is listed in 7.1.6 Materials and methods).  (B) and (C) Spliceosomal complex C purification and TALON™ 
capture of polyhistidine-tagged target protein showing inefficient versus efficient TALON™ capture under (B) 
native and (C) denaturing conditions containing 6 M urea. Left: derived from splicing extract with endogenously 
tagged Prp16-3xFLAG; Right: derived from WT splicing extract supplemented with rPrp16-G378A-3xFLAG-CBP-
His. Top: Western blot probing for 3xFLAG-tag. The expected retention position for the FLAG-tagged protein is 
indicated with a cartoon showing a cyan sphere with a flag; Bottom: SDS-PAGE (original gel) visualising Cy5-
labelled RNA species. The expected retention positions for pre-mRNA and the intron-lariat intermediate are 
indicated with cartoons. Lanes: input (5-fold dilution), top (top) and bottom part (cu) of the glycerol cushion, 
FT (flow-through), W1-3 (washes), E1-2 (elution from amylose), urea (6 M urea wash), salt (1 M NaCl wash), E 
(elution from TALON). In both (B) and (C) left and right are derived from separate gels.  
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3.2.3 Efficient capture of C-terminally tagged Prp16 requires prior denaturation 
By carrying the 3xFLAG-tag, Prp16 becomes trackable throughout the whole procedure (compare  
3.2.2). Thus, spliceosome purification followed by the immunoprecipitation steps of the protein 
were monitored for troubleshooting. Most Prp16 helicase does not assemble into spliceosomes, 
consistent with a much higher proportion of anti-FLAG signal compared to the RNA amount in the 
top part of the cushion (lane 2) than in the cushion (Figure 3-4 B, lane 3). While almost all RNA is 
retained during amylose capture, a comparable higher amount of Prp16 is lost while binding to 
(lane 4) and washing (lanes 5-7) the beads. This confirms Prp16 to be a weakly or transiently bound 
component of the spliceosome. However, in the purified spliceosome, Prp16 is present confirming 
successful purification of spliceosomes containing complex C. Contrary to expectation, the protein 
is hardly captured by TALON™ subsequently, indicating the C-terminal tag of Prp16 is inaccessible 
when assembled into spliceosomes (Figure 3-4 B, lanes 10 to 16).  
The protein capture was clearly improved when the spliceosomes were denatured with 6 M urea 
or 5 M guanidinium hydrochloride prior to loading onto TALON™ beads. Comparing the amounts of 
unbound (lane 9) and captured Prp16 (lane 13), the pulldown efficiency was improved significantly 
under urea conditions (Figure 3-4 C). Denaturation with guanidinium hydrochloride enhanced bind-
ing too, however less effectively (data not shown).  
Comparing these results for WT splicing extract supplemented with rPrp16-G378A-3xFLAG-CBP-His 
and experiments performed on endogenously tagged Prp16, the conclusions are the same (left and 
right panels, Figure 3-4 B and C). A higher amount of rPrp16-G378A is present at the start of the 
procedure, and most excess is lost during the early purification steps. The amount of rPrp16-G378A, 
which is added to the extract before the splicing reaction, was therefore adjusted to reach the same 
level as the WT protein during the immunoprecipitation step. 
 
3.3 Optimisation of UV-crosslinking and enzymatic reactions for in vitro 
spliceosome iCLIP  
3.3.1 UV irradiation can covalently link Prp16 and RNA in purified spliceosomes 
Despite successful TALON™ capture of Prp16-His under denaturing conditions, after a whole iCLIP 
procedure, the expected RNA-Prp16 crosslinked species were still not appearing on SDS-PAGE (data 
not shown, expected result shown in Figure 3-1). In the unsuccessful test in vitro iCLIP experiment, 
UV and RNase amounts were adapted from the standard iCLIP procedure irradiating with 1,000 x 
100 µJ/cm2 UV light and testing two different concentrations of RNase I.  
RNA-protein crosslinking of the target protein is essential to pursue this method, however some 
RBPs fail to covalently link to their target RNA, as nucleobases and the target protein need to be in 
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an optimal conformation to allow photo-activated formation of a covalent bond. Insufficient cross-
linking of Prp16 to its target RNA was considered as an explanation and therefore purified com-
plex C was targeted for UV-titration. The protein migration shifts upwards while the intensity of the 
band corresponding to free Prp16 decreases with increasing UV exposure (Figure 3-5), demonstrat-
ing successful crosslinking of Prp16 and RNA. The labelled pre-mRNA and intron-lariat-intermediate 
likewise fade out with increasing UV irradiation, indicating the RNA substrate crosslinks to proximal 
spliceosomal proteins, producing new RNA-protein species of reduced gel mobility. The crosslinking 
efficiency for Prp16-WT and rPrp16-G378A seems comparable (Figure 3-5 compare A and B).  
 
 
Figure 3-5: Prp16 is crosslinked to RNA by UV irradiation. Irradiation of purified complex C with different 
amounts of UV light including a negative control (Ø), 1,250, 2,500, 5,000, and 10,000 x 100 µJ/cm2. Top: West-
ern blot probing with anti-FLAG antibody; Bottom: SDS-PAGE (original gel) scanned for Cy5-labelled RNA spe-
cies. (A) Spliceosomes purified from extract expressing endogenous Prp16-3xFLAG-His and (B) WT extract sup-
plemented with rPrp16-G378A-3xFLAG-CBP-His. 
 
Ideally, one aims to achieve a maximum of one crosslink event per molecule pair. Thus, all cross-
linked peptides will generate truncation events in later reverse transcription. The UV amount used 
here, however, seems to crosslink the majority of protein-RNA complexes indicating ‘over cross-
linking’. Therefore, UV irradiation had to be precisely adjusted, which is discussed in 3.3.3. 
 
3.3.2 Optimisations for RNase digestion, dephosphorylation and IR-L3 adapter ligation  
The three enzymatic reactions that are necessary for efficient IR-L3 adapter ligation were tested in 
a defined setup to carefully troubleshoot each step, which could prevent formation of the RBP-RNA-
adapter complex.  
In in vitro spliceosome iCLIP, the RNA is cleaved during the immunoprecipitation while the protein 
is bound to beads. In conventional iCLIP, however, RNase digestion is performed in cell lysate, 
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where 2.5 and 0.5 units RNase I per 1 mL of lysate are used for high and low RNase conditions, 
respectively. RNase I cleaves with similar efficiency after all four nucleotides and therefore intro-
duces less bias compared to other RNases. To get a first impression of RNase I digestion on a more 
purified target such as the spliceosome, Cy-5 labelled pre-mRNA was digested by four different 
concentrations of RNase I in a 10-fold dilution series (compare Figure 3-6 A, ‘RNase I digestion’), 
whereby a continuous range of different size fragments is obtained (Figure 3-6 B). In addition, the 
two lower concentrations give an indication for a suitable number of units for the in vitro spliceo-
some iCLIP experiment. Similarly, S1 nuclease was tested, however, the digestion neither led to a 
continuous range of lengths nor showed clear concentration-dependency (data not shown). 
 
 
Figure 3-6: Optimisations for enzymatic RNA digestion and IR-L3 adapter ligation. (A) Schematic diagram of RNA 
fragmentation with RNase I and adapter ligation. RNase I leaves, in contrast to some other RNases, a 2’,3’-cyclic 
phosphate at the 3’-end (depicted as a pentagon) which has to be dephosphorylated before the free OH-group 
can react with the pre-adenylated IR-L3 adapter (depicted as a green bar). (B) Cy5-labelled pre-mRNA substrate 
(UBC4_AC_short) was incubated with different amounts of RNase I in 200 µL RNase buffer as indicated (RNA 
amount: 1.7 pmol). The reaction was stopped and deproteinised before visualising on an 8 % denaturing PAGE. 
(C) In vitro transcribed U5 snRNA A was incubated with pre-adenylated IR-L3 adapter under ligation conditions 
with the indicated amount of RNA ligase I at the indicated temperature for 16 hours. The reaction was stopped 
and deproteinised before separating on an 8 % denaturing PAGE. Molecules attached to the IR-L3 adapter 
appear green in the scan. Free IR-L3 adapter was run in lane 10, and its migration position is indicated with a 
green bar. Ligated products are indicated with a green bar attached to a black line. (D) 7.5 pmol Cy5-labelled 
pre-mRNA substrate was incubated with different RNases as indicated in the figure. After the reaction was 
stopped, deproteinised, and precipitated, the RNA was incubated with (lane 2) or without (lanes 3 and 4) T4 
PNK and fastAP. After another round of deproteinization and precipitation, the RNA was incubated with pre-
adenylated IR-L3 adapter and RNA ligase I at 23 °C for 16 hours. Final deproteinization and precipitation was 
done before separation on an 8 % denaturing PAGE. Molecules with a Cy5-label (starting molecule and prod-
ucts of RNase digest) and molecules attached to the IR-L3 adapter appear red and green, respectively.   
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In a second step, IR-L3 adapter ligation was tested on free RNA. Attaching the pre-adenylated IR-L3 
adapter to the free 3’-OH-group of the target RNA by RNA ligase I is supposedly one of the most 
inefficient steps in iCLIP. In this test, the RNA possesses a free 3’-OH-group, and therefore the liga-
tion efficiency can be tested without prior modification of the 3’-end (compare Figure 3-6 A, 
‘adapter ligation’). An increase in temperature leads to a slight increase in IR-L3-adapter-ligated 
RNA (Figure 3-6 C). The nucleotide species longer than free linker and shorter than correctly linked 
RNA-DNA could either result from degradation at higher temperatures or the formation of IR-L3 
adapter concatamers. In theory, the biotin label at the 3’-end of the IR-L3 adapter should prevent 
concatamer formation. A higher concentration of RNA ligase I clearly leads to more efficient ligation 
(Figure 3-6 C).  
In the full iCLIP experiment, IR-L3 adapter ligation follows RNase digestion. As RNase I leaves a 
2',3'-cyclic phosphate at the 3’-end, this linkage has to be opened and the phosphate removed be-
fore ligation can occur (Figure 3-6 A). The reaction is most successful, when a combination of poly-
nucleotide kinase (PNK) and alkaline phosphatase (AP), as described for iCLIP techniques in (Van 
Nostrand et al. 2016), removes the cyclic phosphate before IR-L3 adapter ligation (Figure 3-6 D, 
compare lane 2 to 1 and 3). S1 nuclease, which has the advantage of leaving a free 3’-OH after 
cutting, making additional dephosphorylation unnecessary, could not be optimised to lead to simi-
larly efficient IR-L3 adapter attachment (Figure 3-6 C, lane 4).  
As a result, RNase I was chosen to be further optimised for the controlled RNA digestion on cross-
linked protein-RNA complexes, while high concentration RNA ligase I was used at 23 °C during the 
in vitro spliceosome iCLIP procedure for IR-L3 adapter ligation. 
 
3.3.3 Adjusted UV dose and RNase I amount lead to appropriate lengths of crosslinked 
RNA  
It is hard to predict the required amount of target protein for in vitro spliceosome iCLIP from con-
ventional iCLIP, where a third of a 10-cm-diameter plate with adherent cells is the starting material.  
Therefore, yields of Prp16 crosslinked to RNA derived from spliceosomes, which were purified from 
a 1.5 mL splicing reaction, were compared by the amount of fluorescence via the Cy5-labelled RNA. 
The amount of input pre-mRNA was assessed against three conditions after TALON™ capture, 
whereby the first was not crosslinked, the second irradiated with the high UV dose used before 
(compare Figure 3-5), and the last condition both irradiated and treated with 0.3 units RNase I. 
RNase digestion releases the Cy5-label indicated by the fluorescence, which drops to the baseline 
level of the non-crosslinked condition (Figure 3-7 A, compare noUV and UV, RNase). Overall, about 
5 fmol of RNA crosslinked to Prp16 are estimated to be captured, which should lead to a sufficient 





Figure 3-7: Optimal UV and RNase dose produces RNA fragments of suitable lengths. (A) Fluorescence quantifi-
cation of input pre-mRNA substrate of a 1.5 mL splicing reaction compared to the amounts measured after 
TALON™ pulldown without UV irradiation (noUV), with prior UV irradiation (UV), and prior UV irradiation fol-
lowed by RNase digestion (UV, RNase). The calculated RNA amounts are denoted above the bars. (B) Parallel 
fine-tuning of UV irradiation and RNase I digestion. Purified spliceosomal complex C was irradiated with 312, 
625, and 1,250 x 100 µJ/cm2 UV light, followed by denaturation, TALON™ capture, and digested with 1, 0.1, 
and 0.01 units RNase I. Subsequent γ-33P-ATP radiolabelling allowed visualisation after SDS-PAGE separation 
and transfer onto nitrocellulose. The data derived from spliceosomes containing Prp16-WT; the highlighted 
lanes show a range for optimal conditions which was obtained likewise for rPrp16-G378A containing spliceo-
somes (not depicted). (C) Blot, showing radiolabelled RNA (left), IR-L3 adapter (right) after an in vitro spliceo-
some iCLIP experiment using FLAG capture including controls (lanes 2, 4, 6, 8, 10 and 12 for non-irradiated 
samples; lanes 1, 2, 7 and 8 for samples without a FLAG-tagged protein). Purified complex C containing either 
Prp16-WT (WT) or rPrp16-G378A (DN) were irradiated with 312 x 100 µJ/cm2 UV light and treated with 0.5 
units RNase I during FLAG capture. (D) Parallel fine-tuning of UV irradiation and RNase I digestion. Purified 
spliceosomal complex C was irradiated with 156, 312, and 625 x 100 µJ/cm2 UV, followed by denaturation, 
FLAG capture, and digestion with 5, 0.5, and 0.05 units RNase I. Subsequent γ-33P-ATP radiolabelling allowed 
visualisation after SDS-PAGE separation and transfer onto nitrocellulose. The data derived from spliceosomes 
containing endogenous SmB-3xFLAG-His, the highlighted lane shows the optimal condition. (B, C, D) The ex-
pected retention position for the FLAG-tagged protein is indicated with a cartoon showing a cyan sphere with 
a flag and a coloured gradient representing crosslinked RNA. 
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The amount of UV irradiation and RNase I were further varied in parallel and the RNA species ob-
tained were visualised by radiolabelling. The inefficient steps of IR-L3 adapter ligation can thereby 
be avoided. Radiolabelled γ-33P-ATP was used for enzymatic labelling of the 5’-end of any cross-
linked RNA by T4 PNK during TALON™ capture of Prp16-His. This ATP-labelling reaction was opti-
mised to be performed in 5 min. The visualised RNA suggests an optimal UV irradiation with 312 x 
100 µJ/cm2 combined with 0.1 to 0.01 units RNase I per experiment (Figure 3-7 B, shown for Prp16-
WT). While increasing the UV dose produces the mandatory crosslink between protein and target 
RNA, the risk of over-crosslinking increases, too. At 312 x 100 µJ/cm2 UV light, the radioactive signal 
does not increase much further by additional irradiation, indicating that the optimal limit for one 
crosslink per RNA-protein complex is reached and additional bonds are only formed with binding 
partners that are already linked. The RNase amount should be optimised to produce RNA species 
of 50–150 nt lengths (Huppertz et al. 2014). Under-digestion will rise into a diffuse signal and can 
later lead to artefacts because truncation events will not be introduced randomly but occur due to 
endogenous ribonucleases which might have preferred sequence or structure specificity. Over-di-
gestion, on the other hand, will give a sharp band that migrates close to the expected molecular 
weight of the protein. IR-L3 adapter ligation may therefore be hindered or the cDNAs produced will 
be too short for later mapping. Besides this conclusion, the blot clearly shows rather high back-
ground. Apparently, TALON™ either captures other proteins non-specifically or nucleic acids adhere 
to the beads. Neither washes under denaturing conditions with 6 M urea nor the more specific 
elution with imidazole could improve the background (data not shown). 
 
To clear the high non-specific background, capture by the FLAG-epitope was taken into considera-
tion as the epitope-antibody interaction is supposedly highly specific. Experiments were therefore 
performed replacing TALON™ by FLAG capture keeping the same conditions for UV crosslinking 
while adjusting RNase digestion slightly (Figure 3-7 C). The FLAG-antibody detaches from the 
epitope under the urea conditions which are essential to access the epitope tag. Therefore, the 
crosslinked samples are diluted back to lower urea before loading onto the anti-FLAG beads. During 
the iCLIP experiment shown here, the RNA was first 5’-end labelled with γ-33P-ATP before the IR-L3 
adapter was attached. Compared to the TALON™ capture, FLAG removes most background (Figure 
3-7, radioblot). Strikingly, the dominant negative rPrp16-G378A binds RNA strongly even without 
crosslinking (Figure 3-7 C lane 5, 6). The blot visualising IR-L3 adapter via the infrared label, which 
should exactly mirror the radioblot when all RNA-protein complexes are ligated to the IR-L3 
adapter, shows a lot of background, some of which might derive from adapter concatamers (Figure 
3-7 C). Stringent washing conditions containing chaotropic agents are not compatible with the 
epitope-antibody interaction, which is clearly a disadvantage of FLAG over TALON™ capture.  
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Several tests combining both affinity purifications resulted in very low yield and similar background, 
and therefore were not considered as any improvement. Hereby, the protein was bound first to 
FLAG, eluted with either high urea or FLAG-peptide followed by TALON™ capture. Isolated tests, 
incubating magnetic beads under ligation conditions with IR-L3 adapter or IR-L3 adapter and RNA 
ligase I showed that the adapter preferentially adheres to TALON™ beads; this behaviour was sig-
nificantly reduced when using FLAG beads (data not shown). In addition, IR-L3 adapters attached 
to proteins of lower molecular weight supposedly gives a stronger IR signal (Zarnegar et al. 2016), 
therefore background of lower molecular weight appears stronger than when visualised by radio-
labelling (compare Figure 3-7 C lanes 1-6 and lanes 7-12). In the final in vitro spliceosome iCLIP 
protocol, an additional step was introduced to remove free IR-L3 adapter by enzymatic deadenyla-
tion and subsequent endonuclease digestion (communication with J. Ule and used e.g. in (Zubradt 
et al. 2017)). Despite the disadvantages discussed above, FLAG capture gave cleaner results and 
therefore all following experiments are carried through under FLAG capture.  
 
Since many obstacles were encountered in establishing in vitro spliceosomal iCLIP for Prp16, SmB1 
protein was introduced as a control for method development. The Ule lab routinely includes the 
SmB control using Sm B’/B/N antibody (Santa Cruz) when adapting conventional iCLIP to a novel 
protein in human cells. SmB is known to form crosslinks to spliceosomal snRNAs with high effi-
ciency; it is an integral step-independent component of the spliceosome and its binding site is well 
described in the literature (Guthrie and Patterson 1988). To obtain a consistent control for in vitro 
spliceosomal iCLIP, a yeast strain expressing SmB-3xFLAG-His8 was generated. Consequently, the 
main steps of the protocol could remain unchanged, merely the amount of UV and RNase I had to 
be adjusted. The optimal signal could be obtained with irradiation of 312 x 100 µJ/cm2 UV light and 
5 units RNase I (Figure 3-7 D). Other potential RNA-protein complexes appear at sizes around 65 
kDa, where other proteins migrate which most likely crosslink to the same RNA and are released by 
this concentration of RNase I. To ensure correct analysis of the data, this part of the membrane was 
excluded when extracting the RNA-protein complexes.  
 
3.4 RNA library preparation produces cDNA for subsequent high 
throughput sequencing 
3.4.1 cDNA amplification correlates with crosslinked RNA amounts 
Even though the infrared signal from the IR-L3 adapter did not always exactly mirror radiolabelled 
RNA, RNA was extracted and transcribed into a cDNA library. Most likely, 100 % ligation efficiency 
was never reached. Extraction of the RNA-RBP complex from the membrane was monitored by 
scintillation counting.  
Establishing iCLIP for helicases in stalled and purified spliceosomes 55 
After reverse transcription and purification of the circularised cDNA, amplification was optimised 
and reached an optimum of 24 cycles in this representative experiment (Figure 3-8 A). Samples 
derived from SmB iCLIP show the strongest signal indicating its high crosslinking efficiency. In the 
same way, more cDNA is generated from the dominant negative mutant of Prp16 compared to the 
WT, underlining a higher RNA binding ability of the mutant protein. Chapter 4.1.2 discusses the 
length of the pre-mRNA substrate as a crucial parameter for obtaining longer fragments of cDNA.  
 
 
Figure 3-8: cDNA library preparation of in vitro spliceosome iCLIP. (A) 6 % TBE PAGE stained with SYBR green 1 
shows cDNA library after multiplexing of non-irradiated and irradiated samples after in vitro spliceosome iCLIP 
of the protein as labelled. (B) The comparison between on-bead ligation and in-solution ligation of the IR-L3 
adapter combined with the gel-free protocols shows a stronger signal for in-solution ligation. The same sample 
was split equally to pursue both strategies. The cDNA was amplified with 21 cycles each. (C) Size distribution 
of a representative multiplexed library of SmB, Prp16-WT and DN gives a peak around 139 nt which most likely 
refers to adapter and primer artefacts. The actual cDNA is presented by the peak around 182 nt reaching until 
about 400 nt. To determine DNA sizes and concentration with the Tapestation, the sample (right panel) is 
compared and aligned to a ladder (left panel). 
 
Overall, most cDNA libraries in this thesis were amplified with 25 ± 2 cycles, which is consistent with 
conventional iCLIP for low abundance proteins. Despite introducing an adapter removal step, all 
libraries showed a strong band at ≤ 130 nt (compare Figure 3-8 A) which corresponds to artefacts 
derived from primers and IR-L3 adapters. Therefore, the libraries were gel purified at least once. 
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The P3/P5 Solexa primers and the barcode sequence combine to a length of 131 nt. All DNA frag-
ments of 131 to ~400 nt length were extracted to retain all cDNA inserts which are larger than 15 nt. 
For quality control, the concentration and the length distribution of the final library was determined 
by Qubit and Tapestation, respectively. Libraries normally reached a yield between 200 and 
1,000 fmol depending on the quality and the number of multiplexed samples. Often, the distribu-
tion trace showed two peaks, where the first, narrow one corresponds to IR-L3 adapter and primer 
artefacts and the second peak shows the desired shape of a library with various lengths of cDNA 
inserts (Figure 3-8 C).   
 
3.4.2 Short versions of iCLIP generate higher yields of RNA 
One of the main aims in iCLIP is the reduction of steps in the protocol to save time, retain more 
material and reduce the possibility of human error. While optimising in vitro spliceosome iCLIP, two 
shorter versions were tested. The main motivation to try the first shorter version derived from low 
capture of RNA requiring a relatively high amplification rate. In the so-called short-iCLIP protocol 
(personal communication with Flora Lee), the SDS-PAGE step is replaced by urea elution. The pro-
tein is released from the antibody-bound beads followed by a second immunoprecipitation from 
which the crosslinked RNA is directly released by proteinase K digestion. The protocol was adapted 
to the previously described in vitro spliceosome iCLIP conditions. Since the urea elution seemed 
inefficient, the crosslinked RNA was directly eluted by proteinase K digestion from the first FLAG 
capture. The amount of eluted RNA was determined higher by scintillation counting and the same 
amount of cDNA was generated with a lower number of amplification cycles. Therefore, the 
short-iCLIP protocol was an improvement superficially, however the protocol was not stringent 
enough to separate crosslinked RNA-protein from background (discussed in chapter 3.5, sequenc-
ing results). 
In a second attempt, a gel-free version was examined (personal communication with Andrea Elser), 
in which the crosslinked RNA-RBP complex is first purified by a selective RNA column followed by 
protein binding beads (7.4.4 Materials and methods). This two-step purification was considered to 
retain only crosslinked RNA-RBP species. Although simplifying the experimental protocol, the main 
motivation for this trial was to reduce background in non-UV control conditions. In addition, this 
protocol offers the possibility of attaching the IR-L3 adapter after proteinase K digestion. By avoid-
ing on-bead adapter ligation, steric hindrance of the crosslinked protein is reduced, which can in 
principle prevent efficient IR-L3 adapter ligation. Starting from a multiplexed cDNA library derived 
from the gel-free protocol, on-bead adapter ligation (left) and in-solution adapter ligation (right, 
ligation after elution from beads and proteinase K digest) were compared (Figure 3-8 B). While both 
libraries were amplified with 21 cycles, the resulting amount for in-solution ligation is much higher 
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indicating an increase in adapter ligation. Although the final cDNA library derived from the gel-free 
protocol showed the highest concentration with 4 pmol, a lower number of reads during sequenc-
ing were finally identified as unique cDNA reads, whilst the background was highly increased com-
pared to the protocol including the SDS-PAGE (Appendix folder, session_1). 
 
3.5 Next-generation sequencing data confirms Sm site  
A novel bioinformatics pipeline was written in Snakemake (Köster and Rahmann 2012) for in vitro 
spliceosome iCLIP data based on the command-line interface iCount (Chakrabarti et al. 2017) to 
visualise crosslink positions on RNA (this pipeline was completely developed by Charlotte Capi-
tanchik) (Appendix folder). First, a separate genome was generated that only contains the 
pre-mRNA substrate used for the in vitro splicing reaction and all spliceosomal snRNAs; from now 
on, this will be called ‘substrate-ome’ throughout the thesis. Reads were trimmed to remove IR-L3 
adapter and barcode sequences. Subsequently, trimmed reads were mapped first to the substrate-
ome and retained if they mapped uniquely and in the correct orientation (Figure 3-9). Unmapped 
reads were then mapped to the yeast genome. Due to the use of unique molecular identifiers 
(UMIs), PCR duplicates could then be collapsed based on the UMI and start position of the mapped 
reads, such that each crosslink represents one cDNA. The crosslink position corresponds to the -1 
position of the sequence read. The number of truncation events per position is shown in histograms 
on the target RNA.  
 
A first indication of the quality of the in vitro spliceosome iCLIP data is that control experiments 
without any tagged protein contain very few reads. Reads which map to the total yeast genome 
seem to truncate at random locations and fall below background levels and are therefore not shown 
(Appendix folder, session_2a and 2b for substrate-ome and genome mapped iCLIP data, respec-
tively). The background level of reads in non-UV-irradiated control samples aligned to the sub-
strate-ome is low for SmB, too (Figure 3-9 A). As expected, reads map to U2 and U5 snRNA, which 
are part of spliceosomal complex C. In addition, reads also align to U1 and U4 snRNA, which are 
part of earlier spliceosomal complexes present in the spliceosome preparation and not removed by 
additional purification of a second-step specific factor such as Prp16. Reads which map to U6 
snRNA, which holds the LSm site rather than a Sm site, or the RNA substrate fall below background 
level. Denaturation with urea after crosslinking dismantles the spliceosome and therefore only RNA 
molecules that are in direct contact with SmB proteins are expected to give rise to cDNA reads. Less 
stringent conditions, however, could possibly produce cDNA reads which terminate at crosslink 
sites of auxiliary spliceosomal proteins through indirect contacts; this was shown in (Briese et al. 
2018) applying conventional SmB iCLIP under mild conditions. The location of the peaks agrees with 
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the known Sm sites with the sequence element PuAU4-6GPu (Pu = purine) (Guthrie and Patterson 
1988). On U2 snRNA, the Sm site locates close to the 5’-end at 110 nt. The Sm site on U5 snRNA is 
found at ~170 nt. A second peak maps to ~150 nt and allows speculations of an alternative binding 
site. In previous studies, the U5 Sm site showed to be very tolerant towards mutations (Jones and 
Guthrie 1990) and yeast was still viable when then the complete U5 Sm site was deleted (Dix et al. 
1998; O'Keefe, Norman, and Newman 1996). The Sm site of U1 snRNA is found at 550 nt at its very 
3’-end (Seipelt et al. 1999), whereas the site is located at 150 nt on U4 snRNA. All mapped regions 
locate slightly upstream of the PuAU4-6GPu sequence motif and the truncation events spread sev-
eral bases (Figure 3-9). All these results validate in vitro spliceosome iCLIP.  
 
The landscape for Prp16 binding in complex C shows a broad accumulation of truncations between 
the branchpoint adenosine (brA) and +5 nucleotides from the 3’SS (Figure 3-10 and Appendix 
folder, session_3). Further, prominent peaks are located at the 5 ’SS, ~+10 nt from the 5’SS, and at 
the brA. Hardly any reads were generated from experiments capturing the dominant negative mu-
tant Prp16-G378A. In addition, reads derived from non-UV-irradiated control samples result in a 
similar landscape. Since control experiments without tagged proteins are very clean (compare lines 
1 and 2 with lines 3-6), this background might be due to strong direct or indirect interaction of the 
helicase with its target RNA. The appearance of prominent peaks at the 5’SS and the brA will be 
discussed in chapter 4, which is fully devoted to Prp16 in vitro spliceosome iCLIP data interpreta-
tion. A negligibly small number of reads map to the snRNAs (Figure 3-10).  
Short-iCLIP data reveals a landscape where most reads truncate at the 5’SS or the brA throughout 
control and non-control samples (Appendix folder, session_4). Since truncation events are also ob-
tained from untagged protein samples, those reads are most likely Prp16 independent. Conse-
quently, the additional steps including SDS-PAGE separation of the long protocol are necessary to 
reduce the amount of non-crosslinked RNA species present in the sample as well as the cleanliness 
of control samples.  
In summary, this initial analysis of iCLIP data requires further improvement but certainly supports 
the applicability of in vitro spliceosome iCLIP for Prp16 helicase.  
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Figure 3-9: Mapping of SmB in vitro spliceosome iCLIP data to the substrate-ome. Crosslink events (-1 position 
of truncation) are presented as histograms aligned to the indicated RNA (U2 snRNA, U5 snRNA, U1 snRNA, 
U4 snRNA, U6 snRNA and the transcript 3xMS2_UBC4_AC_short). Boxed regions are enlarged on the right, 
showing the nucleotide sequence and the position of the first and last nucleotide. The Sm sequence element 
is highlighted in bold. Signal on U2, U5, U1, and U4 snRNAs locate to the Sm sites. Neither U6 nor the pre-mRNA 
substrate contains reads above background. The scale of the histograms (number of truncated reads/nucleo-
tide) is given at the left corner in each lane. The data was generated applying the in vitro spliceosome iCLIP 
method that includes the SDS-PAGE separation step. 
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Figure 3-10: Mapping of Prp16-WT and Prp16-G378A in vitro spliceosome iCLIP data to the substrate-ome. Cross-
link events (-1 position of truncation) are presented as histograms aligned to the indicated RNA (the transcript 
3xMS2_UBC4_AC_short (exons are in purple, brA is represented by a *), U1 snRNA, U2 snRNA, U4 snRNA, U5 
snRNA, U6 snRNA). Boxed regions are enlarged underneath, showing the nucleotide sequence and the position 
of brA (bold A), and the exons (purple). Reads accumulate between the brA and 3’SS. Sharp peaks locate to the 
5’SS and the brA. Reads on the snRNAs are at background level. The scale of the histograms is indicated at the 
left corner or is given as the y-axes for enlarged parts. The data was generated applying the in vitro spliceosome 
iCLIP method that includes the SDS-PAGE separation step. 
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3.6 Helicases are suitable targets for iCLIP of defined spliceosomal states 
In summary, this chapter describes the development of a complete pipeline, which catches the 
RNA-binding position of tagged proteins in spliceosomal complex C (summarised in Figure 3-11). 
The method was verified by SmB in vitro spliceosome iCLIP data, which generates the expected Sm 
site landscape on spliceosomal snRNAs.  
The position of Prp16 could not be determined with similarly high confidence. The broad peak 
around +15 nt from the brA agrees with previously published data (McPheeters and Muhlenkamp 
2003; Semlow et al. 2016), however, cleaner data would allow a more confident prediction. The 
number of cDNAs derived from rPrp16-G378A is much lower than from the WT protein, which is 
not in agreement with the stronger RNA binding activity of the mutant protein. Besides this, the 
proportion of cDNAs mapping to the substrate-ome is low as well (Appendix Figure 8-2). Binding of 
a protein close to the 3’-end of an RNA, naturally results in short cDNAs which is a limiting factor. 
Short cDNAs are more likely to have multiple possible mapping positions, making confident assign-
ment more difficult. Therefore, cDNA reads shorter than 11 nt are excluded for data analysis in the 
bioinformatic pipeline. Since the landscape for Prp16 suggests a binding position close to the 3’-end 
generating a lot of short reads, this restriction might exclude a high number of reads lowering the 
overall signal at the binding site (see Appendix, Figure 8-3). In addition, a large number of trunca-
tion events happen at the intron-lariat junction. Both events are unique to in vitro spliceosomal 
iCLIP where the short RNA substrate is converted into intron-lariat intermediate. These problems 
are not present in the data for SmB in vitro spliceosome iCLIP since the target sites are located on 
linear RNA, most with a sufficient distance to the 3’-end.  
 
Attempts at improvement such as increasing the length of the pre-mRNA substrate and including 
an enzymatic debranching step are discussed in chapter 4. The promising landscape for SmB and 
Prp16 in vitro iCLIP supports the potential for the method to be transferred onto other helicases in 
the spliceosome, as well as giving sufficiently accurate information to be used as a starting point 













Figure 3-11: Workflow of in vitro spliceosomal iCLIP. Splicing extract is made from endogenously FLAG-tagged 
yeast strains or supplemented with recombinant protein expressing the FLAG-tag. Different strategies stall 
spliceosomes at various stages during the in vitro assembly, such as a substitution at the 3’SS of the pre-mRNA 
or dominant negative Prp16 for complex C. The spliceosomes are purified via the MS2-tag on the RNA and 
irradiated with 254 nm UV light to covalently link protein and RNA. Denaturation of the complex with urea 
makes the FLAG-tag accessible, which is necessary for Prp16. While capturing the protein of interest, controlled 
RNase I digestion fragments the RNA into suitable pieces for Illumina sequencing, the 5’-end is radiolabelled, 
and the 3’-end is dephosphorylated to allow IR-L3 adapter ligation. The covalently linked RNA-protein com-
plexes are separated by SDS-PAGE, blotted onto nitrocellulose membrane, and extracted by proteinase K di-
gestion. Reverse transcription truncates at the crosslink site occupied by the remaining protein peptide. Bar-
coded primers will identify reads from different experiments and the random sequence allows identification 
of reads derived from PCR duplicates later. The cDNA is circularised, and the RNA template digested. After 
further purification of the cDNA, it is amplified directly with P3 and P5 Solexa primers. The resulting library is 
further purified on a 6 % TBE PAGE to separate cDNA from free IR-L3 adapter and primer artefacts. After gel 
extraction and quantification, the libraries from different experiments are multiplexed and loaded onto the 
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4 Prp16 binds around 15 nt downstream of the intron branch 
in order to remodel the catalytic core  
 
In the previous chapter (3), in vitro spliceosome iCLIP was developed for the helicase Prp16 in 
spliceosomal complex C and the method was validated by determining the binding profile of SmB 
in spliceosomes at and before the first step, which reflects the expected Sm sites (Guthrie and 
Patterson 1988). The work described in this chapter aims at improving the quality of the in vitro 
spliceosome binding profile for Prp16 in order to analyse its RNA interactions with more confidence.  
In spliceosomal complex C, the DEAH-box helicase Prp16 is located at the periphery and binds to 
the intron-lariat intermediate somewhere downstream of the branch point (Figure 4-1 and (Galej 
et al. 2016)). In order to remodel the spliceosome to a second step conformation, a rearrangement 
has to happen at the catalytic core. Prp16 is thought to initiate the remodelling by pulling on the 
transcript from its peripheral location (Semlow et al. 2016). The branch site sequence, which forms 
the branch helix together with U2 snRNA, moves out of its binding pocket in order to allow 3’SS 
docking in the catalytic centre (Galej et al. 2016; Fica et al. 2017; Wilkinson et al. 2017). Splicing 
factors of the first catalytic step, such as Cwc25 and Yju2 are released and binding sites for second 
step factors generated. Prp16 promotes, together with the second step factors, remodelling to-
wards the exon-ligation conformation of the spliceosome (Schwer and Guthrie 1992a; Ohrt et al. 
2013). 
 
Through cryoEM studies, the location of Prp16 on the spliceosome has been determined, however, 
the path of the RNA transcript which would identify the binding site of Prp16 on the transcript could 
not be resolved in these flexible regions. The distance from brA to the RNA entry site of Prp16 was 
measured to be around 18 nucleotides for the UBC4 transcript (Galej et al. 2016). Previous biochem-
ical crosslinking studies, in which individual substrate RNA nucleotides were replaced by the pho-
toreactive 4-thiouridine, located the Prp16 binding site within the last four nucleotides of the intron 
and the first 13 nucleotides of the second exon of the ACM13 transcript (McPheeters and 
Muhlenkamp 2003). ACM13 is an actin-derived pre-mRNA substrate, in which the distance between 
the branch site and the 3’SS is shortened to 13 nt, and commonly used in in vitro splicing assays. In 
a second study, spliceosomes were assembled on the UBC4 transcript in which Prp16 crosslinked 
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to 4-thiouridine, which was introduced at the -8 position on the intron counted from the intron-
exon boundary (Semlow et al. 2016).  
 
 
Figure 4-1: Structures of spliceosomal complex C highlighting the position of the helicase Prp16. Prp16 (dark 
cyan) locates at the periphery of the complex, whereas the catalytic core is in the centre of the particle (Galej 
et al. 2016). The RNA substrate which consists of exon 1 and the intron-lariat-exon2-intermediate (location of 
exon 1 and intron are indicated), the snRNAs, and the branch (br) are highlighted. Left: overview of the particle; 
Right: zoom-in of the helicase region and the target RNA; dashed lines represent some of the unmodeled RNA 
parts which should be connected.   
 
As described in chapter 3.5, Prp16 in vitro spliceosome iCLIP reveals a binding profile in which most 
truncation events accumulate between the positions of -22 and +5 nucleotides of the second exon 
with the highest peak at -11 on the 3xMS2_UBC4_AC substrate (UBC4_AC: 3’SS alteration to AC). 
This region includes the position found by 4-thiouridine replacement in (Semlow et al. 2016); the 
direct comparison is possible since both experiments were based on the UBC4 transcript.   
Compared to SmB in vitro spliceosome iCLIP, which reveals precise locations of the Sm sites, the 
interpretation of Prp16 in vitro iCLIP data is less straightforward. First, the proportion of reads 
mapped to the substrate-ome is low (Appendix Figure 8-2, < 5% for Prp16), while a relatively high 
number of truncation events is obtained from non-UV irradiated samples. In this chapter, a strategy 
using an extended version of the transcript will be discussed as means for improvement. Second, 
prominent peaks at the 5’SS and the branch point adenosine can in principle derive from either 
peptide- or RNA-induced terminations. The latter are caused when the reverse transcription stops 
at the 2'-5' phosphodiester bond of the intron-lariat intermediate, which could obscure real cross-
link events and lead to misinterpretation of the data. In this chapter, debranching of the intron-
lariat intermediate is explored for in vitro spliceosome iCLIP on catalytic step 1 spliceosomes.  
Finally, the chapter aims at giving a general picture of where the natural binding site of Prp16 is 
located before the helicase starts translocating to promote remodelling towards the second step 
conformation. Three different datasets are compared to analyse Prp16 in complex C: (1) the WT 
protein stalled in the complex using a transcript with a 3’SS mutation, (2) the dominant negative 
protein Prp16-G3678A on the same transcript, and (3) Prp16-G378A which stalls the spliceosome 
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through its ATPase deficiency in the context of an unmodified RNA transcript. The Prp16-G378A 
carries an amino acid substitution in helicase motif I (Walker A) where the consensus sequence 
AxxGxGKT, which forms a phosphate binding loop required for the interaction with Mg2+ and ATP, 
is altered to AxxGxAKT. The conserved residue G in GKT is supposed to maintain a flexible confor-
mation of this loop (Walker et al. 1982).   
In addition, the binding profiles of Prp16 on two different substrates are compared to identify what 
determines the start location for Prp16 translocation.  
 
4.1 The binding profile of Prp16 WT and mutant protein is identical 
4.1.1 Truncation events co-localise for Prp16 WT and mutant protein 
In in vitro spliceosome iCLIP, the intrinsic crosslinking activity of the RNA enables one to locate the 
binding site of a protein on its unperturbed target RNA within its natural context, the spliceosome. 
Here, we aim at identifying the location of Prp16 before translocation starts and remodelling is 
initiated or in other words the RNA binding site for Prp16 in spliceosomal complex C. Both the al-
teration of the 3’SS of the RNA transcript (Vijayraghavan et al. 1986) and ATPase deficient dominant 
negative mutant proteins of Prp16 (Schneider, Hotz, and Schwer 2002) have shown to stall splicing 
at the complex C stage. Since it was never confirmed to my knowledge, that the two strategies lead 
to the exact same spliceosomal state, it is important to determine Prp16 binding profiles with both. 
This will allow us to identify the location of Prp16 before remodelling with high confidence. There-
fore, this subchapter describes the generation of in vitro spliceosome iCLIP data for rPrp16-G378A 
on UBC4_WT substrate for comparison with the results obtained in the previous chapter (Figure 
3-10, data on UBC4_AC).  
 
To set up in vitro spliceosome iCLIP for complex C solely stalled by the dominant negative 
Prp16-G378A, the same concentration of rPrp16-G378A as in the context of 3xMS2_UBC4_AC was 
used here. This concentration was sufficient to inhibit the second step of splicing comparable to 
stalling with the UBC4_AC substrate (Figure 4-2 A and Figure 3-3 B). The purification yield of the 
assembled spliceosomes on the 3xMS2_UBC4_WT transcript was comparable to that obtained us-
ing 3xMS2_UBC4_AC. The proportion of pre-mRNA and intron-lariat-intermediate spliceosomes af-
ter the purification was also similar (compare Figure 4-2 A to Figure 3-3 B).  
 
Further sample preparation followed the pipeline developed in chapter 3. The obtained binding 
profile for Prp16-G378A on 3xMS2_UBC4_WT transcript is aligned with the two datasets for Prp16 
on the 3xMS2_UBC4_AC transcript for comparison (Figure 4-3, for Prp14 UBC4_AC data also com-
pare Figure 3-10; Appendix folder, session_3 and 5). The overall peak pattern derived from the 
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three experiments is identical: the major peaks locate at the 5’SS, +12 nt on the intron, and the brA, 
while an accumulation of truncation events locates between the brA and the beginning of the sec-
ond exon.  
Potential concern in the interpretation of the data is the background, which is obtained from sam-
ples without UV irradiation, in which peaks resemble the pattern found in UV-irradiated samples 
with lower intensity (Figure 4-3, all three experimental conditions).  
Further, most truncation events map to the last 40 nucleotides of the transcript. Short reads are 
likely to be excluded from mapping by not passing the 11 nt length threshold or are lost during the 




Figure 4-2: Spliceosomes are stalled at the complex C stage by dominant negative rPrp16-G378A. (A) Spliceo-
some assembly on 3xMS2_UBC4_WT_short transcript in rPrp16-G378A supplemented splicing extract, fol-
lowed by glycerol cushion and amylose purification. (B) Spliceosome assembly on 3xMS2_UBC4_WT_long tran-
script in rPrp16-G378A supplemented splicing extract, followed by glycerol cushion and amylose purification. 
(A and B) RNA species are visualised by the Cy5-label on a 10 % denaturing PAGE: before splicing (0’) after 30 
min incubation (30’), top (top) and cushion (cu) after centrifugation through the glycerol cushion, flow-through 
(FT) and elution (E) of the amylose capture. The band with the fastest migration in (B) appearing at 30’ corre-
sponds to debranched lariat-intermediate. (A) and (B) were run side-by-side on the same gel but split for the 
figure, meaning the migration is directly comparable. For both splicing substrates, spliced RNA would migrate 
between pre-mRNA and intron-lariat intermediate on the 10 % denaturing PAGE. (C) This 10 % denaturing 
PAGE shows a comparison of splicing reactions of 3xMS2_UBC4_WT_short and 3xMS2_UBC4_AC_short in ab-
sence of the dominant negative rPrp16-G378A to confirm that the band indicated as intron-lariat intermediate 
in (A) corresponds to intron-lariat intermediate. Originally, the lanes were run on the gel in a different order 
than shown here.  
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Figure 4-3: Prp16-WT and Prp16-DN produce the same binding profile in in vitro spliceosome iCLIP. Crosslink 
events (-1 position of truncation) are presented as histograms aligned to the 3xMS2_UBC4_AC_short or 
3xMS2_UBC4_WT_short transcript as indicated in the enlarged parts. Exons are depicted in purple; the brA is 
marked with a *. Boxed regions are enlarged underneath, giving the nucleotide sequence, while highlighting 
the position of brA (bold A) and the exons (purple). The scale of the histograms is given in the left corner or as 
the y-axis. Read truncations accumulate between the brA and 3’SS. Further peaks locate to the 5’SS, +12 nt on 
the intron and to the brA. Reads mapped to the snRNAs are at background level and therefore not shown 
henceforth for Prp16 in vitro spliceosome iCLIP data (included in Appendix folder, session_3 and 5). 
 
4.1.2 Extension of the transcript on the second exon increases number of reads 
To increase the probability for reads to map, the length of the 25 nt long second exon of UBC4 was 
increased by 36 nt (named 3xMS2_UBC4_long). With a complete exon length of 61 nt, the required 
minimal 11 nt for unique mapping should be exceeded by far.  
Samples for in vitro spliceosome iCLIP were prepared as previously described for 
3xMS2_UBC4_short (Figure 4-2 B for spliceosome purification). 
The proportion of reads which map to the substrate-ome increased substantially (Appendix Figure 
8-2, Appendix folder session_6 and 7). The histogram height representing the number of truncation 
events increased up to 14-fold (Figure 4-4 compare dark cyan and red bars). The position and prom-
inence of the other sharp peaks remained unchanged.  
Overall, the binding profile for rPrp16-G378A gives histograms of lower intensity compared to 
Prp16-WT (Figure 4-3, Figure 4-4 and Figure 4-7). Since the proportion of reads mapping to the 
yeast genome, however, does not differ between the two proteins, rPrp16-G378A should not carry 
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pre-bound RNA from its purification into the iCLIP procedure but its crosslinking efficiency might 
simply vary (Appendix Figure 8-2). 
 
 
Figure 4-4: Increase of the transcript length increases the number of uniquely mapped reads on the sub-
strate-ome. Crosslink events (-1 position of truncation) are presented as histograms aligned to the transcript 
3xMS2_UBC4_AC_long or 3xMS2_UBC4_WT_long as indicated in the enlarged parts. Exons are highlighted in 
light purple; the position of the brA is marked with a *. The scale of the histograms is given in the left corner 
or as the y-axis. Boxed regions are enlarged underneath, showing the nucleotide sequence, the position of the 
brA (bold A), and the exons (purple). Reads accumulate between the brA and 3’SS. Further peaks locate to the 
5’SS, +12 nt on the intron and to the brA. Dark cyan histograms are derived from the transcript 
3xMS2_UBC4_long and compared in scale to the transcript 3xMS2_UBC4_short, which is presented in red 
(compare Figure 4-3).  
 
The first peak on the UBC4 transcript directly corresponds to the 5’SS and a second peak corre-
sponds to the brA (Figure 4-4). These two peaks also dominate the pattern of control samples (light 
cyan histograms). The peaks are likely derived from reverse transcription stopping at the intron-
lariat branch rather than at a Prp16-derived covalently liked peptide. When reverse transcription 
starts downstream of the branch but is not terminated by a crosslinked peptide of Prp16, the tran-
Prp16 binds around 15 nt downstream of the intron branch in order to remodel the catalytic core 69 
scriptase will be stopped in most cases by the obstacle caused from the additional 2'-5' phos-
phodiester bond at the brA. SuperScript III stops at this junction in 85 % of cases (Chen et al. 2018). 
When the RT is transcribing downstream of the 5’SS towards the junction, it is even less likely that 
the enzyme will continue upstream of the brA by crossing the 2’-5’ phosphodiester bond. The ter-
mination rate for SuperScript III was determined to be 99 % (Chen et al. 2018). Reads starting from 
upstream of the brA on the intron-lariat intermediate will therefore terminate at the 5’SS. The gen-
eration of these reads in unavoidable, since all RNA fragments which include the intron-lariat junc-
tion will expose two 3’-ends after RNase digestion and therefore offer a second starting point for 
reverse transcription. Further, in contrast to positions of genuine crosslink events, which are tran-
scribed by RT with an accuracy of > 90 %, a high rate of mutations is found here. The brA itself is 
identified as an adenine in only 62 % of reads and is read as cytosine in > 30 % of reads (Figure 4-5 
A, right). The nucleotide, which would be upstream of the 5’SS is identified as a mix of adenine, 
guanosine, and uridine (Figure 4-5 A, left for x|GU). The mutation rate leads to the conclusion that 
these two sharp peaks correspond to the 5’SS and brA, respectively. By monitoring terminations 
caused by lariat-junctions, (Chen et al. 2018) successfully predicts branch points in yeast introns by 
spliceosome profiling. Similarly, conventional SmB iCLIP performed under native conditions was 
shown to generate cDNA reads of intron-lariat splicing intermediates that allowed the prediction 
of branch points (Briese et al. 2018).  
 
Assuming the peak at the 5’SS is not a crosslink-site, it can be used as a reference point to compare 
the amount of signal in the region downstream of the brA between UV-irradiated and non-irradi-
ated samples. More truncation events are clearly acquired in the presence of UV (Figure 4-4, rows 
1-6 for experiments of this subchapter). I conclude that truncation events must have therefore been 
also induced by UV dependent protein crosslinks. Nevertheless, obtaining a similar binding pattern 
around the crosslink site in control samples is quite likely when a protein binds strongly to its target 
RNA. In the previous chapter, both Prp16-WT and mutant protein were shown to bind RNA after 
the stringent iCLIP procedure in the absence of UV irradiation (compare Figure 3-7 C). The bound 
RNA fragments, which have an average length of 30 nt (Appendix Figure 8-3), align close to the 
protein binding site and therefore generate a crosslink-like profile. Similar biases in iCLIP data de-
rived from inappropriate read length is discussed in (Haberman et al. 2017). 
Another strong peak is observed around position +12 nt in the intron (AG|UU, +10 to +13 nt). The 
hypothesis of an alternative splice site is weakened by the correct assignment of a guanine nucleo-
base just upstream in more than 90 % of the reads; the signal can most likely be considered as a 
genuine crosslink site. When comparing this crosslink site with the 5’SS as reference point, about 
three times less crosslinks are obtained for rPrp16-G378A on the 3xMS2_UBC4_WT transcript than 
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of Prp16 and rPrp16-G3678A on the 3xMS2_UBC4_AC transcript. To my knowledge, an interaction 
site for Prp16 at this position has not been reported yet. Since the sample subjected to in vitro 
spliceosome iCLIP contained spliceosomes before and at the first catalytic step of splicing purified 




Figure 4-5: Quantitative comparison of peaks at the 5’SS, brA, and the region downstream of the brA. (A) Nucle-
obases at the 5’SS (left) and the brA (right) are not read correctly by RT. At the 5’SS the position x|GU (wherein 
| indicates the splice site) was analysed. In the event of a non-spliced product a G and in the event of a contin-
uing read in the intron-lariat an A would follow. At the brA, the read accuracy for the branch point adenosine 
was analysed directly. Numbers include the experiments shown in Figure 4-4 (excluding ‘no_FLAGed_protein’ 
control) and are taken from all reads, including transversion reads, to be compared in a box plot. Black squares 
give the mean. (B) Data derived from UV-irradiated samples show a higher proportion of reads in the region 
downstream of the brA in comparison to at the 5’SS on UBC4 substrates. Scores are calculated as follows: the 
sum of truncation events of position 234 to 279 nt (corresponds to the region downstream of the brA) divided 
by the number of truncation events at position 162 (corresponds to the 5’SS). 
 
The remaining truncation events predict the Prp16 binding site to around +15 nt from the brA (Fig-
ure 4-3 and Figure 4-4). The region, in which these crosslinks locate to, spans at least 15 nucleotides; 
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a distance which is longer than one would expect for the occluded site of a DEAH-box helicase 
(Tauchert et al. 2017). Uridines have a higher tendency than other nucleotides to be crosslinked to 
protein by 254 nm UV light (Sugimoto et al. 2012), which might explain the more prominent peaks 
at uridine positions compared to other nucleotides in this area. As discussed earlier, a similar posi-
tion was found, when a photoreactive 4-thiouridine was introduced to the +18 position in UBC4 
(Semlow et al. 2016).  
Further, the area in which most crosslink events are mapped is consistent between the three tested 
conditions (Figure 4-3 and Figure 4-4). Neither the location of the mutant nor the WT protein is 
shifted by the mutation at the 3’SS.  Most likely, Prp16-WT protein would also crosslink at this exact 
position in the ‘natural’ complex C without interfering through a splice-site mutation induced block-
age. This finding is important as it determines the start location and is a first reference point for 
Prp16 time-resolved translocation experiments in the future.  
 
4.2 Debranching reduces truncation events at brA 
4.2.1 Dbr1 acts only on the branch in the absence of the spliceosome 
Debranching the intron-lariat intermediate before reverse transcription was considered as a possi-
bility to reduce peaks at the branched position. Both the human and yeast RNA lariat debranching 
enzyme (Dbr1) was shown to hydrolyse the 2'-5' phosphodiester bond of the intron-lariat interme-
diate, while leaving a 2’-hydroxyl group at the branch attachment site and a 5’-phosphate end at 
the 5’ SS (Ooi et al. 2001).  
 
 
Figure 4-6: Dbr1 debranches protein-free 2'-5'-phosphodiester-bond-linked lariats. The control shows 
pre-mRNA before splicing (lane C). After splicing, the reaction was either directly incubated with 0.8 µg Dbr1 
(lane E), or the RNA was first extracted and then incubated with the indicated amounts of Dbr1 (lanes: after 
deproteinization). Each single experiment was set up with 50 fmol Cy5-labelled pre-mRNA. 0.4 µg enzyme ef-
ficiently open the junction of 50 fmol RNA, which equals a concentration of 8 µg enzyme per pmol RNA. The 
three parts of the gel (C, E, after deproteinization) are derived from the same gel, on which they were originally 
run in a different order. 
 
In a first step, commercial human Dbr1 from recombinant source was tested for its debranching 
activity. The branched intron-lariat intermediate was generated through in vitro splicing reactions 
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with the 3xMS2_UBC4_AC_short transcript stalling splicing after the first catalytic step. Subse-
quently, the whole reaction was either incubated with Dbr1 (first condition) or the obtained RNA 
was deproteinised and purified before incubation with Dbr1 (second condition). In the first condi-
tion, the intron lariat intermediate is not affected by the debranching enzyme (Figure 4-6, lane E), 
indicating that the spliceosome hinders access of the substrate to the enzyme. As a result, the en-
zymatic debranching step cannot be inserted into the in vitro spliceosome iCLIP procedure before 
denaturation of the spliceosome (compare Figure 3-11 for the experimental pipeline). In the second 
condition, in which the RNA was isolated prior to treatment with Dbr1 (Chapman and Boeke 1991), 
the enzyme efficiently resolves the 2’-5’ phosphodiester bond at a concentration of 8 ng enzyme 
per pmol RNA (Figure 4-6). Urea, unfortunately, impaired the enzymatic activity even at low con-
centrations (tested by C. Norman), so that debranching with Dbr1 was introduced as the first step 
during FLAG capture in the in vitro spliceosome iCLIP procedure. Extensive, prior washing with the 
reaction buffer should ensure total removal of residual urea.  
Due to low RNA levels at this stage, the activity of Dbr1 cannot be monitored in in vitro spliceosome 
iCLIP. In addition, a possibility remains that Prp16, which crosslinks close to the brA, hinders sub-
strate accessibility for Dbr1 and thereby interferes with debranching.   
 
4.2.2 Dbr1 reduces truncation events at the brA 
To analyse the effect of Dbr1 on in vitro spliceosome iCLIP, both Prp16 and rPrp16-G378A contain-
ing spliceosomes assembled on 3xMS2_UBC4_AC substrate were subjected to the in vitro spliceo-
some iCLIP procedure including the additional debranching step during FLAG capture. The peak at 
the 5’SS is unlikely to disappear through debranching, as most truncation events will still happen at 
the natural end of the transcript.  
Treatment with Dbr1 reduced the prominence of the peak located to the brA by more than three-
fold when comparing to the height of the 5’SS peak (Figure 4-7, both Prp16-WT and Prp16-DN; 
Appendix folder, session_8). Similarly, the read coverage beyond the brA (upstream of the brA) 
increased in all experimental conditions through Dbr1 treatment, which supports that a number of 
intron-lariat junctions were successfully debranched during the in vitro spliceosome iCLIP proce-
dure (Figure 4-8).  
In principle, a complete elimination of the peak would be desirable. I am still working on optimising 
the conditions for the debranching enzyme. The debranching step could also be moved to a later 
stage in the protocol, when Prp16 is broken down to a small peptide at the attachment site. Further 
improvement of Dbr1 reaction conditions combined with the use of the 3xMS2_UBC4_long tran-
script, will hopefully lead to clearer results.  
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Figure 4-7: Dbr1 reduced the truncation events at the brA. Crosslink events (-1 position of truncation) are pre-
sented as histograms aligned to the transcript 3xMS2_UBC4_AC_short. Exons are highlighted in purple; the 
location of the brA is indicated with a *. The scale of the histograms is given in the left corner or as the y-axis. 
Boxed regions are enlarged underneath, showing the nucleotide sequence and the position of brA (bold A), 
and the exons (purple). Reads accumulate at similar positions with and without the debranching step. Dark 
cyan histograms are derived from in vitro spliceosome iCLIP preparation including the debranching step and 
compared to data without Dbr1 treatment Figure 4-3 (red) in scale. The total histogram height for the mutant 
protein was increased.  
 
 
Figure 4-8: Read coverage increases for the region upstream of the brA through Dbr1 treatment. Bars show the 
ratio between the coverage upstream and downstream of the brA. The coverage is defined as number of 
aligned reads per nucleotide in the respective region on the pre-mRNA substrate. Experiments depicted in 
Figure 4-3 (-Dbr1, grey) and Figure 4-7 (+Dbr1, cyan) were compared; all conditions show an increase in the 
coverage ratio, when Dbr1 treatment was included in the procedure.   
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4.3 The binding profile of Prp16 WT and mutant is identical on ACT1 
4.3.1 ACT1 can be used for in vitro spliceosome iCLIP sample preparation  
Up to this point, all in vitro spliceosome iCLIP data was generated from spliceosomes assembled on 
UBC4 transcript. UBC4 is popular in biochemical and structural studies of pre-mRNA splicing due to 
its high splicing efficiency and its short intronic sequence. As already shown for the length of the 
second exon, short stretches of RNA are not necessarily beneficial for crosslinking and sequencing 
approaches. The likeliness of one RNA molecule being both crosslinked to a protein peptide while 
being part of the lariat junction will decrease with longer distances between the recognition se-
quences (5’SS, brA, 3’SS).  
At the same time, general conclusions about Prp16 binding profile can only be gained through the 
comparison of different transcripts. As a second transcript, I have chosen ACT1, which codes for 
yeast actin, and is used throughout the literature for splicing studies both in vitro and in vivo 
(Domdey et al. 1984; Frank and Guthrie 1992; Tardiff and Rosbash 2006). The precise transcript used 
for in vitro spliceosome iCLIP carries three MS2 stem loops at the 5’-end, followed by 25 nt of the 
first exon, the intronic ACT1 sequence with 309 nt, and 164 nt of the second exon. All distances 




Figure 4-9: In vitro splicing of ACT1 transcripts. 3xMS2_ACT1_WT (left) and 3xMS2_ACT1_AC (right) produce 
mRNA and intron-lariat intermediate after 60 min, respectively. The Cy5-labelled RNA species were separated 
on a 7 % gel. 
 
Both 3xMS2_ACT1_WT and 3xMS2_ACT1_AC were generated and tested in in vitro splicing. To 
reach a similar splicing efficiency as for UBC4, the incubation time had to be doubled (Figure 4-9). 
In vitro iCLIP experiments were set up in the same way as carried out previously with UBC4. The 
amounts of rPrp16-G378A protein were as before, too. First, spliceosomes were assembled on 
3xMS2_ACT1_AC and purified via amylose capture of the MS2-tag (as for 3xMS2_UBC4_AC in Figure 
3-3). In a second step, the UV dose and RNase I levels were titrated to the same dose and a 20-
times higher amount of enzyme as before, respectively to obtain optimally crosslinked RNA-protein 
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complexes; suitable conditions were evaluated as before (shown for UBC4 in Figure 3-7). Enzymatic 
debranching was included during FLAG capture as described in chapter 4.2. 
 
4.3.2 Binding profiles for ACT1 show reduced background  
Mapping of the data to the ACT1 substrate shows that the overall histogram score is low compared 
to UBC4 (Figure 4-10, score 5; Appendix folder, session_9 and 10). On the other hand, the pattern 
between control samples and UV irradiated samples is more distinct for in vitro spliceosome iCLIP 
on the ACT1 transcript.  
Both peaks at the 5’SS and the brA correlate with incorrectly interpreted nucleobases indicating 
RNA-mediated truncation events once more (similar nucleobase distribution as in Figure 4-5 A). The 
peak at the brA is prominent, most likely debranching was not completely efficient. Most reads 
terminate at locations between the brA and the beginning of the second exon, which is consistent 
throughout the three conditions and also in good agreement with the data derived from UBC4 sub-
strate. It is necessary to perform replicates of the experiment while increasing the number of 
uniquely mapped reads to be more confident about the crosslinking sites.  
 
 
Figure 4-10: Prp16-WT and Prp16-G378A produce the same binding profile on ACT1 transcript. Crosslink events 
(-1 position of truncation) are presented as histograms aligned to the transcript 3xMS2_ACT1_AC or 
3xMS2_ACT1_WT as indicated in the enlarged parts. Exons are highlighted in navy; the location for the brA is 
indicated with a *. The scale of the histograms is given in the left corner or as the y-axis. Boxed regions are 
enlarged underneath, showing the nucleotide sequence and the position of brA (bold A), and the exons (navy). 
Read truncations accumulate between the brA and 3’SS (around +15 nt from the brA). Sharp peaks locate to 
the brA. 
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4.4 Prp16 binds similar locations on UBC4 and ACT1 
Taken together, this chapter has demonstrated how several issues arising specifically for Prp16 
crosslinking and sequencing in the context of a first catalytic step spliceosome can impede data 
interpretation and how they can be resolved.  
First, in vitro spliceosome iCLIP is restricted by the RNA length downstream of the crosslink site. By 
increasing the length of the second exon in the UBC4 pre-mRNA, which doubled the distance from 
the major crosslink site to the 3’-end, the number of mapped truncation events could be increased 
by up to 14-fold.  
Second, two sharp peaks in the in vitro spliceosome iCLIP data on the UBC4 transcript could be 
interpreted as RNA-mediated truncation events. The 5’SS showed a strong peak throughout the 
experiments on UBC4, even in the absence of a pulldown protein. Similarly, many truncation events 
repeatedly mapped to the brA which could be reduced by including an enzymatic debranching step 
in the in vitro spliceosome iCLIP procedure.  
Overall, the same binding profile is produced for Prp16 in complex C from three different condi-
tions: (1) Prp16-WT on AC substrate and the ATPase-deficient helicase Prp16-G378A on both (2) AC 
and (3) WT substrate. Since the mutant protein is non-functional in splicing and has a residual 
ATPase activity of only 2 % (Schneider, Hotz, and Schwer 2002), which should hinder its helicase 
activity, the binding location in the spliceosomes stalled at complex C should correspond to the 
starting point for Prp16 translocation before remodelling.  
In vitro spliceosome iCLIP data derived from ACT1 transcript made it possible to draw sequence- 
and substrate-independent conclusions or Prp16 binding. Most truncation events accumulate 
around +15 nt from the branch on the intron of UBC4. Similarly, the major interaction site for Prp16 
was found to be about 15 nucleotides downstream of the brA on ACT1 (Figure 4-11). This suggests 
that Prp16’s binding site on the transcript in complex C is determined through a molecular ruler 
mechanism. An obvious measure could be the spliceosome itself providing the binding surface for 
Prp16 in exactly this distance as implied by the three-dimensional structure of the particle (compare 
Figure 4-1). Like other members of the DEAH-box helicase family, Prp16 is expected to act in a se-
quence independent fashion and find its target for instance through protein-protein interactions 
and the spliceosome architecture. To prove this hypothesis, the distance between the brA and the 
determined binding site could be artificially increased in either UBC4 or ACT1 and analysed by in 
vitro spliceosome iCLIP. 
The determination of Prp16’s position in complex C supports the model of Prp16 acting from a 
distance and is the first essential step towards time-resolved in vitro spliceosome iCLIP experiments 
in the future. CryoEM studies have confirmed that the spliceosome core stays almost unchanged 
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through the C to C* transformation supporting the model that Prp16 will act from a distance while 
mediating this remodelling event.  
 
 
Figure 4-11: Comparison for Prp16 in vitro spliceosome iCLIP on UBC4 and ACT1. Binding profiles of Prp16 on 
the transcript 3xMS2_UBC4_long (first three lanes) and on the transcript 3xMS2_ACT1 (second three lanes) 
derived from Prp16-WT on AC substrate, Prp16-G378A on AC, and Prp16-G378A on WT substrate (indicated in 
the enlarged parts). Control lanes are depicted in Figure 4-4 and Figure 4-10. Exons are highlighted as bars 
(purple for 3xMS2_UBC4_long and navy for 3xMS2_ACT1), while the location of the brA is marked with a *. 
The scale of the histograms is given in the left corner. The boxed regions are enlarged at the bottom (not to 
scale) and aligned to the brA. The profiles derived from UBC4 (dark cyan) and ACT1 (black boxes) are overlaid 
for each condition. Nucleotides are counted from the brA (bold A) and every 10th is numbered; the second 

















5 Setting up in vitro spliceosome iCLIP to investigate 
additional spliceosomal helicases 
 
In chapter 3, I describe the development and validation of the method ‘in vitro spliceosome iCLIP’. 
This chapter describes pilot experiments how the method can be modified to investigate additional 
spliceosomal helicases.  
Whenever a novel target protein is analysed, the protein-specific steps in the iCLIP protocol have 
to be adjusted anew. In addition, the spliceosomal complex in which the helicase acts has to be 
stalled specifically and purified to provide a controllable system. Obtaining a homogeneous and 
tight stall is especially important if in vitro spliceosomal iCLIP will be employed to observe time-
resolved helicase activity. The subchapters 5.3 and 5.4 discuss a possible set-up to monitor the 
translocation of Brr2 and Prp16 on their target RNA over time and give a first impression of its 
feasibility.  
 
Prp22 helicase is essential for mRNA release after ligation (Schwer and Gross 1998). Prp22 and 
Prp16, which both belong to the DEAH-box helicase family, are structurally very similar. In spliceo-
somal complex C, C* and P, they occupy the same position at the periphery of the spliceosome in a 
mutually exclusive fashion (Galej et al. 2016; Fica et al. 2017; Wilkinson et al. 2017). Prp22 was pro-
posed to act from a distance pulling the ligated exons out of the spliceosomal core (Semlow et al. 
2016), where the mRNA is held by base-pairing with U5 snRNA (Newman and Norman 1992; 
Sontheimer and Steitz 1993; Aronova et al. 2007) (compare Figure 5-1 B). The exact binding site for 
Prp22 in complex C* could not be precisely determined by cryoEM, as the density for the RNA sub-
strate emerging from the core towards Prp22 is very weak (Fica et al. 2017) (Figure 5-1 A). In com-
plex P, however, the local resolution is sufficient to locate the occluded site of Prp22 to approxi-
mately nucleotides 14 to 21 on the second exon of UBC4 (Wilkinson et al. 2017) (Figure 5-1 B). The 
location is in agreement with the position found by 4-thiouridine crosslinking when mRNA release 
was blocked with a dominant negative Prp22 mutant (Schwer 2008). The first rearrangement me-
diated by Prp22, which requires additional recruitment of the second step factors Slu7 and Prp18, 
leads to the formation of the mRNA and was predicted to be ATP-independent (Schwer and Gross 
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1998). To release the mRNA from the spliceosome, however, Prp22 requires ATP (Schwer and Gross 
1998; Wagner et al. 1998).  
My intention to determine the binding site for Prp22 on its RNA target arose before the structure 
of complex P was solved. Nevertheless, a clear determination of its binding site in a stalled complex 
will become essential, when Prp22 translocation will eventually be analysed by time-resolved in 
vitro spliceosome iCLIP. The strategy which revealed the binding profile for Prp16 in complex C 
(compare chapter 3.6), can equally be applied to Prp22 stalled in either complex C* or P.  
 
 
Figure 5-1: Structures of spliceosomal complexes highlighting helicase position and target. (A) In spliceosomal 
complex C*, Prp22 (purple) locates at the periphery of the complex, whereas the catalytic core is in the centre 
of the particle (Fica et al. 2017). The RNA substrate (exon 1, intron-lariat-exon2-intermediate) and the snRNAs 
are highlighted. (B) Spliceosomal complex P shows Prp22 at a similar position at the periphery of the complex 
(Wilkinson et al. 2017). The ligated exons, the intron and the snRNAs are highlighted. (C) Spliceosomal com-
plex B shows Brr2 helicase (light cyan) loaded onto U4 snRNA which is base-paired with U6 snRNA (Hahn et al. 
2012; Nguyen et al. 2016; Plaschka, Lin, and Nagai 2017). Parts of the pre-mRNA and the snRNAs are high-
lighted. (A-C) Top panels: overview of the particle; Bottom panels: zoom-in of the helicase region and the target 
RNA; dashed lines represent some connected RNA parts which are disordered in the structure.  
 
The Ski2-like helicase Brr2 is already pre-loaded onto its target RNA, U4 snRNA, when it joins the 
spliceosome. Brr2 mediates the complex B to Bact transition by unwinding the U4/U6 snRNA duplex 
(Laggerbauer, Achsel, and Luhrmann 1998; Raghunathan and Guthrie 1998; Kim and Rossi 1999) 
Biochemical analysis and structural approaches (Nielsen and Staley 2012; Plaschka, Lin, and Nagai 
2017) have mapped this pre-unwinding location of Brr2 to about nucleotides 70–90 of U4 snRNA 
(Figure 5-1 C). To date, unwinding of Brr2 was characterised in minimal recombinant systems or in 
tri-snRNP, neither of which reflect the natural context of the spliceosome (Small et al. 2006; 
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Mozaffari-Jovin et al. 2013; Henning et al. 2017). Brr2 was also proposed to be involved in the sec-
ond step of splicing but its exact role remains unclear (Hahn et al. 2012). Following the path of Brr2 
in a time-resolved manner would be an excellent approach to understand in which order specific 
RNA structures are actively remodelled by Brr2. Other structures might passively adopt a new con-
formation as a result of Brr2 helicase activity elsewhere in the complex. The complex B to Bact tran-
sition is a major rearrangement in which at least 24 proteins and the U4 snRNA are released while 
22 other proteins join the complex (Plaschka, Lin, and Nagai 2017; Will and Luhrmann 2011). The 
factors required for the transition can be provided directly from splicing extract, avoiding the need 
for recombinant protein production. To make this transition targetable for in vitro spliceosome 
iCLIP, the protocol developed in chapter 3 has to be modified. Chapter 5.3 gives a first impression 
how Brr2 can be crosslinked to RNA in spliceosomal complex B and how the complex can be chased 
towards the catalytic stages.   
 
Following the path of Prp16 on the intron-lariat intermediate requires a quite different strategy. A 
pre-steady state kinetic iCLIP experiment would be suitable to describe the translocation of Prp16 
along its RNA target. Prp16-depleted spliceosomes were shown before to stall at the complex C 
stage and can be advanced to the next stage by addition of rPrp16 and ATP. This set-up was used 
for single molecule experiments that provided insights into the RNA substrate conformation 
(Semlow et al. 2016) and can serve as a starting point for time-resolved in vitro spliceosome iCLIP 
for Prp16. In chapter 5.4 preliminary experiments were designed to deplete Prp16 from splicing 
extract and to determine the RNA binding ability of Prp16 under different conditions. 
 
5.1 In vitro spliceosome iCLIP setup for Prp22 in C* complex  
5.1.1 Purification of spliceosomal complex C*  
Spliceosomal complex C* corresponds to the state after Prp16 remodelling but before exon ligation. 
Mutation of the pre-mRNA substrate at the 3’SS prevents exon ligation (Figure 5-2 A). To set up in 
vitro spliceosome iCLIP, a deoxynucleotide was introduced into 3xMS2_UBC4_short to replace the 
G| (where | indicates the 3’SS); the same substitution was used to solve the structure of complex C* 
(Fica et al. 2017). The following |AG was substituted with an |AC to block use of this cryptic splice 
site. Similar to blocking the second step of splicing with an AC|AC substitution for complex C, this 
stall can be combined with either WT or dominant negative Prp22. A WT substrate combined with 
a dominant negative version of Prp22, however, does not lead to complex C*. The spliceosome 
would efficiently catalyse the ligation step but fail to release the ligated exons, yielding spliceoso-
mal complex P (Wilkinson et al. 2017). This method is used to obtain complex P in chapter 5.2. 
Firstly, a yeast strain expressing Prp22-3xFLAG was produced by tagging the genomic copy of PRP22. 
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We also produced recombinant Prp22-K512A-3xFLAG in yeast and purified it in two steps via CBP- 
and polyhistidine-tags (7.3.1 Materials and methods, Figure 5-2 B). The lysine is part of helicase 
motif I (Walker A) where the triad GKT forms the phosphate binding loop which normally coordi-
nates the nucleotide. The dominant negative Prp22-K512A protein was shown to have a highly re-




Figure 5-2: Purification of spliceosomal complex C*. (A) Substitution with deoxyguanosine at the 3’SS leads to 
the stall of complex C* which can either be combined with Prp22-WT or a dominant negative version of Prp22 
(here Prp22-K512A). For visualisation during the purification procedure, the pre-mRNA substrate is labelled 
with Cy5 (indicated with a blue *). (B) Western blot probing with anti-FLAG antibody for endogenous 
Prp22-3xFLAG in whole yeast extract (left) or for rPrp22-K512A-3xFLAG overexpressed in yeast extract (right: 
cells were induced with galactose and harvested at a similar OD compared to the cells used for the left lane). 
A 10-fold excess of total protein was loaded on the left. (C) Purification overview of the splicing substrate 
separated on a 10 % denaturing PAGE. After splicing, purification via amylose capture of the substrate produces 
a mixture of spliceosomes of the pre-catalytic and first catalytic step. The faint band which migrates with a 
mobility similar to the spliced RNA is most likely a product spliced at a cryptic splice site (see grey spliced RNA 
indication on the left of the gel). Lanes are as follows in both (C) and (D): before splicing (0’, only in (C)) after 
30 min splicing reaction (30’, lane input is a 5-fold dilution), top (top) and bottom (cu) of the glycerol cushion, 
flow-through (FT) as well as ATP incubation (ATP) on amylose and elution (E) thereof, flow-through (FT) and 
elution (E) of the FLAG capture. (D) Western blot probing for Prp22 throughout the spliceosome preparation 
followed by FLAG capture, either derived from splicing extract expressing endogenous Prp22-3xFLAG (left) or 
splicing extract supplemented with rPrp22-K512A-3xFLAG (right). The image contains two separately run west-
ern blots (left and right). 
82 
After assembly in an in vitro splicing reaction, spliceosomes were firstly captured via the RNA sub-
strate on amylose beads using the MS2-MBP system. To stimulate the rearrangement of spliceo-
somes from complex C to the C* stage, which is Prp16 dependent, an additional incubation with 
ATP and magnesium was introduced during the capture as in (Fica et al. 2017). Despite Prp16 being 
bound to the spliceosome, Prp22 can presumably be loosely associated with the complex. Some 
Prp22, however, is lost during this incubation step (Figure 5-2 D, lane 5 and 13). A mixture of spliceo-
somes bound to pre-mRNA and intron-lariat-intermediate is eluted from amylose beads, some of 
which complex C*, as indicated by the presence of Prp22 (Figure 5-2 C lane 7 and 14, and Figure 
5-2 D lane 5 and 13). A substantial amount of Prp22 can be bound under native conditions in the 
subsequent FLAG capture (compare lane 6/14, 7/15 with 8/16 in Figure 5-2 D for left/right panel). 
In the final in vitro spliceosome iCLIP preparation prior denaturation with 6 M urea was imple-
mented as before. Although the amount of rPrp22-G512A added to the splicing extract far exceeds 
the WT levels, much more is lost during the whole purification procedure (Figure 5-2 D compare 
left and right panel). Despite this excess, even lower levels are eluted in a similar amount of spliceo-
somes (compare Figure 5-2 C lane 7/14  and  Figure 5-2 D, lane 6/14), implying a decreased RNA 
binding ability of the dominant negative protein. The input concentration of rPrp22-K512A was ad-
justed to reach the same level as WT protein in purified spliceosomes. The final concentration in 
the extract thus reached a similar level as rPrp16-G378A for the complex C preparation (compare 
chapter 3).  
 
5.1.2 Crosslinking and cDNA preparation suggests a reduced RNA binding ability for 
the dominant negative mutant of Prp22 
After successful purification of spliceosomal complex C* and FLAG capture of Prp22, all further 
steps of the in vitro spliceosome iCLIP procedure can be performed according to the iCLIP protocol 
developed in chapter 3. Firstly, crosslinking of Prp22 to RNA had to be tested, and the RNase I 
concentration had to be optimised to produce suitable fragments for NGS. A dose of 312 x 
100 µJ/cm2 UV light is high enough to crosslink most protein-RNA complexes without over cross-
linking the complex, which is indicated through a saturated radioactive signal (Figure 5-3). Compar-
ing the different amounts of RNase I, digestion with 5 units produces the strongest signal fading 
from the protein size towards higher molecular weight species. A lower concentration would likely 
produce longer RNA fragments; however, the higher concentration is required to release an addi-
tional protein which crosslinks to the same RNA target (Figure 5-3, compare highlighted, lower mo-
lecular weight band). A larger amount of dominant negative rPrp22-K512A crosslinks to a lower 
amount of RNA than in the case of the WT protein, indicating that the mutant protein binds RNA 
less tightly (Figure 5-3 compare radioactive blot (top) to western blot (bottom)). This observation 
Setting up in vitro spliceosome iCLIP to investigate additional spliceosomal helicases 83 
is unexpected as the ATPase deficient Prp16-G378A binds RNA more tightly than the WT protein 




Figure 5-3: Prp22-WT binds RNA more tightly than rPrp22-K512A. Parallel fine-tuning of UV irradiation and 
RNase I digestion. Purified spliceosomal complex C* was irradiated with 156, 312, and 625 x 100 µJ/cm2 UV 
light, followed by denaturation. The RNA was fragmented with 5, 0.5, and 0.05 units RNase I during FLAG cap-
ture. Subsequent γ-33P-ATP radiolabelling allowed visualisation of bound RNA after SDS-PAGE separation and 
transfer onto nitrocellulose (top). The data presented derived from spliceosomes containing endogenous 
Prp22-3xFLAG-His (left) or rPrp22-3xFLAG-His (right), the highlighted lanes show the optimal condition which 
produces RNA-protein species from ~130 kDa upwards. The box at a lower molecular weight (~40-50 kDa) 
marks an additional crosslinked protein-RNA complex which is released at higher RNase concentrations. The 
left and right part of the image are derived from separate blots and were subsequently probed with anti-FLAG 
antibody to visualise and compare the amounts of Prp22 and rPrp22-K512A (bottom).  
 
The optimised UV and RNase conditions were used to prepare cDNA libraries for both Prp22-WT 
and rPrp22-K512A in complex C*. cDNA amplification resulted repeatedly in short fragments on the 
TBE gel (data not shown). Regarding the sequencing data, hardly any reads aligned to the substrate-
ome or the yeast genome (Appendix folder, session_11).  
Prp22 proposed binding site included nucleotide 17 of the second exon in the ACT1 transcript, 
which was determined by 4-thiouridine labelled RNA crosslinking in the context of a dominant neg-
ative Prp22 mutant protein (Schwer 2008). Assuming Prp22 binds at a similar location on the second 
exon of UBC4 (here 25 nt long) of the purified complex C* in this work, less than 8 nucleotides 
would extend from the occluded site towards the 3’-end of the transcript. This extremely short 
distance could be the reason for the short cDNA fragments which are almost impossible to separate 
from primer- and adapter artefacts during gel purification. Given that a minimum length of 11 nt is 
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required for unique mapping in the bioinformatic pipeline, these experiments must be repeated 
with RNA substrates having a more extended second exon.  
 
5.2 In vitro spliceosome iCLIP setup for Prp22 in complex P 
In spliceosomal complex P, the intron-lariat is excised and the exons are ligated, while both of the 
products are still bound by the complex. To allow exon ligation, the WT version of UBC4_short is 
used during the splicing reaction for the in vitro spliceosome iCLIP procedure. Supplying dominant 
negative Prp22 stalls splicing at complex P (Figure 5-4 A). The recombinant protein 
rPrp22-K512A-3xFLAG, which was produced to locate Prp22 in complex C*, was used here, too. The 
ATPase-deficient mutant is incapable of removing the ligated exons efficiently and therefore hin-
ders the progression towards ILS.  
Using the previously shown purification strategy involving capture via the RNA substrate leads to a 
mixture of spliceosomal complexes predominated by complex C/C*. (Wilkinson et al. 2017) opti-
mised the strategy by including specific antisense-DNA directed RNase H digestion targeting an un-
docked second exon when using UBC4_short_3xMS2 as splicing substrate. Precatalytic spliceo-
somes containing pre-mRNA and spliceosomes of the first catalytic step are ablated by this diges-
tion, which is indicated by the absence of the pre-mRNA after incubation with the antisense oligo-
nucleotide (Figure 5-4 B, compare lane 2 and 3). After amylose elution (lane 7), a mix of spliceoso-
mal complex P, fragments of the RNase H digestion and possibly some free mRNA, released by re-
sidual activity of Prp22-K512A, are eluted. In in vitro spliceosome iCLIP, subsequent FLAG capture 
on Prp22-K512A ensures all data derives solely from complex P. 
 
 
Figure 5-4: Purification of spliceosomal complex P. (A) The dominant negative rPrp22-K512A stalls the spliceo-
some at the complex P stage when assembled on WT pre-mRNA substrate, the yellow * indicates a fluorescein 
label. (B) RNA species are visualised by the 3’-fluorescein-label on a 10 % denaturing PAGE during complex P 
preparation. After 30 min incubation mRNA accumulates (0’ and 30’). Incubation with the antisense oligonu-
cleotide for endogenous RNase H digestion leads to the reduction of pre-mRNA species (lane 3). Spliceosomes 
bound to mRNA are rather found in the cushion (lane 5) than the top (lane 4) fraction after centrifugation 
through the glycerol cushion. The eluate (lane 7) of the amylose capture contains complexes bound to mRNA 
and fragments of the RNase H digest, whilst the flow-through (lane 6) is very clean. Purification of spliceosomal 
complex P essentially followed the protocol in (Wilkinson et al. 2017) with the exception of stalling with the 
dominant negative mutant rPrp22-K512A instead of rPrp22- S635A.  
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The optimal UV dose and RNase I amount was titrated to 312 x 100 µJ/cm2 and 0.5 units, respec-
tively (Figure 5-3 shows and explains the titration in the context of complex C*). In contrast to the 
observation in complex C*, higher RNase I concentrations did not release co-crosslinking proteins. 
To retain longer RNA fragments, the lower concentration was adopted. 
cDNA libraries were produced according to the in vitro spliceosome iCLIP protocol described in 
chapter 3. Data from the short CLIP protocol resulted in a binding profile independent of UV irradi-
ation, further highlighting the lack of stringency during the short procedure. Most truncations ac-
cumulate on the second exon between nucleotides 8 to 26 (Appendix folder, session_12; read cov-




Figure 5-5: Mapping of Prp22 in vitro spliceosome iCLIP data to the substrate-ome for spliceosomal complex P. 
First three lines: in vitro spliceosome iCLIP crosslinking data. Signal accumulates on the transcript. Both non-
UV and irradiated samples accumulate truncations around nucleotide 12 and 41 of the second exon with a 
different distribution pattern. Further four lines: short-iCLIP experiments showing the coverage (reads/nucle-
obase) and some representative cDNA reads (grey horizontal bars with arrow head) for the indicated condi-
tions that are derived from spliced RNA. The blue line between the grey bars implies that reads are spanning 
splice junctions. The black line marks a deletion in the mapped read. The coverage of short-iCLIP experiments 
is depicted here, as the coverage of the SDS-PAGE derived data (first three lines) was very low. 
 
The method including separation by SDS-PAGE did not produce many uniquely mapped reads (Fig-
ure 5-5, first three lines, score 8; Appendix folder session_13). Since the used transcript is extended 
by ~100 nt through the MS2 stem loops at the 3-end here, read loss due to a length restriction can 
be excluded. Most reads map to the RNA transcript, with an accumulation of truncations between 
position 12 and 41 of the second exon (Figure 5-5, first three lines). Despite the different pattern 
derived from UV and non-UV irradiated samples, the difference in signal to background is too low 
to draw firm conclusions. Most aligned reads which span the length of the ligated exons, exclude 
the intronic sequence indicating homogenous sample preparation of complex P (Figure 5-5, last 
four lanes, short CLIP experiment). This experiment has to be optimised and repeated until a clean 
background signal will allow meaningful interpretation.  
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5.3 Towards time-resolved in vitro spliceosome iCLIP for Brr2 starting 
with complex B 
5.3.1 Purification of spliceosomal complex B 
Brr2 in vitro spliceosome iCLIP was initiated with the intention to follow helicase translocation dur-
ing U4/U6 snRNA unwinding, starting from Brr2’s pre-loaded position on U4 snRNA in complex B.  
 
 
Figure 5-6: Purification and crosslinking of complex B. (A) Limiting ATP amounts stall spliceosome assembly at 
the complex B stage during in vitro splicing. For visualisation during the purification procedure, the pre-mRNA 
substrate is labelled with Cy5 (indicated with a blue *). (B) Time course for splicing reactions with no added 
ATP (left), 50 µM ATP (middle), and 2 mM ATP (right) separated on a 10 % denaturing PAGE. Splicing extract 
shows strong activity under normal splicing conditions with 2 mM ATP where about half the pre-mRNA is pro-
cessed into mRNA after 20 min. Lowering the ATP concentration to 50 µM in the splicing reaction stalls the 
reaction as efficiently before the first catalytic step as performing splicing in the absence of ATP (compare 50 
µM ATP and - ATP). (C) 10 % denaturing PAGE shows RNA species during complex B purification before the 
splicing reaction (0’), after the incubation under limiting ATP concentrations (45’), top (top) and bottom (cu) 
of the glycerol cushion, as well as flow-through and elution of the amylose capture. The band appearing after 
45 min below pre-mRNA on the 10 % gel, does not correspond to mRNA or intron-lariat-intermediate, and only 
appears when the reaction is performed in an in vitro spliceosome iCLIP reaction scale with MS2-MBP. (D) Fine-
adjusting of UV dose and RNase I. The splicing reaction was irradiated with 156, 312 or 625 x 100 µJ/cm2 UV 
light as indicated. Glycerol gradient purification and amylose capture were performed before FLAG capture, 
when the RNA was fragmented by 50, 5, 0.5 or 0.05 units RNase I as indicated by the decreasing triangle. 
Radiolabelling with γ-33P-ATP allowed visualisation of RNA after separating the complexes on SDS-PAGE and 
transfer onto nitrocellulose.  
 
In a first step, a yeast strain was generated introducing the 3xFLAG-polyhistidine-tag at the C-ter-
minus of endogenous Brr2. As described in the literature (Tarn, Lee, and Cheng 1993; Chan et al. 
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2003) limiting ATP concentration to 50 µM stalls a splicing reaction at the complex B conformation. 
This strategy was successfully used to purify spliceosomal complex B for structural analysis 
(Plaschka, Lin, and Nagai 2017), and will be employed to generate complex B for in vitro spliceosome 
iCLIP, too (Figure 5-6 A).  
Splicing extract derived from Brr2-3xFLAG-His8 cells was extensively dialysed to remove most ATP. 
I tested three additional techniques to remove residual ATP, which all showed the desired effect: 
(1) prior incubation of the extract with 2 mM glucose to deplete ATP as in (Abovich, Liao, and 
Rosbash 1994), (2) buffer exchange of the extract via G25 column removing small molecules includ-
ing ATP, and (3) performing the splicing reaction additionally under limiting magnesium concentra-
tions of 300 µM (Bertram et al. 2017) (data not shown). Finally, I implemented pre-incubation with 
glucose into my protocol for complex B preparation. Typical activity under usual splicing conditions 
was observed, whereas the reaction was arrested before the first catalytic step under limited ATP 
concentrations (Figure 5-6 B, compare 2 mM and 50 µM ATP). Subsequent purification via glycerol 
gradient and amylose capture produced a mostly homogeneous sample (Figure 5-6 C, lane 6).  
 
5.3.2 Brr2 can be crosslinked to RNA under low ATP conditions in splicing extract 
Brr2 is pre-loaded onto U4 snRNA in complex B (Plaschka, Lin, and Nagai 2017), and is then activated 
to unwind the U4/U6 snRNA duplex by an unknown signal, which in turn will result in a major rear-
rangement and exchange of proteins to produce spliceosomal complex Bact. To observe Brr2 trans-
location in the most controllable and also most natural format, spliceosomes shall be chased and 
UV-irradiated in extract for time-resolved in vitro spliceosome iCLIP. Thus, all required components 
for remodelling such as the extended NTR/NTC as well as unknown factors will be provided by the 
extract. 
Therefore, after assembly of spliceosomal complex B at 50 µM ATP, the extract was irradiated to 
compare different UV doses. Following purification by glycerol gradient and amylose capture, the 
crosslinked complex was subjected to the iCLIP procedure including denaturation by urea, FLAG 
capture, and finding the right concentration of RNase I for fragmentation. Optimal conditions, in 
which RNA fragmentation seemed to give the desired pattern, are achieved by irradiation with 312 
x 100 µJ/cm2 UV light and a condition between 5 and 0.5 units RNase I (Figure 5-6). Additional ex-
periments to optimise the RNase I concentration further did not give a clearer indication for optimal 
amounts.  
Therefore, cDNA libraries were produced from both conditions to assess the data quality at the 
start point of Brr2 unwinding. The experimental set-up used is comparable to the one used later to 
follow remodelling but slightly shorter. Unfortunately, not many reads could be mapped at all from 
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this experiment to the substrate-ome and reads which locate to the yeast genome seem to termi-
nate randomly scattered (Appendix folder, session_14).  
 
5.3.3 Purified complex B can be chased to later stage spliceosomes in splicing extract  
To provide controlled conditions for a chase the following was considered: complex B shall be pu-
rified from extract containing the 3xFLAG-tagged Brr2 and then be transferred to a different splicing 
extract which provides additional factors required for the progression of the splicing reaction while 
inhibiting the exchange of snRNPs and helicases.  
Having a FLAG-tagged version of Brr2 only in the first extract ensures that iCLIP data is solely derived 
from Brr2 of the pre-assembled complex B. Treatment of splicing extract with micrococcal nuclease 
was shown to prevent splicing by degrading snRNAs (Cheng and Abelson 1986; Yeh et al. 2011) and 
can therefore be included to prevent snRNP exchange in the second splicing reaction. 
 
 
Figure 5-7: Complex B can be chased in micrococcal nuclease treated extract. (A) Splicing extract was treated 
with 5, 10, or 20 units nuclease per 1 µL splicing extract in the presence of 2 mM CaCl2 at 30 °C. Lanes 2, 4 and 
6 (digest) contained RNA before the enzymatic reaction. For lanes 3, 5, and 7 (inactivation), the extract was 
treated with the nuclease, inactivated with 8 mM EGTA and then incubated with RNA to test for residual nu-
clease activity. Likewise, treated extract was subjected to a time course of a splicing reaction to screen for 
efficient removal of splicing activity (lanes 8-19). Lanes 8-10 show a control time course without nuclease 
treatment. Parts of this image are derived from separate gels. (B) Spliceosomal complex B was assembled un-
der 50 µM ATP for 45 min, applied to a glycerol cushion, followed by amylose capture. The amylose eluate was 
subjected to a further splicing reaction containing either 50 µM (no timepoints taken) or 2 mM ATP (lanes 7-
11). The splicing extract of the second reaction was pre-treated with micrococcal nuclease. Both conditions 
were irradiated with 312 x 100 µJ/cm2 UV light (lane 12 for 2 mM ATP; lane 15 for 50 µM ATP) and applied to 
another glycerol gradient (lanes 13/14 and 16/17). The denaturing 10 % PAGE shows the RNA-species by 
Cy5-label.  
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Micrococcal nuclease requires Ca2+ for its activity and can be inactivated by the chelating agent 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA). Complete inhibition of 
splicing activity while preventing digestion of added RNA after EGTA inactivation is a measure to 
find optimal conditions. Full digestion of the RNA amount used for an in vitro splicing reaction (1.5 
fmol / 1 µL extract) was obtained with 5 units nuclease per 1 µL splicing extract supplemented with 
2 mM Ca2+ (Figure 5-7 A lane 2). A concentration of 8 mM EGTA was required to block the activity 
of the nuclease completely (final concentration shown in Figure 5-7 A inactivation). A concentration 
of 20 units/(µL extract) is needed to block the splicing activity, meaning extract treated in this way 
will be unable to provide intact snRNPs (lanes 17-19).  
In a second step, chasing of purified spliceosomal complex B was tested in the nuclease-treated 
extract. The first purification under limiting ATP concentrations produced spliceosomal complexes 
mainly bound to pre-mRNA as expected for complex B (Figure 5-7 B, lane 6). A second splicing re-
action set up with the purified spliceosomes and micrococcal nuclease-treated extract shows the 
formation of mRNA after 10 min incubation under standard splicing conditions (2 mM ATP) (Figure 
5-7 B, lane 9). After 45 min about a quarter of pre-mRNA is turned into mRNA (lane 11) indicating 
that complex B can be chased to later spliceosomal complexes under these conditions.  
A control experiment was performed with limiting ATP concentrations (50 µM ATP) during the sec-
ond splicing reaction. Assembled spliceosomes obtained from both conditions were crosslinked 
with the dose determined in the previous subchapter 5.3.2, and then applied to another glycerol 
cushion and denatured by 2 M urea before FLAG capture to separate Brr2-crosslinked species. After 
the iCLIP specific steps and visualization by radioactive RNA labelling, both conditions showed 
strong background lacking the specific signal for Brr2-RNA complexes despite giving a clear signal 
for Brr2 protein in western blot (data not shown).  
The high background can be explained as crude extract is loaded onto FLAG beads and denatured 
with a lower concentration of urea compared to the previously described in vitro spliceosome iCLIP 
method (chapter 3). Increasing urea to 6 M followed by dialysis to allow FLAG capture was no im-
provement. In a different format, complex B was retained on the amylose beads during the second 
splicing reaction aiming to get a cleaner result by applying more purified components onto the FLAG 
beads. However, the rearrangement of complex B to later spliceosomal complexes was massively 
hindered on beads: hardly any mRNA was produced during the chase (data not shown).  
 
Successful generation of crosslinked Brr2-RNA species by irradiation of a splicing reaction implies 
crosslinking should have been successful in these conditions, too and the signal might simply be 
obscured by non-specifically captured RNA (compare previous chapter 5.3.2 and Figure 5-6 D). For 
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future experiments, the MS2 binding protein will be coupled to an additional tag to allow two sub-
sequent steps of capture on the RNA substrate, thereby avoiding the need to load crude extract 
onto FLAG beads.  
In summary, chasing spliceosomal complex B towards the catalytic stages in inactivated extract 
while crosslinking Brr2 seems feasible. Finding conditions providing a suitable time scale to allow 
time resolved crosslinking, however, will be another challenging task. 
 
5.4 Chasing Prp16 in C complex  
5.4.1 Prp16 can be depleted from splicing extract by its epitope tag 
Previously, Prp16-mediated transition of spliceosomes at the complex C state was observed by FRET 
(Semlow et al. 2016). In the mentioned study, ΔPrp16 spliceosomes were incubated with recombi-
nant Prp16, ATP and magnesium while the conformational change of the RNA transcript was ob-
served by FRET. This clearly indicates that a rearrangement of the RNA network can be obtained by 
the action of Prp16 itself. Here, we want to investigate this Prp16-mediated transition by visualising 
Prp16’s path on the RNA via in vitro spliceosome iCLIP. Next, a complete transition spanning the 
rearrangement towards the second step might be investigated by adding second step factors such 
as Slu7, Prp18, and Prp22 from recombinant source.  
 
 
Figure 5-8: Prp16 depletion from splicing extract. (A) Protein amounts are compared between the original ex-
tract (10-fold dilution) and extracts depleted of Prp16-3xFLAG by FLAG capture. Incubation of the extract thrice 
with either 1/40th, 1/10th or 1/4th volume of beads strongly reduces the protein amount. (B) Splicing test for 
WT extract (expressing Prp16-3xFLAG, non-depleted, lanes 1 and 2) and depleted from Prp16 (ΔPrp16, lanes 
3-7, extract derived from lane 4 in (A)). Addition of two concentrations rPrp16-G378A (lanes 5,6), addition of 
two concentrations rPrp16-WT (lanes 3, 4), no addition of recombinant protein (lane 7). The overall splicing 
activity of the extract is very low. The bottom panel shows only the lower part of the gel with increased con-
trast. 
 
To purify ΔPrp16 spliceosomes, Prp16 has to be depleted from splicing extract. In contrast to using 
antibodies raised against Prp16, here the extract is depleted using the endogenously introduced 
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C-terminal epitope tag and magnetic beads coupled to the complementary antibody. In an initial 
trial, Prp16 was depleted from yeast extract expressing endogenous Prp16-3xFLAG. To rescue the 
loss of splicing activity of the depleted extract, rPrp16-WT-3xFLAG was expressed and purified 
(7.3.1). Three consecutive incubations of splicing extract with 1/4th bead volume reached about 
100-fold reduction of the protein (Figure 5-8 A, compare lane 4 to lane 1). When comparing this 
extract to the original extract, it does not build up mRNA implying a second step splicing defect 
(Figure 5-8 B, compare lane 7 to lane 2). When supplementing the splicing extract with 
rPrp16-G378A, this phenotype is enhanced, while mRNA is produced again when supplemented 
with rPrp16-WT (Figure 5-8 B, lanes 5/6, 3/4). The levels of mRNA obtained from WT extract, how-
ever, cannot be reached indicating insufficient amounts of rPrp16 were added back to the extract 
or the antibody depletion of the Prp16 influences the second step of splicing in an additional way 
by e.g. co-depleting other essential factors. The depletion experiment has to be improved to rule 
out this possibility. For in vitro spliceosome iCLIP, Prp16 would ideally have an epitope tag for de-
pletion different to the one on the rPrp16-WT which is used to chase the complex and captured 
during iCLIP immunoprecipitation. To fulfil this requirement, a yeast strain expressing Prp16-3xHA 
is currently under construction.  
 
5.4.2 Prp16 binding to RNA is ATP-independent and compatible with pre-steady state 
ensemble kinetics 
Following the path of a helicase with in vitro spliceosome iCLIP would be a bulk kinetic experiment, 
meaning several molecules are observed together while the translocation of a single helicase mol-
ecule will be averaged out by others. In contrast, single molecule experiments can distinguish be-
tween each molecule and are therefore more accurate.  
In so called pre-steady state ensemble kinetic experiments, differences in translocation velocity are 
kept to a minimum. The molecules are synchronised at the start of the experiment, which provides 
a short time window to observe translocating helicases which are still synchronised (Fischer and 
Lohman 2004). Rebinding of helicases to the target RNA would lead to incorrect assumptions about 
kinetics and processivity. In single-turnover experiments a protein trap such as heparin, poly-U RNA 
or the natural substrate will catch unbound helicases before rebinding the target RNA (Lucius et al. 
2003). This subchapter aims at determining pre-steady state and single-turnover conditions with 
the intention of following the path of Prp16 in ΔPrp16 spliceosomes.  
 
Initially, binding properties of Prp16 should determine if the helicase needs ATP and/or magnesium 
for RNA binding in order to find a pre-steady state condition in which rPrp16 is bound to ΔPrp16 
spliceosomes but unable to translocate. With most techniques, binding of the comparatively small 
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protein Prp16 to the spliceosome cannot be monitored. Therefore, the binding of rPrp16 to single 
stranded RNA was determined by polarisation experiments. 
 
 
Figure 5-9: Fluorescence polarisation determines low micromolar Kd for binding of Prp16 to poly-U RNA. (A) Di-
lution series of Prp16 to bind fluorescein-labelled poly-U RNA in reaction buffer with and without the addition 
of ATP and Mg2+ (triplicates, error bars show standard deviation). (B) Dilution series of Prp16 to bind fluores-
cein-labelled poly-U RNA under the following conditions: no addition, +ATP/Mg2+, +Mg2+, +AMP-PNP/Mg2+. (A) 
and (B) binding buffer contains 100 mM KCl. The data points were fitted to a one-site specific binding event 
with the following formula Y=Bmax*x/(Kd + x) in GraphPad Prism. Bmax = maximum specific binding (same unit 
as Y-axes). The obtained Kd-values are indicated in the graph. Top: linear representation of the data. Bottom: 
logarithmic representation. 
 
The Kd for binding fluorescein-labelled poly-U RNA was calculated to the low µM-range by fitting 
the polarisation values, measured over an increasing concentration of rPrp16, to a one-site specific 
binding event curve (Figure 5-9). Complete saturation could not be reached, since rPrp16 precipi-
tated at concentrations higher than ~30 µM. Comparing the influence of ATP and Mg2+, the Kd was 
lowest in the absence of both (Figure 5-9). The addition of ATP in combination with Mg2+ reduces 
the binding affinity slightly, which could indicate that the helicase starts translocating or loses con-
tact with the RNA substrate. The same effect can be observed by addition of solely Mg2+ or the non-
hydrolysable ATP analogue AMP-PNP in combination with Mg2+ (Figure 5-9 B). The reduced binding 
affinity through Mg2+, ATP/Mg2+ or AMP-PNP/Mg2+, might indicate the recombinant helicase is 
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bound to ATP already. Taken together, these results indicate that rPrp16 can bind RNA without the 
external addition of ATP or Mg2+ which in turn means the helicase can be bound to the stalled 
ΔPrp16 spliceosome and the reaction can be started with the addition of either ATP/Mg2+ or Mg2+ 
in a pre-steady state ensemble kinetic format. In addition, the experiment clearly shows that poly-
U RNA can be used as a trap to ensure single-turnover.  
A more accurate Kd could be determined through switchSENSE technologies, in which association 
rate (kon) and dissociation rate (koff) are measured separately. The measurements would allow one 
to judge whether a decrease in affinity derives from an increased off-rate and vice-versa. Since 
setting up these experiments only provides secondary information but require a lot of optimisation, 
this option will be considered when needed.  
 
5.5 In vitro spliceosomal iCLIP can be transferred to additional helicases 
In summary, this chapter shows that the DEAH-box helicase Prp22 can be analysed by in vitro 
spliceosome iCLIP in a similar way to the closely related Prp16. Hardly any cDNAs were generated 
and uniquely mapped to the target transcript in the context of spliceosomal complex C*, possibly 
because Prp22 might locate near the 3’-end of the artificial pre-mRNA substrate. Assembling the 
spliceosome on UBC4 transcript with the extended second exon (61 nt) or the ACT1 transcript, 
which both improved mapping for Prp16 in vitro iCLIP data (compare chapter 4), is expected to 
generate longer reads and might therefore result in a clear binding profile for Prp22. 
In a similar way, the DEAH-box helicases Prp2 and Prp43 could be analysed by in vitro spliceosome 
iCLIP as soon as purification methods for spliceosomal complexes bound by the respective helicase 
are established. Prp43 is reported to be involved in disassembly of different stage spliceosomes 
arrested when remodelling by Prp16 or Prp22 is hindered (Mayas, Maita, and Staley 2006; 
Koodathingal et al. 2010). Obtaining the binding profile of all helicases, would allow for comparison 
of binding properties within and between different families of helicases as well as between differ-
ent spliceosomal complexes.  
Furthermore, this chapter gives first indications for possible time resolved in vitro spliceosome iCLIP 
formats and their potential workflow is summarised in Figure 5-10.  
For both Brr2 and Prp16 time-resolved in vitro spliceosome iCLIP, finding the right time-scale will 
be the most challenging task. It might require performing the chase with slow- or non-hydrolysable 
ATP, low magnesium concentrations or low temperatures. The optimal time frame can most likely 
only be determined by the comparison of final binding profiles. Of course, it remains unclear if 
unwinding events can even be captured by UV irradiation. The process might instead lead to a 
broader peak distribution or the short-lived events will only allow capture of the start and/or end 
points.  
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This chapter has certainly shown, that there is a potential for time-resolved in vitro spliceosome 
iCLIP, however a lot of work still has to be done. In the future, combining the binding profile of 
different helicases might enable one to follow the entire spliceosome remodelling process from 
assembly to activation, catalysis and disassembly from the viewpoint of the spliceosomal helicases.  
 
 
Figure 5-10: Possible formats for time-resolved Brr2 and Prp16 in vitro spliceosome iCLIP. (A) Spliceosomal com-
plex B is purified under limited ATP conditions from Brr2-3xFLAG splicing extract. The complex is transferred 
to micrococcal nuclease treated extract and splicing is initiated by increasing ATP. While the assembled com-
plex B remodels into later spliceosomal complexes, the extract is irradiated with UV light at different time 
points. The previously described iCLIP procedure will then identify the path of Brr2 while unwinding the U4/U6 
snRNA duplex. (B) Spliceosomal complex C is purified from Prp16-depleted extract. After binding of 
rPrp16-3xFLAG to the complex, the chase can be initiated by ATP and magnesium. Addition of a protein trap 
such a poly-U RNA will prevent rebinding of the same molecule to the spliceosome. During the chase UV irra-
diation over time will capture the translocation of Prp16 which can be visualised in the binding profile obtained 


















The spliceosome plays a major role during eukaryotic gene expression by determining the amount 
and composition of expressed proteins and non-coding RNAs (Pawlicki and Steitz 2010). Under-
standing the mechanism of spliceosome-catalysed pre-mRNA splicing in detail is crucial to explain 
post-transcriptional gene regulation through transcript maturation in the nucleus.   
 
In recent years, our understanding of the spliceosome benefitted greatly from snapshots taken dur-
ing the splicing process picturing both composition and structure of the spliceosome (Fica and Nagai 
2017) as well as profiling of spliceosome substrates in a genome-wide manner (Burke et al. 2018; 
Chen et al. 2018). Despite being objectives of many biochemical studies, it is crucial to study the 
extensive remodelling events, responsible for conversion between different spliceosomal states, 
before spliceosome catalysed splicing is thoroughly understood (Makarov et al. 2002; Schwer 2008; 
Mefford and Staley 2009; Hoskins, Gelles, and Moore 2011; Tseng, Liu, and Cheng 2011; Krishnan et 
al. 2013; Semlow et al. 2016; Hahn et al. 2012; Boesler et al. 2016). As described in the introduction, 
the major initiators of remodelling are the spliceosomal helicases, which in cryoEM structures are 
often poorly resolved due to their peripheral location, making mechanistic conclusions difficult 
even in a static spliceosomal particle. During the course of this thesis, in vitro spliceosome iCLIP was 
developed as a tool to investigate spliceosomal helicases biochemically within the spliceosome.  
 
The following chapter will concentrate on discussing and giving future perspectives on in vitro 
spliceosome iCLIP (compare chapters 3, 4, and 5). Concluding remarks for the chapter dealing with 
the spliceosomal protein Snu114 can be found at the end of the respective chapter (2.3).  
 
6.1 In vitro spliceosome iCLIP is a versatile tool to study spliceosome 
remodelling  
In vitro spliceosome iCLIP applies the NGS technique iCLIP to fully assembled spliceosomes to obtain 
the complete RNA-binding profile of even transiently bound spliceosomal helicases within the 
spliceosome.  
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A full pipeline for in vitro spliceosome iCLIP was initially developed to target two proteins in spliceo-
somal complex C: I have chosen Prp16 and SmB as the first target helicase and control protein to 
obtain binding profiles, respectively. SmB binding sites correlate with the known Sm sites and 
thereby validated the method (Figure 3-9 and (Guthrie and Patterson 1988)). The final workflow for 
in vitro spliceosome iCLIP is summarised in Figure 6-1.  
The starting material for the method consists of specifically stalled and purified spliceosomes, which 
were assembled from yeast extract onto defined pre-mRNA substrates. The experimental setup 
allows one to draw mechanistic conclusions through variation of the pre-mRNA substrate and the 
comparison of binding profiles between helicase mutants.  
 
 
Figure 6-1: Workflow of in vitro spliceosome iCLIP. In vitro assembled and stalled spliceosomes containing a 
FLAG-tagged target protein are purified and irradiated with 254 nm UV light to induce covalent crosslinking 
between RNA and protein. The UV amount has to be adjusted anew for every target protein. Sometimes de-
naturation of the complex is necessary to liberate the FLAG-tag. During FLAG-capture, controlled RNase I di-
gestion fragments the RNA suitable for NGS; another step which requires adjustment for every target protein. 
Since RNase I seemed to be best for fragmentation, 3’-ends have to be dephosphorylated. The 5’-end is radi-
olabelled to support visualisation of the RNA-protein complex and the 3’-end is linked to the IR-L3 adapter 
allowing later visualisation and RT primer annealing. The protein-RNA complexes are separated by SDS-PAGE, 
blotted onto nitrocellulose, and extracted by proteinase K digestion. Reverse transcription truncates when the 
enzyme reaches the crosslink site which is occupied by the remaining peptide. Amplification and purification 
steps produce a cDNA library for single read sequencing with the Illumina HiSeq 2500 system. Data analysis 
identifies the crosslink sites and their abundance on the substrate-ome (splicing substrate and spliceosomal 
snRNAs) and the yeast genome.  
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Besides its variable setup concerning pre-mRNA substrate and helicase mutants, in vitro spliceo-
some iCLIP has the following advantages: Only direct protein-RNA contacts are observed due to the 
required proximity for efficient UV-crosslinking. By using the intrinsic crosslinking ability of RNA, 
base modifications in the substrate RNA or in endogenous snRNAs are avoided. A full binding profile 
is obtained from one experiment, in contrast to e.g. traditional crosslinking with photoreactive de-
rivatives in vitro, in which normally only a small number of specific nucleotides are tested one after 
the other for interaction. Binding to all RNAs, contained in the spliceosome at the given spliceoso-
mal stage, is captured simultaneously and the RNAs are unambiguously identified by sequencing. 
The method can be further developed to be combined with other sequencing approaches such as 
hiCLIP, which identifies not only the target RNA region but also determines RNA secondary structure 
in the vicinity (Sugimoto et al. 2015). Finally, in vitro spliceosome iCLIP can be adapted to other 
spliceosomal helicases which act at various stages during splicing as shown through preliminary 
experiments in chapter 5.  
Like every method, in vitro spliceosome iCLIP has several restrictions: Uridines crosslink with higher 
efficiency to proteins than other nucleotides introducing bias (Sugimoto et al. 2015). Secondary 
structure elements might crosslink with different efficiency than single-stranded unstructured RNA 
regions. The overall experimental procedure consists of many time-consuming steps, which are not 
automated and therefore require extensive hands-on time. In addition, we are still working on re-
ducing the background signal from non-UV irradiated samples to increase the confidence in the 
identification of genuine crosslinks at nucleotide resolution.  
By generating a binding profile of a target protein on the RNA, in vitro spliceosome iCLIP cannot 
reveal information on which parts of the protein interact with the RNA, nor where the protein is 
located in the spliceosome.  
 
6.1.1 Specific and general obstacles for in vitro spliceosome iCLIP 
While developing and analysing the binding profile for Prp16 in complex C, several issues arose, 
while most could be resolved (compare chapter 4). Although the obstacles were found in this spe-
cific setup, some of them are generally worth considering before setting up in vitro spliceosome 
iCLIP.    
(1) In vitro spliceosome iCLIP is restricted by the number of nucleotides downstream of the 
crosslink site. In the binding profile of Prp16, the major crosslink site was found around 40 
nt from the 3 -end of the splicing substrate used, which directly restricts the generation of 
uniquely mapped reads. A ~2-fold increase in the distance between the location of the ma-
jor crosslink site and the 3’-end of the RNA substrate led to a 14-fold increase in the histo-
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gram height (Figure 4-4; histogram height = number of reads with the same crosslink posi-
tion). To avoid read loss, one should ideally aim to use an RNA substrate with an adequate 
extension at the 3’-end to allow mapping of the maximal 90 nt long reads (for read length 
in the included experiments, compare Appendix Figure 8-3). 
(2) In vitro spliceosome iCLIP on spliceosomes of the first catalytic step is prone to false positive 
truncation events at the intron lariat-junction. Forming the unusual 2’-5’ phosphodiester 
bond, both the brA and the 5’SS location become obstacles for the reverse transcriptase. 
In the binding profile of Prp16, both positions showed sharp peaks (Figure 4-3 and Figure 
4-4). We could show that nucleobases at both positions are, in contrast to genuine crosslink 
positions, often mutated after reverse transcription (Figure 4-5 A). In addition, the sharp 
peak at the brA could be decreased and the coverage upstream the brA increased by in-
cluding an enzymatic debranching step in the in vitro spliceosome iCLIP procedure (Figure 
4-7 and Figure 4-8). Consequently, one should consider RNA-induced termination events, 
when performing sequencing approaches on the spliceosome.  
(3) In vitro spliceosome iCLIP produces high background signal. Control samples, which derived 
from non-UV irradiated samples, resemble the binding profile of Prp16 in lower intensity 
(Figure 4-3 and Figure 4-4). We could show that the region harbouring most crosslinks was 
clearly UV-dependent (Figure 4-5). Truncation events may be derived from very strong 
binding of the target protein to RNA, which is supported by signal on SDS-PAGE in the ab-
sence of UV irradiation (Figure 3-7). Possibly, the average 30 nt-long reads which are gen-
erated during in vitro spliceosome iCLIP accumulate around the binding site due to the 
strong RNA-protein interaction and then resemble crosslink events in the same region. Aim-
ing to retain longer reads and applying even more stringent washing conditions will hope-
fully decrease the background level. 
 
6.1.2 In vitro spliceosome iCLIP supports the model for Prp16 acting from a distance 
In vitro spliceosome iCLIP data revealed the binding site for Prp16 in complex C. Crosslinks were 
found only on the splicing substrate, not on any of the spliceosomal snRNAs (Figure 3-10). The same 
binding profile was produced from the following three conditions: (1) Prp16-WT on AC (3’SS) sub-
strate and the ATPase-deficient helicase Prp16-G378A on both (2) unmodified and (3) AC (3’SS) 
splicing substrate (Figure 4-4 and Figure 4-9). Since the mutant protein has a residual ATPase activ-
ity of only 2 % (Schneider, Hotz, and Schwer 2002) which should severely restrict its helicase activity, 
the crosslink profile should reflect the starting point before Prp16 starts translocating to remodel 
spliceosomal complex C. To draw sequence and substrate-independent conclusions, the experi-
ments were performed with both UBC4 and ACT1 pre-mRNA substrate. The major interaction site 
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for Prp16 was found to be about 15 nucleotides downstream of the brA independent of the sub-
strate (Figure 4-11). Our data is in good agreement with previously determined positions from 
4-thiouridine photo crosslinking (McPheeters and Muhlenkamp 2003; Semlow et al. 2016). Prp16’s 
binding site seems to follow a molecular ruler mechanism, in which the binding distance from the 
brA is determined by the dimensions of the spliceosome body. In the cryoEM structure of com-
plex C, the distance between the brA and Prp16 binding site was reported to span approximately 
18 nt (Galej et al. 2016). Consequently, our data supports the model of Prp16 acting from its pe-
ripheral location to remodel distant RNA structures located in the catalytic core of the spliceosome. 
The model suggests that the translocation movement is transmitted into a pulling action when the 
helicase is physically obstructed by spliceosomal components (Semlow et al. 2016). Performing in 
vitro spliceosome iCLIP on UBC4 or ACT1 splicing substrates with artificial extensions between the 
brA and Prp16’s binding site, could be used to validate the distance.  
 
6.1.3 Pilot experiments on Brr2 and Prp16 suggest two strategies towards 
time-resolved in vitro spliceosome iCLIP 
In addition to observing static interactions of spliceosomal helicases with their target RNA, we had 
the aspiration to modify in vitro spliceosome iCLIP towards a time-resolved method. Only binding 
profiles recorded over the course of the remodelling event have the potential to reveal the range 
of the helicases’ translocation. Pilot experiments for the two helicases Brr2 and Prp16 suggest ap-
plying different strategies (Figure 6-2). 
 
(1) In spliceosomal complex B, Brr2 is pre-loaded onto U4 snRNA (Plaschka, Lin, and Nagai 
2017). To monitor Brr2 helicase translocation during the transition to complex Bact, purified 
complex B will be incubated in splicing extract, which provides all the factors required. 
While the assembled complex B remodels into later spliceosomal complexes, the extract is 
irradiated with UV light (Figure 6-2 left).  
We could already show that RNA-Brr2 crosslinks can be generated in stalled spliceosomal 
complex B when splicing extract was irradiated with UV light (Figure 5-6 D). In addition, we 
could show that purified complex B can remodel into later stage spliceosomes in micrococ-
cal nuclease inactivated extract (Figure 5-7 B). The nuclease treatment is necessary to pro-
hibit interchange of snRNPs between preassembled complexes and the splicing extract.   
(2) To follow Prp16’s translocation on RNA, we aimed to develop a system starting from Prp16 
depleted spliceosomes, similar to the method described previously in (Semlow et al. 2016). 
We could show that depletion of Prp16-3xFLAG by epitope-antibody interactions, almost 
completely inhibits the second splicing reaction, stalling at the complex C stage (Figure 5-8). 
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In fluorescence polarisation experiments, we determined similar affinities for rPrp16-WT 
binding to poly-U RNA in the presence and absence of ATP/Mg2+ (Figure 5-9). This finding 
is crucial to establish pre-steady state conditions, in which Prp16 will firstly be bound onto 
the spliceosome and translocation initiated by the addition of the cofactors (Lucius et al. 
2003). Poly-U RNA can then be used as a protein trap catching released helicases to guar-
antee single turnover conditions. 
Once the pre-steady state set-up is developed to monitor Prp16 translocation, one could 
potentially determine Prp16 binding profiles for a complete transition to post-catalytic 
spliceosomes by providing second step factors such as Slu7, Prp18, and Prp22 from recom-
binant source (Figure 6-2 right). 
 
 
Figure 6-2: Potential workflow for time-resolved in vitro spliceosome iCLIP. (left) In vitro spliceosome iCLIP for 
time resolved profiles during a transition which is experimentally best performed in extract (e.g. complex B to 
Bact). The stalled complex including the helicase is purified, and then transferred into micrococcal nuclease 
treated extract in which a second incubation initiates remodelling which is captured by UV irradiation over 
time. The tethered protein-RNA complexes are subsequently applied to the regular in vitro spliceosome iCLIP 
procedure as described in Figure 6-1. (right) Potential workflow for time resolved in vitro spliceosome iCLIP 
starting from purified spliceosomes, which were stalled by depleting the target helicase from splicing extract. 
The recombinantly produced helicase is then loaded onto the purified spliceosome before the chase is initiated 
by addition of the cofactors NTP and Mg2+. A protein trap such as poly-U can ensure single turnover conditions. 
Additional recombinant factors can be added to follow an extended remodelling event. UV irradiation over 
time and the subsequent general iCLIP procedure (compare Figure 6-1) will produce the time-resolved binding 
profiles. Ideally, the epitope tags of depleted and repleted helicase differ.   
 
In chapter 5, these pilot experiments are described only as a small step towards time-resolved in 
vitro spliceosome iCLIP. For instance, finding the right time-scale will be one of the most challenging 
tasks. For Brr2 unwinding, the literature gives an approximate duration of 4 sec at 4 °C (Small et al. 
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2006), a time frame which would be too short for the current crosslinking format. Hopefully, the 
implementation of slow- or non-hydrolysable NTPs, low concentrations of Mg2+ and low tempera-
tures will increase the apparent reaction time. To ensure precise timing and mixing of components, 
kinetic experiments could be performed in a microfluidic setup which leads the reactants in a con-
trolled manner directly to the UV light source. Similar innovations are in the development phase 
for time-resolved cryoEM (Frank 2017). 
By comparing the binding profile of helicases on different splicing substrates, time-resolved in vitro 
spliceosome iCLIP, once developed, will allow us to draw many mechanistic conclusions. In the fu-
ture, binding profiles of the different spliceosomal helicases might enable us to follow the entire 
spliceosome remodelling process from assembly and activation over catalysis to disassembly from 
the viewpoint of the spliceosomal helicases.  
  
6.2 Implications of in vitro spliceosome iCLIP for the understanding of 
spliceosomal helicase functions 
As described in the previous section, in vitro spliceosome iCLIP can be adapted to reveal the binding 
profile of additional spliceosomal helicases. We showed that Prp22 is a suitable target for in vitro 
spliceosome iCLIP in both complex C* and P (chapters 5.1 and 5.2). 
Being straightforward to adapt to further targets, we predict in vitro spliceosome iCLIP and time 
resolved in vitro spliceosome iCLIP will prove valuable for the understanding of spliceosomal hel-
icases. First some general aspects are listed, while implications for answering some more specific 
questions are described in further detail afterwards.  
(1) To date, we still lack knowledge about the RNA targets for some spliceosomal helicases 
which could be identified through binding profiles. 
(2) It is unclear, how and when helicases are positioned and recognise a specific spliceosome 
stage. The time-point when they are released is equally unknown.  
(3) Is the winching mechanism a universal model for all spliceosomal DEAH-box helicases? 
(4) How processive are spliceosomal helicases? It is unclear if only one helicase molecule is 
involved per remodelling event and wheather consecutive release and rebinding of RNA by 
one or several helicase molecules is required. 
(5) Proofreading activity of helicases can potentially be tested with suboptimal splicing sub-




6.2.1 Towards a better understanding of Prp16 helicase 
The role of Prp16 in 3’SS selection could, for example, be directly investigated by in vitro spliceo-
some iCLIP using a splicing substrate harbouring two 3’SS consensus sequences. It was reported 
that the splice site which is proximal to the brA is favoured over the distal site (Luukkonen and 
Seraphin 1997), but it remains unclear how and if Prp16 has an influence in the choice. The trans-
location path of Prp16 generated from splicing substrates with a single 3’SS and from splicing sub-
strates with varied distances between two 3’SS might help to shed light on the mechanism. Addi-
tionally, sequencing approaches have the advantage of determining the usage of splice sites in a 
quantitative manner (Burke et al. 2018).  
Prp16 was proposed to proofread the branching step by rejecting pre-mRNA substrates with branch 
point mutations (Burgess and Guthrie 1993; Koodathingal et al. 2010). By obtaining Prp16’s binding 
profile in the context of a suboptimal BPS, and by comparing binding profiles of Prp16 on substrates 
with two branch point sequences, we might gain a better understanding of Prp16 mediated proof-
reading.  
 
6.2.2 Towards a better understanding of Prp22 helicase 
Prp22 is one of the best-studied spliceosomal helicases. The RNA binding position was determined 
by 4-thiouridine photo crosslinking to include the 17th nucleotide of exon 2 when mRNA release 
was blocked with dominant negative Prp22 (Schwer 2008). In agreement with the cryoEM structure 
of complex P (Bai et al. 2017; Liu et al. 2017; Wilkinson et al. 2017), this should be the starting point 
for Prp22-mediated mRNA release. Little is known, however, about the mechanism. Time-resolved 
in vitro spliceosome iCLIP might allow us to determine if Prp22 releases the RNA for example in a 
corkscrew-like fashion or if a short translocation on the mRNA is enough to destabilise interactions 
to U5 snRNA and proteins, which then leads indirectly to mRNA release.  
In addition to its conventional role in mRNA release, Prp22 was reported to bind close to the 3’SS 
within the last eight nucleotides of the intron before the second catalytic step (McPheeters, Schwer, 
and Muhlenkamp 2000; McPheeters and Muhlenkamp 2003). The studies were done on spliceo-
somes which stalled due to a 3’SS alteration, however it is unclear which exact spliceosomal state 
was captured. Generating in vitro spliceosome iCLIP data for Prp22 from various spliceosomal 
stages might answer the question. In the cryoEM structure of complex C*, the distance between 
the catalytic centre and Prp22 is claimed to equal 16 or 17 nucleotides (Fica et al. 2017), which the 
authors put into agreement with the finding of (Schwer 2008), despite a low local resolution which 
does not allow the RNA path to be visualised.  
After having characterised this second binding site of Prp22, there might be the possibility to re-
construct the complete transition towards exon ligation and mRNA release to analyse how Prp22 
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changes between the two binding locations lying in opposite direction to its translocation specific-
ity. The intronic position, could of course also derive from Prp22 proofreading activity of the 3’SS, 
supported by the fact that dysfunctional Prp22 permits splicing of substrates with 3’SS mutations 
(Mayas, Maita, and Staley 2006). 
 
6.2.3 Towards a better understanding of Brr2 helicase 
As described above, time-resolved in vitro spliceosome iCLIP is a suitable tool to study Brr2-medi-
ated U4/U6 snRNA duplex unwinding in the natural context of the spliceosome. Components, which 
join the spliceosome during the complex B to Bact transition, can be supplied from micrococcal nu-
clease deactivated extract (Figure 5-7).  
 
 
Figure 6-3: Schematic illustration of the RNA interaction network in complex B and Bact. In complex B, Brr2 (light 
cyan) is pre-loaded onto U4 snRNA (yellow). To unwind the U4/U6 snRNA duplex, Brr2 unwinds stem l first and 
then faces the U4 5’SL before unwinding of stem II can happen. Illustrations are adapted from (Plaschka, Lin, 
and Nagai 2017).  
 
Following the path of Brr2 in a time-resolved manner would be an excellent approach to understand 
in which order specific RNA structures are actively remodelled by Brr2 in order to allow formation 
of the catalytic centre; bridging the data from in vivo studies in (Hahn et al. 2012) and the recombi-
nant system in (Mozaffari-Jovin et al. 2012).  
One of the main open questions can possibly be answered: After Brr2 has left its preloaded position 
on U4 snRNA and unwound U6/U4 stem I of the duplex, what happens when the helicase encoun-
ters the U4 5’ stem loop (5’SL) which is tightly held by proteins in the centre of complex B (compare 
Figure 6-3)? Four possible scenarios were described in (Nielsen and Staley 2012): (1) Brr2 could 
potentially unwind U4 5’SL, while using an RNPase activity to replace the proteins and then con-
tinue to unwind stem II (Laggerbauer, Achsel, and Luhrmann 1998; Mozaffari-Jovin et al. 2012). 
(2) The active unwinding of the U4 5’SL and protein replacement by Brr2 could have a destabilising 
effect onto stem II which separates indirectly. This model can be supported by in vivo data, in which 
Brr2 crosslinks to the 3’-side of the U4 5’SL but not to stem II (Hahn et al. 2012). (3) Brr2 could 
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directly continue unwinding stem II after stem I without encountering U4 5’SL. (4) The last model 
suggests Brr2 would unwind only stem I, and then stop before the 5’SL. The unwinding of stem II 
would then actively be done by other factors (Theuser et al. 2016).  
In addition to generating the binding profile to conclude where exactly Brr2 actively translocates, 
one could implement hiCLIP, which would enable the identification of duplex RNA regions in the 
vicinity of the crosslinked protein. Pinpointing what determines the timing of U4/U6 snRNA un-
winding, an event that certainly has to be regulated accurately to avoid unwinding before complete 
spliceosome assembly, will be challenging and requires the interplay between different techniques.  
 
Beside investigation of the canonical role for Brr2 in spliceosome activation, the helicase was pro-
posed to be involved prior and at the second step of splicing (Hahn et al. 2012). Most of the results 
in this study were based on Brr2-G858R, which carries a mutation in the β-hairpin motif that sup-
presses defects in exon ligation without hindering the first step of splicing. In vitro spliceosome iCLIP 
could produce binding profiles for Brr2 to identify a direct RNA target in the later spliceosomal 
stages. 
 
6.2.4 Towards a better understanding of spliceosome disassembly  
Two helicases have been proposed to be involved in disassembly of the ILS. The target of the DEAH-
box helicase Prp43 has not yet been identified unambiguously. Both the disruption of the U2 
snRNA-BPS helix (Fourmann et al. 2016) and translocation on U6 snRNA (Wan et al. 2017) were 
suggested as Prp43 targets during disassembly. A combined approach of Prp43 in vitro spliceosome 
iCLIP in ILS stalled by dominant negative Prp43 and genome-wide iCLIP data from Prp43 in vivo 
should help to identify the helicase substrate. 
In addition, Prp43 is proposed to disassemble spliceosomes that were directed to the discard path-
way by Prp16 or Prp22 (Koodathingal et al. 2010; Mayas et al. 2010). The RNA target of Prp43 in 
these particles could be analysed in the context of ΔPrp16 or ΔPrp22 spliceosomes by in vitro 
spliceosome iCLIP. How Prp43 is recruited to spliceosomes, however, is beyond the scope of in vitro 
spliceosome iCLIP.  
Similarly, the role and RNA target of Brr2 during disassembly is unclear. In vitro spliceosome iCLIP 
on stalled ILS might allow one to determine if and where Brr2 is loaded in ILS. Time-resolved in vitro 
spliceosome iCLIP of ΔPrp43 ILS, in which disassembly is induced by recombinant Prp43 would im-
prove our understanding of disassembly.  
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6.3 Spliceosome remodelling and future directions 
In vitro spliceosome iCLIP is of course not restricted to obtain binding profiles for the translocating 
helicases. Similarly, the tool can be applied to investigate DEAD-box helicases. Possibly, we can 
learn more about their duplex melting activity (Cordin and Beggs 2013), mainly when the investiga-
tion is combined with the hiCLIP approach. Further, binding profiles for splicing factors such as Slu7 
and Prp18 could be targeted in the future. Maybe we can learn why some splicing factors are spe-
cifically required for substrates with longer distances between the brA and the 3’SS (James, Turner, 
and Schwer 2002; Ohrt et al. 2013).  
Further, we predict that in vitro spliceosome iCLIP can easily be transferred from the intron reduced 
yeast to the human system. All data obtained in vitro could be complemented with either in vivo 
iCLIP or with spliceosome profiling in order to test gained hypotheses in a genome-wide environ-
ment and to increase our knowledge of substrate-specific effects.  
Many open questions regarding spliceosome remodelling, however, are beyond the scope of in 
vitro spliceosome iCLIP and require a combination of different approaches. Conceivably, single mol-
ecule studies, time-resolved cryoEM or even tomography of the nucleus will help to answer the 
open questions: 
(1) How are suboptimal substrates recognised during proofreading? What promotes the reac-
tion to proceed backwards and into a discard pathway to increase splicing fidelity? 
(2) Which parts of spliceosome remodelling require active restructuring and what can be con-
sidered as passive remodelling? 
(3) How is the consecutive action of the helicases coordinated? What determines when each 
helicase joins or leaves the spliceosome? How do helicases work together in the way pre-
dicted for Brr2 and Prp16? 
(4) How do helicases relocate when they are involved at different stages of splicing for differ-
ent functions? 
Most likely, many more questions will arise during the journey until we fully understand spliceo-
some remodelling which is essential to drive the splicing process, while providing regulation- and 
checkpoints. Finally, all this will bring us a step closer to understanding the process of eukaryotic 










7 Materials and methods 
 
RNA and protein sequences used throughout the study derived from the yeast Saccharomyces cere-
visiae unless otherwise stated.  
 
7.1 Plasmids and yeast strains 
7.1.1 Plasmids for in vitro RNA transcription 
In general, DNA sequences were inserted under the T7 promoter into pUC cloning vectors for in 
vitro transcription. The modified U5 snRNA A, B and C sequences were PCR amplified from a plasmid 
containing full length U5 snRNA (provided by W. Galej) and cloned into pUC18 by C Oubridge. Ad-
ditionally, C Oubridge inserted a 5‘-hammerhead ribozyme sequence (Price et al. 1995) upstream 
of the U5 snRNA sequence. 
Plasmid 1 was a gift from A. Newman, containing the sequence of three MS2 stem loops (Zhou, Sim, 
et al. 2002), the last 25 nt of the first exon of UBC4, the 84 nt-long UBC4 intron, and the hepatitis 
delta ribozyme under the T7 promoter.  
Plasmid 2 was designed to transcribe UBC4_3xMS2. The sequence for the transcription of the three 
MS2 stem loops was firstly cloned into the BamHI and EcoRI site of pUC19 by assembly of four DNA 
oligonucleotides (Table 7-1, primers 1 to 4). The oligonucleotides were enzymatically phosphory-
lated by T4 PNK (NEB) and annealed by decreasing the temperature slowly from 80 to 23 °C before 
ligation. In a second step, a construct containing the T7 promoter, the last 25 nt of the first exon, 
the intronic sequence and 25 nt of the second exon of UBC4 were PCR amplified from a plasmid 
(gift from S. Fica) with primers compatible for HindIII- and BamHI-based cloning into the vector 
containing the 3xMS2 sequence (Table 7-1, primers 5 and 6). 
 
7.1.2 Plasmids for protein tagging in S. cerevisiae  
Vectors to introduce C-terminal His8- and 3xFLAG-His8-tag originated on pAG25 (Addgene plasmid 
#35121), which codes for the nourseothricin (ClonNAT) selection marker cassette downstream of a 
multicloning site. To generate pAG25-His8, primers were constructed to contain the octa histi-
dine-tag sequence (Tagwerker et al. 2006) while amplifying the 3’ untranslated region (3’UTR) of 
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SV40 by PCR from a pRS424 expression vector (Table 7-1, primer 7 and 8). Restriction digestion of 
the amplified DNA allowed subsequent cloning into the HindIII and BamHI sites of pAG25. 
To generate pAG25-3xFLAG-His8, the His8-SV40-region was amplified form pAG25-His8 extending 
the sequence by a primer coding for 3xFLAG (Table 7-1, primer 8 and 9) and cloned into the 
HindIII/BamHI sites of pAG25.  
 
Table 7-1: Oligonucleotides for plasmid cloning to be used in in vitro transcription and endogenous protein tag-
ging. Primers are listed under the number as they appear in the text, their name and the DNA sequence. 
# oligonucleotide 
1 primer 1 – MS2 
 5’-GATCCGATATCCGTACACCATCAGGGTACGAGCTAGCCCATGGCGTACACCATCAGGGTACGA-3’ 
2 primer 2 – MS2 
 5’-CTAGTAGATCTCGTACACCATCAGGGTACGG-3’ 
3 primer 3 – MS2 
 5’-CATGGGCTAGCTCGTACCCTGATGGTGTACGGATATCG-3’ 
4 primer 4 – MS2  
 5’-AATTCCGTACCCTGATGGTGTACGAGATCTACTAGTCGTACCCTGATGGTGTACGC-3’ 
5 HindIII – T7 promoter – UBC4 (forward) 
 5’-TCGAAAGCTTTAATACGACTCACTATAGGGAACTAAGTGATCTAGAAAGG-3’ 
6 BamHI – UBC4 (reverse) 
 5’-AGCTTGGATCCAACATGAAGTAGGTGGATCTCTAGTTCAATAG-3’ 
7 HindIII – His8 – SV40 3’UTR start (forward) 
 5’-GTGCCTCGAAGCTTCAGGGGTTCACATCATCACCACCATCATCACCACTAATAGTAAGTCGACTTTGTTC CCACTG-3’ 
8 BamHI – SV40 3’UTR end (reverse) 
 5’-GTTTAAGAGGATCCGATCTTCGAGGGGAATTCTC-3’ 
9 HindIII – 3xFLAG – His (forward) 
 5’-GTGCCTCGAAGCTTCGACTACAAAGACCATGACGGTGATTATAAAGATCATGATATCGATTACAAGGATG ACGATGACAAGAGGGGTTCACATCATCAC-3’ 
 
7.1.3 Yeast strains 
The yeast strain BCY123 (MATa, can1, ade2, trp1, Ura3-52, his3, leu2-3, 112, pep4::his+, prb1::leu2+, 
bar1::HisG+, lys2::pGAL1/10-GAL4+) is the mother strain for all modifications unless stated other-
wise.   
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7.1.4 Protein tagging in S. cerevisiae strains 
To introduce the sequence coding for a C-terminal protein tag into the yeast genome, the region 
containing the tag, the 3’UTR of SV40 (terminator) and the ClonNAT resistance cassette were am-
plified from pAG25-His8 or pAG25-3xFLAG-His8. Herby, the forward primer was designed with ~60 
nt homology to the target gene upstream of the stop codon and 20 nt sequence similarity to the 
vector for amplification. The reverse primer was designed accordingly with 60 nt homology to the 
beginning of the 3’UTR of the target gene (compare Table 7-2).  
The PCR product was gel purified (QIAEX II Gel Extraction Kit, Qiagen) and concentrated by precip-
itation to allow chemical transformation of at least 100 ng DNA into 20 µL BCY123 cells (lithium 
acetate method). Cells were kept in 1 mL yeast extract peptone dextrose (YEPD) for at least 9 h at 
30 °C before further growth on selective plates containing 100 µg/mL ClonNAT. After three days, 
the genomic DNA of ClonNAT-positive cells was extracted (lithium-SDS method) and analysed for 
the insertion by PCR amplification with primer pairs annealing 300 nt up- and downstream of the 
original stop codon of the target gene. Successfully amplified insertions were verified by Sanger 
sequencing.  
Additionally, western blot probing with anti-FLAG® M2-Peroxidase (Sigma) for the 3xFLAG-tag ver-
ified expression of the correctly tagged protein. C. Norman conducted most parts to generate Brr2-
3xFLAG-His8 strain.  
 
Table 7-2: Oligonucleotides for endogenous protein tagging by homologous recombination. The first line shows 
the forward primer used to introduce the respective sequence downstream of the coding region of the target 
gene, the second line gives the reverse primer. Prp16-His8 and Prp16-3xFLAG-His8 were generated by amplifi-
cation with the same reverse primer from the two different vectors.  
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7.1.5 Plasmid shuffle  
Shuffling plasmids expressed the Snu114 gene under its own promoter in pRS413 vector, which has 
a centromeric replication origin and codes for the resistance marker HIS3 (gift from A. Newman). 
Mutations were introduced using the Kunkel mutagenesis method (Kunkel 1985) by either K. Ngu-
yen or myself. The plasmids were transformed into the YSNU114KO1 strain (Frazer, Lovell, and 
O'Keefe 2009), in which the genomic copy of Snu114 is deleted. The essential Snu114 gene is pro-
vided on a pRS416 vector, which carries the URA3 selection cassette and a centromeric replication 
origin. Transformants were first grown on selective plates lacking histidine and positive clones were 
transferred onto plates containing 5-FOA (5-fluoro orotic acid), which tests the growth phenotype 
after the Snu114-WT copy is lost under URA3 anti-selection. Viable mutant clones were further 
transferred onto YEPD to monitor growth phenotypes at different temperatures.  
 
7.1.6 Plasmids for recombinant protein expression 
Vectors for recombinant expression in yeast were based on pRS424 and pRS426 vectors carrying 
the selection cassette for TRP1 and URA3, respectively, to allow co-expression. The desired coding 
sequence is under control of the GAL-GAP promoter. Construct modification by Kunkel mutagenesis 
(Kunkel 1985) was verified by sequencing. Expression plasmids for helicases are listed together with 
mutagenesis primers in Table 7-3.  
 
Table 7-3: Plasmids for recombinant expression of spliceosomal helicases in yeast. To allow expression in YM4 
selective media, pRS424 or pRS426 (# 4 or 5) were co-transfected into yeast when expressing a single protein. 
Depending on the directionality of the GAL-GAP cassette, forward (for) or reverse (rev) primers were used in 
mutagenesis.  
# protein N-term. tag C-term. tag vector modification 
1 Prp16 - CBP-3xFLAG-His6 pRS424 AA substitution on #2 to obtain WT 
 primer (rev.) 5’-CATATAAATACTGTGCAAGTTGCGTGGTTTTACCTGAGCCCGTTTCACCAATTATCA 
CC-3’ 
2 Prp16-G378A - CBP-3xFLAG-His6 pRS424 3xFLAG-tag insertion into Prp16-
G378A-CBP-His (gift from A. New-
man) 
 primer (rev.) 5’-CTTTTTCCATCGTCGCTTCGATCCCCCCTTGTCATCGTCATCCTTGTAATCGATATCAT 
GATCTTTATAATCACCGTCATGGTCTTTGTAGTCAAAAAAAGGCTTCCTTCTTTTG-3’  
3 Prp22-K512A CBP 3xFLAG-His6   3xFLAG-tag insertion into CBP-
Prp22-K512A-His (gift from A. New-
man) 
 Primer (rev.) 5’-CCCTCAATGATGATGATGATGGTGATGATGTGAACCCCTCTTGTCATCGTCATCCTTGTA 
ATCGATATCATGATCTTTATAATCACCGTCATGGTCTTTGTAGTCCCTCTTGATACCTAATGC 
CCTTTC-3’ 
4 - - - pRS424 Gift from A. Newman 
5 - - - pRS426 Gift from A. Newman 
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Plasmids for Snu114 and Prp8-N expression were constructed by C. Oubridge, W. Galej and myself 
(Appendix Table 8-1 and Table 8-2 indicating location of purification tags and expression success).  
 
For bacterial expression vectors, constructs were PCR amplified from plasmids containing the cod-
ing sequence for Prp8 and cloned into either pGEX-6P-I or pET-based vectors by restriction-enzyme 
based cloning. In addition, a codon-optimised construct of Prp8 was synthesised directly by gene 
synthesis (Invitrogen) and similarly transferred into a pET-based expression vector. All constructs 
are listed in Appendix Table 8-1.  
 
7.2 RNA techniques 
Several different strategies were used to produce the RNA molecules included in this work. The 
following paragraphs will describe the general methods separately, while Table 7-4 will specify 
which methods were used to generate each specific RNA transcript. Table 7-5 lists reaction buffers 
and their components.  
 
Table 7-4: RNA transcripts generated for this work. The name of the transcript is listed as and where (column 
chapter) it appears in the thesis. Details on how the molecule was generated are given under methods.  
transcript chapter method 
U5 snRNA A 2.1 In vitro transcription from plasmid 
U5 snRNA B 2.1 In vitro transcription from plasmid 
U5 snRNA C 2.1 In vitro transcription from plasmid 
3xMS2_UBC4_short 4.1, 4.2, 4.3 In vitro transcription from plasmid 1, ligation to a Cy5-la-
belled 36 nt RNA oligonucleotide  
3xMS2_UBC4_AC_short 3, 4.1, 4.2, 4.3 In vitro transcription from plasmid 1, ligation to a Cy5-la-
belled 36 nt RNA oligonucleotide 
3xMS2_UBC4_dG_short 5.1 In vitro transcription from plasmid 1, ligation to a Cy5-la-
belled 36 nt RNA oligonucleotide  
UBC4_3xMS2 5.2 In vitro transcription from plasmid 2, 3’-end labelling with 
fluorescein 
3xMS2_UBC4_long 4.1.2 In vitro transcription from plasmid 1, two consecutive liga-
tions to attach two 36 nt RNA oligonucleotides with the 
second carrying a Cy5 label 
3xMS2_UBC4_AC_long 4.1.2 In vitro transcription from plasmid 1, two consecutive liga-
tions to attach two 36 nt RNA oligonucleotides with the 
second carrying a Cy5 label 
3xMS2_ACT1_WT 4.4 In vitro transcription of PCR generated template followed 
by enzymatic Cy5-labelling 
3xMS2_ACT1_AC 4.4 In vitro transcription of PCR generated template followed 
by enzymatic Cy5-labelling 
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Table 7-5: Buffers and reaction conditions used for RNA preparation. The name of the buffer is listed together 
with its composition., The total volume is given in brackets for reactions which were conducted in a specific 
volume. Buffers were prepared with Milli Q water (Millipore) and filtered through 0.22 µm filters. Enzymatic 
reactions were set up with RNase free water (Ambion). Tris: tris(hydroxymethyl)aminomethane, DTT: dithio-
threitol 
buffer composition 
oxidation solution  0.1 M sodium peroxide, 0.1 M sodium acetate pH 5.3 
Cy5 labelling reaction 1 nmol RNA, 1 mM ATP, 1 x RNA ligase buffer (NEB), 10 % dimethyl sulfoxide 
(DMSO), 2 nmol pCp-Cy5 (= 2-fold excess over RNA), 1 µL RNasin (Promega), 
2 µL RNA ligase I (high concentration) (25 µL total) 
in vitro transcription 0.1 mg/mL DNA template (for plasmid DNA; PCR product optimum usually 
lower), 24 μg/mL T7 RNA polymerase (purified by K. Nagai or C. Oubridge), 
40 mM Tris-Cl pH 8.0, 15 mM MgCl2, 10 mM DTT, 2 mM spermidine and 4 mM 
of each ATP, GTP, CTP and UTP 
RNA elution buffer 300 mM sodium acetate pH 5.3, 0.1 % SDS, 1 mM ethylenediaminetetraacetic 
acid (EDTA) 
10 x TBE 108 g Tris base, 9.3 g EDTA, 55g boric acid in 1 L (LMB media kitchen) 
formamide loading dye 95 % formamide, 10 mM EDTA, pinch of bromophenol blue  
ribozyme cleavage buffer 5 mM Tris-Cl pH 7.4, 5 mM NaCl, 25 mM MgCl2 
2 x ligation mix 27 µL water, 8 µL 10 x T4 DNA ligase buffer (NEB), 1 µL RNasin (Promega) and 
4 µL T4 DNA ligase (gift from K Nagai), (40 µL total) 
 
Table 7-6: Primers used for PCR derived transcription templates and to extend RNA fragments. Primers are listed 
under the number as they appear in the method section, together with their name and sequence. DNA oligo-
nucleotides (1 – 4b) highlight the 3’SS in bold; RNA oligonucleotides (5 – 8) carried a Cy5-label on the 3’-end 
as indicated in the text, the (dG) represents a deoxynucleotide.  
# oligonucleotide  sequence 
1 XmaI – T7 promoter (forward) 5’-CGGGCGATCCCGGGTTTAATACGACTCACTATAGGCGG-3’ 
2 SacI – exon2-164 nt (reverse) 5’-ACAATCTGGAGCTCAGCTTCATCACCAACGTAGG-3’ 
3a 3’SS – WT (forward) 5’-ATGTTTAGAGGTTGCTGCTTTGGTTATTGATAA-3’ 
3b 3’SS – ACAC (forward) 5’-ATGTTTACACGTTGCTGCTTTGGTTATTGATAA-3’ 
4a 3’SS – WT (reverse) 5’-TTATCAATAACCAAAGCAGCAACCTCTAAACAT-3’ 
4b 3’SS – ACAC (reverse)  5’-TTATCAATAACCAAAGCAGCAACGTGTAAACAT-3’ 
5 UBC4_AC exon2 (-11 to 25) 5’-TATTGAACTACACATCCACCTACTTCATGTTCACGC-3’ 
6 UBC4_dG exon2 (-11 to 25) 5’-TATTGAACTA(dG)ACATCCACCTACTTCATGTTCACGC-3’ 
7 UBC4 exon2 (-11 to 25) 5’-TATTGAACTAGACATCCACCTACTTCATGTTCACGC-3’ 
8 UBC4 exon2 (26 to 61)  5’-GGTCCACTCGGCGATGATCTATATCACTGGCAAGCA-3’ 
 
 
7.2.1 In vitro RNA transcription 
Templates for in vitro transcribed RNA were either PCR product or plasmid DNA containing the 
desired sequence under the T7 promoter. Plasmid DNA was linearized by restriction digestion prior 
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to transcription. Transcription reactions were performed in volumes from 500 µL to 10 mL contain-
ing 0.1 mg/mL linearized plasmid. Optimal concentrations of PCR template input were determined 
by small scale transcription. 
To generate a PCR fragment for the ACT1 transcript, a region containing the T7 promoter, the last 
25 nt of the first exon, the intron and 25 nt of the second exon were first PCR amplified (primers 1 
and 4 a/b in Table 7-6) from a pUC-like vector (gene synthesis). Secondly, the sequence of ACT1 
starting 8 nt upstream of the 3’SS until nucleotide 164 of the second exon was amplified from ge-
nomic BCY123 DNA (primers 2 and 3a/b). Lastly, these two DNA fragments overlapping by 33 nt 
were annealed and amplified by PCR (primers 1 and 2). Mismatches in the primer sequences at the 
3’SS allowed to generate both the WT and the AC-version of the transcript (named a and b in Table 
7-6, the 3’SS sequence is highlighted in bold).  
DNA, derived from either linearized plasmid or PCR fragment, was purified by PCI (phenol:chloro-
form:isoamyl alcohol, 25:24:1, v/v) extraction and precipitated before in vitro transcription for 4 h 
at 37 °C (reaction composition in Table 7-5). Precipitated magnesium phosphate was pelleted by 
centrifugation, and the supernatant purified by PCI extraction followed precipitation with either 
ethanol or isopropanol at -20 °C. RNA containing pellets were dissolved in formamide loading dye 
and separated on 1 x TBE 7 M urea PAGE (acrylamide percentage depending on the transcript 
length). The RNA product was visualised by UV shadowing and extracted by electroelution in 1 x 
TBE or by passive elution in RNA elution buffer. The extracted RNA was either concentrated using 
Amicon Utra centrifugal filter concentrators (Millipore) or PCI extracted and precipitated until fur-
ther use. Final concentration was measured by absorption at 260 nm using a Nanodrop spectro-
photometer (Thermo Scientific).  
 
7.2.2 3’-end labelling of RNA with fluorescein 
In vitro transcribed RNA, gained from 1 mL transcription reaction, was resolved in 500 µL oxidation 
solution and incubated for 1.5 h in the dark at 23 °C. The reaction was quenched with 0.25 M KCl 
(final concentration) and kept on ice for 10 min, before removal of the precipitate by centrifugation. 
The supernatant was incubated with 550 µL fluorescein-5-thiosemicarbazide (Sigma) for 4 h in the 
dark at 23 °C. The fluorescein labelled RNA was separated from free label and transferred into H2O 
using a NAP-10 column (GE Healthcare) according to the manufacturer’s instructions.  
 
7.2.3 Enzymatic 3’-end labelling of RNA with Cy5 
1 nmol in vitro transcribed RNA was enzymatically labelled by RNA ligase I (NEB, high concentration) 
in a 25 µL Cy5-labelling reaction for 1 h at 37 °C (Table 7-5). Excess pCp-Cy5 (Jena Bioscience) was 
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removed by phenol extraction. The labelled RNA was precipitated and dissolved in a suitable 
amount of H2O. 
 
7.2.4 Ligation of in vitro transcribed RNA and oligonucleotides 
Some UBC4 transcripts were partially produced by in vitro transcription and then extended by liga-
tion to RNA oligonucleotides (Sigma or Integrated DNA Technologies, Table 7-6). First, the DNA 
sequence coding for 3xMS2 stem loops, exon 1 and parts of the intron of UBC4 ending with the 
hepatitis delta virus ribozyme was transcribed in vitro in a 1 mL reaction (compare 7.2.1, plasmid 
1). After precipitation, the RNA was dissolved in 400 µL ribozyme cleavage buffer and cleavage in-
duced by the temperature ramps given in brackets (2 cycles: 5 sec at 80 °C, 20 min temperature 
ramp to 50 °C; 10 min temperature ramp to 30 °C).  
The product was separated from the primary transcript and the ribozyme by denaturing PAGE (1 x 
TBE, 7 M urea, 5 % polyacrylamide) and visualised by UV shadowing. RNA was eluted in 5 volumes 
RNA elution buffer at 37 °C for 14 h before PCI extraction and precipitation. The 2’,3’-cyclic phos-
phate on the 3’-end was removed by 3 µL T4 PNK in 200 µL 1 x T4 PNK buffer (both NEB) at 37 °C 
for 120 min. The reaction was incubated for further 60 min after the addition of 10 µL 1 M Tris-Cl 
pH 8.0 and 1 µL AP (Roche, 20 U/µL). The final product was cleaned up by PCI extraction, precipi-
tated and dissolved in H2O. Final concentration was measured by absorption at 260 nm.  
Second, one or two RNA oligonucleotides were attached to generate UBC4 short and long tran-
scripts, respectively. 2,000 pmol RNA oligonucleotides were phosphorylated in a 100 µL reaction 
containing 1 x T4 DNA ligase buffer (NEB), 1 µL RNasin and 4 µL T4 PNK for 90 min at 37 °C. This 
RNA oligonucleotide was ordered with a Cy-5 label at the 3’-end for the short versions (25 nt exon 
2).  The product was purified by phenol extraction, precipitated and dissolved in H2O. 1,000 pmol 
each of the in vitro transcribed RNA fragment, the phosphorylated RNA oligonucleotide and a DNA 
oligonucleotide with at least 30 nt complementary sequence spanning both RNA fragments, were 
annealed in 40 µL H2O by slowly decreasing the temperature from 80 °C to 25 °C. After addition of 
40 µL 2 x ligation mix the reaction was incubated at 25 °C for 16 hours, PCI extracted and precipi-
tated. The final product was separated from non-ligated components and the DNA oligonucleotide 
by denaturing PAGE (5.5 % polyacrylamide, 7 M urea, 1 x TBE), excised and eluted in elution buffer 
at 37 °C for 16 h.  After PCI extraction and precipitation, the concentration was determined by 
absorbance at 260 nm in H2O.  
For UBC4_long, the ligation step was repeated with an additional phosphorylated RNA oligonucle-
otide containing nucleotide 26-61 of UBC4 exon 2 and a Cy-5 labelled 3’-end (primer 8, Table 7-6). 
Some of the RNA transcripts produced according to this method were produced by A. Newman. 
 
114 
7.3 Spliceosome and protein purification including biochemical 
techniques 
Table 7-7: Buffers used for expression and purification of spliceosomes and spliceosomal proteins. The name of 
the buffer is listed as it appears in the text together with the components. Buffers which were provided by the 
LMB media kitchen are marked as such. Buffers were prepared with Milli Q water (Millipore) and filtered 
through 0.22 µm. PEG: polyethylene glycol, ACN: acetonitrile, HEPES: 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid 
buffer Composition 
YEPD 11 g yeast extract, 22 g peptone, 55 mg adenine sulphate, 100 mL 20 % glu-
cose for final volume of 1 L (LMB media kitchen) 
YM4 6.9 g yeast nitrogen base, 11 g casamino acid, 55 mg adenine, 55 mg tyro-
sine for a final volume of 1 L (LMB media kitchen) 
2 x lysis buffer 2 M NaCl, 100 mM Tris-Cl pH 9.0, 2 mM imidazole, 20 mM β-mercaptoeth-
anol (β-ME), 0.2 % IGE pal CA-630, 4 mM CaCl2, 2 mM magnesium acetate, 
EDTA-free protease inhibitor cocktail (Roche) 
CAL wash buffer 500 mM NaCl, 20 mM Tris-Cl pH 8.0, 2 mM CaCl2, 1 mM magnesium ace-
tate, 1 mM imidazole, 10 mM β-ME 
CAL elution buffer 500 mM NaCl, 20 mM Tris-Cl pH 8.0, 2 mM EGTA, 1 mM magnesium ace-
tate, 1 mM imidazole, 10 mM β-ME 
Ni-NTA binding buffer 1 M NaCl, 20 mM Tris-Cl pH 8.5, 5 mM imidazole, 10 mM β-ME 
Ni-NTA wash buffer 1 M NaCl, 20 mM Tris-Cl pH 8.5, 15 mM imidazole, 10 mM β-ME 
Ni-NTA elution buffer 1 M NaCl, 20 mM Tris-Cl pH 8.5, 250 mM imidazole, 10 mM β-ME 
storage buffer Prp16 250 mM KCl, 20 mM HEPES pH 7.9, 0.2 mM EDTA, 0.5 mM DTT, 20 % glyc-
erol (similar to buffer D) 
storage buffer Prp22 300 mM KCl, 20 mM HEPES pH 7.9, 0.2 mM EDTA, 0.5 mM DTT, 20 % glyc-
erol (similar to buffer D) 
storage buffer Prp8/Snu114 500 mM NaCl, 20 mM Tris-Cl pH 8.5, 5% glycerol, 1 mM DTT 
TEV buffer 1M NaCl, 20 mM Tris-Cl pH 8.5, 5 mM imodazole, 1 mM DTT 
low salt buffer 500 mM KCl, 20 mM HEPES pH 7.8 
reverse phase buffer 100 mM potassium phosphate pH 6.5, 10 mM tetra-n-butylammonium bro-
mide, 7.5 % ACN 
AKG buffer 10 mM HEPES pH 7.9, 1.5 mM MgCl2, 200 mM KCl, 10 % glycerol, 0.5 mM 
DTT 
buffer D 20 mM HEPES pH 7.9, 0.2 mM EDTA, 50 mM KCl, 20 % glycerol, 0.5 mM 
DTT 
stop mix 1 mg/mL proteinase K, 50 mM EDTA, 1 % SDS 
splice diluent 300 mM sodium acetate pH 5.3, 1 mM EDTA, 0.1 % SDS, 1 % glycogen 
MS2-assembly buffer 3 % PEG6000, 60 mM KPO4, 40 % buffer D 
splice buffer 2 mM ATP, 2.5 mM MgCl2, 60 mM potassium phosphate pH 6.5 
G70 buffer 20 mM HEPES pH 7.9, 70 mM KCl, 0.1 % Igepal CA-630, 0.5 mM EDTA 
K75 20 mM HEPES pH 7.9, 75 mM KCl, 0.05 % Igepal CA-630, 0.25 mM EDTA, 5 
% glycerol 
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K75G10 20 mM HEPES pH 7.9, 75 mM KCl, 0.05 % Igepal CA-630, 0.25 mM EDTA, 10 
% glycerol 
maltose elution buffer 20 mM HEPES pH 7.9, 75 mM KCl, 0.05 % Igepal CA-630, 0.25 mM EDTA, 5 
% glycerol, 12 mM maltose 
 
7.3.1 Recombinant protein expression in yeast 
BCY123 cells were co-transfected with expression vectors pRS426 and pRS424. Positive trans-
formants were grown in 24 L YM4 selective media supplemented with 1 % raffinose at 30 °C. Protein 
expression was induced with 2 % galactose (final concentration) at OD600 1.0. After 12-16 hours 
further growth at 30 °C, cells were harvested, resuspended in 1 volume 2 x lysis buffer, and frozen 
in liquid nitrogen in droplet form. Cells were disrupted in a 6870 Freezer/Mill (SPEX SamplePrep) 
under the following settings: 4 cycles, 2 min precool time, 2 min run time, 1 min cool time between 
cycles and a rate of 12 cps. After thawing, the pH of the extract was raised to 8.5 by Tris base. Cell 
debris were removed by ultracentrifugation at 195,000 x g for 90 min. 
The supernatant was incubated with 2 mL Calmodulin-sepharose beads (produced by C. Oubridge) 
for 12-16 hours at 4 °C. Beads were washed with 5 x 50 mL CAL wash buffer and the proteins eluted 
in 10 x 5 mL CAL elution buffer. Protein-containing fractions were pooled and dialysed against Ni-
NTA binding buffer for 4 h at 4 °C. After 14 h binding to 4 mL Ni-NTA agarose beads (Quiagen), the 
beads were first washed with 15 mL Ni-NTA binding buffer and then with 15 mL Ni-NTA wash buffer. 
The protein was eluted in about six 4 mL fractions with Ni-NTA elution buffer.   
rPrp16-G378A, rPrp16 WT and rPrp22-K512A were dialysed against the respective helicase storage 
buffer for 4 h at 4 °C and stored at -80 °C until further use (see 7.3.10 splicing reactions). For storage 
and removal of the purification tag of Snu114:Prp8-N dimers, the sample was incubated with TEV 
protease while dialysing against storage buffer for 14 h at 4 °C before storing at -80 °C. Samples 
containing a protein with an internal TEV protease cleavage site were equally incubated with TEV 
protease but dialysed against TEV buffer. Additional incubation with 4 mL Ni-NTA agarose beads 
was used to remove the cleaved and polyhistidine-tagged fraction including TEV protease, retaining 
the purified sample in the flow-through. Snu114:Prp8-N dimers were concentrated in an Amicon 
Ultra centrifugation filter concentrator at 16 °C while increasing the salt concentration to 0.9 M KCl 
by addition of concentrated KCl or buffer exchange. Subsequent gel filtration was performed in 1 
M KCl, 20 mM Tris-Cl pH 8.5 and 1 mM DTT using a Superdex 200 10/300 gel filtration column (GE 
Healthcare). Protein-containing fractions were pooled and directly used for downstream applica-
tions.  
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7.3.2 Protein-RNA complex formation  
Snu114:Prp8-N and RNA were mixed in a 1.25:1 ratio for reconstitution. The RNA was prepared in 
a buffer without salt (20 mM Tris-Cl pH 8.5, 10 mM β-ME) and added to the protein solution con-
taining 1 M KCl to yield a final concentration of 0.2 M KCl. Fast mixing avoided exposure of the 
protein to low salt concentrations and therefore prevented aggregation. After incubation for 1 hour 
on ice, the sample was concentrated while simultaneously increasing salt to 0.3 M KCl. EMSA com-
paring free RNA and complex confirmed the efficiency of reconstitution (0.5 % agarose, 1 x TB, 40 
V, 90 min; stained after electrophoresis with ~0.5 μg/mL ethidium bromide). 
 
7.3.3 Limited proteolysis  
Limited proteolysis was performed on Snu114:Prp8-N reconstituted with U5 snRNA (A) with three 
different constructs for Prp8-N (Prp8 122-735, Prp8 1-770, Prp8 122-770) (compare 7.3.2 Protein-
RNA complex formation). In addition, Snu114:Prp8 1-770 was proteolyzed as a protein complex. 
Five different proteases were used: trypsin, chymotrypsin, subtilisin, Glu-C, and Lys-N. Proteolysis 
was performed with 5 μg protein at two different protease ratios (1:100 and 1:250 protein/protein-
RNA-complex:protease) in a 20 µL reaction volume in either protein-RNA complex buffer (0.3 M 
KCl, 20 mM Tris-Cl pH 8.5, 1 mM DTT) or protein buffer (1 M KCl, 20 mM Tris-Cl, 1 mM DTT). Reac-
tions were stopped after 30 min, 1 hour or 2 hours, respectively, by adding 7 µL of 2 x NuPAGE™ 
LDS Sample buffer (Invitrogen). Samples were heated at 90 °C for 3 min before separation on on 4-
12 % NuPAGE Bis-Tris protein gels (Invitrogen).  
 
7.3.4 Crystallography  
Crystallisation trials were set up using the sitting-drop vapour diffusion technique in a 96 well for-
mat provided by the LMB crystallisation facility (Table 7-1) at both 277 K and 293 K. The protein 
solution (approx. 4.5 mg/mL in either (a) 300 mM KCl, 20 mM K-HEPES, pH 8.5, 1 mM DTT or (b) 0.2 
M KCl, 0.15 M ammonium acetate, 20 mM Tris-Cl pH 8.5, 1 mM DTT) was mixed with an equal 
volume of reservoir solution to obtain 200 nL drops. For promising crystallisation conditions, four-
corner screens varying two of the different components were used. 
 
Table 7-8: LMB screening plates, used in this work, giving their composition of commercial screens. 
LMB screen commercial screens included in particular LMB screen 
LMB1 Crystal Screen 1 (1-48) (Hampton Research) 
Crystal Screen 2 (1-48) (Hampton Research) 
LMB2 Wizard 1 (1-48) (Emerald BioStructures) 
Wizard 2 (1-48) (Emerald BioStructures) 
LMB4 PEG6000 (1-24) (Hampton Research)  
MPD (1-24) (Hampton Research) 
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MembFac (1-48) (Hampton Research) 
LMB5 PEG-Ion screen (1-48) (Hampton Research) 
Natrix (1-48) (Hampton Research) 
LMB6 CrystalScreen Lite (1-48) (Hampton Research) 
CrystalScreen Cryo (1-48) (Hampton Research) 
LMB8 JBS1 (PEG 400-3K) (JenaBioScience) 
JBS2 (PEG 4K) (JenaBioScience) 
JBS3 (PEG 4K +) (JenaBioScience) 
JBS4 (PEG 6K-8K) (JenaBioScience 
LMB9 JBS 5 (PEG 8K-20K) (JenaBioScience) 
JBS 6 (Ammoniumsulfate) (JenaBioScience)  
JBS 7 (MPD) (JenaBioScience) 
JBS 8 (MPD/alcohols) (JenaBioScience 
LMB10 JBS9 (alcohols/salt) (JenaBioScience) 
JBS10 (salt) (JenaBioScience)  
Clear Strategy Screen 1 pH 4.5 (1-24) Molecular Dimensions Limited (see below !!) 
Clear Strategy Screen 1 pH 5.5 (1-24) Molecular Dimensions Limited 
LMB12  Clear Strategy Screen 2 pH 5.5 (1-24) Molecular Dimensions Limited 
Clear Strategy Screen 2 pH 6.5 (1-24) Molecular Dimensions Limited 
Clear Strategy Screen 2 pH 7.5 (1-24) Molecular Dimensions Limited 
Clear Strategy Screen 2 pH 8.5 (1-24) Molecular Dimensions Limited 
LMB16  JCSG+ (Qiagen / Nextal) 
LMB17 Morpheus Screen (F. Gorrec) 
 
7.3.5 Nucleotide analysis by HPLC 
Snu114:Prp8-N was prepared as described in 7.3.1 and concentrated to ~7.5 mg/mL. About 100 µL 
protein solution were dialysed against low salt buffer in a Slide-A-Lyzer MINI dialysis unit (Thermo 
Scientific, 10K MWCO) at 4 °C for 14 hours. To release the nucleotide, the protein was denatured 
at 90 °C for 5 min. 30 µL protein were diluted with 90 µL H2O to decrease the salt concentration. 
The solution was mixed by vortexing and any precipitate removed by centrifugation. HPLC was run 
on a SUPELCOSIL™ LC-18-DB HPLC column (5 μm particle size, L × I.D. 25 cm × 4.6 mm, Supelco) 
with reverse phase buffer. GTP and GDP nucleotides were diluted to 25 µM in 1/4th low salt buffer 
and analysed equally for their retention volume.  
  
7.3.6 Fluorescence polarisation 
The concentration of U15-RNA with a 6-carboxyfluorescein at the 5’-end (Integrated DNA Technol-
ogies) was held constant at 20 nM throughout the experiments. rPrp16 was mixed with the RNA 
substrate in 100 mM KCl reaction buffer in a 1.5-fold dilution series. Supplements of ATP and Mg2+ 
as well as the exact protein concentration are indicated in the respective figures (compare chapter 
5.4.2). Fluorescence polarisation (FP) and fluorescence intensity (FI) were measured in a PHERAstar 
plate reader with the modules FP 485 520/520 and FI 485 520, respectively. The obtained data 
points were inspected for constant FI, before FP was blotted against the protein concentration. FP 
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data points were fit to a binding curve in GraphPad with the parameters for ‘one-site – specific 
binding’, and Kd values determined. One site – specific binding:  Y = Bmax*X/(Kd + X); Bmax = maximum 
specific binding; X in M; Y and Bmax in relative units (RU). 
 
7.3.7 Splicing extract preparation  
Yeast cells were grown in YEPD at 30 °C. The cells were harvested by centrifugation, when reaching 
a density of 1.6 OD600. Cell pellets were washed with H2O and AKG buffer before resuspending in 
0.6 volumes AKG buffer. Frozen cell droplets were disrupted in a 6870 Freezer/Mill (SPEX SampleP-
rep) with the following settings: 2 cycles, 2 min precool time, 2 min run time, 1 min cool time bet-
ween cycles and a rate of 10 cps. Cell debris were separated by centrifugation at 37,000 x g for 30 
min. Subsequent centrifugation at 117,000 x g for 75 min separated the extract into two layers. The 
top layer was dialysed twice against buffer D for 90 min at 4 °C. The dialysis time was extended to 
2 h followed by 14 h for splicing extract for spliceosomal complex B purification. After removing 
precipitate during centrifugation at 3,000 x g for 5 min, 600 µL aliquots were frozen in liquid nitro-
gen and stored at -80 °C until further use.  
 
7.3.8 In vitro splicing reactions 
Small scale splicing reactions were performed with 2.5 nM fluorescently labelled pre-mRNA sub-
strate and 40 % splicing extract in splice buffer and incubated at 23 °C.  To obtain a time course, 10 
– 20 µL samples were removed at various time points and mixed with 5 – 20 µL stop mix. The sam-
ples were deproteinised at 37 °C for 20 min. 100 µL splice diluent was added before PCI extraction. 
The aqueous phase was ethanol precipitated at -20 °C. Pellets were taken up in 4 – 7 µL formamide 
loading dye, dissolved by vortexing and heated up for 90 sec at 90 °C before separating on a dena-
turing PAGE (1 x TBE, 7 M urea, polyacrylamide percentage depending on the RNA substrate). Flu-
orescently-labelled RNA species were visualised with an Amersham Typhoon (GE Healthcare). 
 
7.3.9 MS2-MBP assembly  
90 nM MS2-tagged pre-mRNA substrate were heated up to 90 °C for 2 min in 75 µL MS2-assembly. 
Slowly decreasing the temperature to 23 °C ensured proper folding of the MS2 stem loops. MgCl2 
was added to a final concentration of 2 mM, and the reaction was incubated with 1.25 excess of 
MS2-MBP protein for 30 min at 4 °C. Recombinant MS2-MBP fusion protein was purified from E. 
coli by C. Oubridge.   
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7.3.10 First purification steps for spliceosomal complex C 
Splicing of the MS2-MBP assembled pre-mRNA substrate was performed in a 1.5 mL reaction with 
40 % splicing extract in splice buffer at 23 °C for 30 min. Splicing extract derived from the following 
yeast strains as described in the respective chapter: BCY123 (untagged), SmB-3xFLAG, Prp16-
3xFLAG-His8-tag, BCY123 supplemented with rPrp16-G378A. Recombinant rPrp16-G378A was pre-
incubated at 4 °C in splicing extract at a concentration to yield 15 ng/mL in the splicing reaction. 
Pre-mRNA substrates are indicated likewise in the respective chapter.  
After splicing, the reaction was adjusted to 2 mM glucose and the incubation prolonged for 5 min 
to deplete ATP. After dilution with 1.5 mL G70 buffer, precipitate was removed by centrifugation at 
3,000 x g. The solution was layered onto 800 µL buffer G75 containing 40 % glycerol for ultra-cen-
trifugation at 237,000 x g for 3 hours in a swing-out rotor. The high glycerol containing cushion was 
collected and adjusted to a final concentration of 0.025 % Igepal CA-630 before applying to 100 µL 
amylose resin (NEB). After nutation for 14 hours at 4 °C, the beads were washed thrice with K75 
buffer. Spliceosomes were eluted with 200 µL maltose elution buffer. The elution efficiency was 
monitored in a PHERAstar plate reader with the modules FI 640 680 or FI 485 520 measuring the 
fluorescence intensity of the Cy5- or fluorescein-labelled RNA, respectively. Compare (Galej et al. 
2016) for a similar purification strategy.  
 
7.3.11 First purification steps for spliceosomal complex C* 
Splicing was performed with the pre-mRNA substrate 3xMS2_UBC4_dG_short essentially as de-
scribed for spliceosomal complex C. rPrp-K512A was used at a final concentration of 15 ng/mL. After 
binding on amylose, an additional step was inserted. The beads were washed with K75G10 and 
incubated with 2 mM ATP/2mM MgCl2 in 1 mL K75G10 for 30 min nutating at 23 °C. Subsequent 
washes and the elution were performed according to the complex C procedure. This purification 
strategy was adapted from (Fica et al. 2017). 
 
7.3.12 First purification steps for spliceosomal complex P 
Splicing was performed as describes for complex C with UBC4_WT_3xMS2 pre-mRNA substrate and 
15 ng/mL final concentration of rPrp-K512A. After splicing, the reaction was incubated with 5 µM 
of DNA oligonucleotide complementary to the 3'-exon (sequence: ATGAAGTAGGTGGAT) for an-
other 20 min to induce cleavage of the 3'-MS2 tag by the RNase H activity present in the splicing 
extract. Spliceosomes without a docked 3'-exon were removed while complex P with a docked 3'-
exon was protected from RNase H cleavage and could be subsequently purified via amylose capture 
as described for complex C. This purification strategy was adapted from (Wilkinson et al. 2017). 
 
120 
7.3.13 First purification steps spliceosomal complex B 
Splicing extract was pre-treated with 2 mM glucose and incubated for 10 min at 23 °C. Spliceosomes 
were assembled onto 3xMS2_UBC4_WT as described for complex C, reducing ATP to 50 µM and 
extending the incubation time to 45 min.  
In contrast to all other in vitro spliceosome iCLIP experiments described in this thesis, crosslinking 
for complex B was performed in a 6-well plate on the 1.5 mL splicing reaction with 312 µJ/cm2 
254 nm UV light (Stratalinker 2400). Purification of the complex via MS2-MBP fusion protein was 
done as for complex C. The purification strategy for complex B was inspired by (Plaschka, Lin, and 
Nagai 2017). The in vitro spliceosome iCLIP procedure continued with urea denaturation of the am-
ylose elution (see 7.4.2).  
 
For chasing experiments (compare results subchapter 5.3.3), a 1.5 mL splicing reaction was set up 
with 40 % micrococcal nuclease treated extract, 2 mM ATP containing splice buffer, while the RNA 
proportion was replaced by purified complex B. 20 µL samples were taken at the indicated time 
points during incubation at 23 °C. A control was prepared in the same way with 50 µM ATP in the 
splice buffer. Glycerol cushion centrifugation was performed as described before.  
 
7.3.14 Protein depletion from splicing extract via epitope tag 
Prp16-3xFLAG depletion was done via its epitope tag using anti-FLAG M2 magnetic beads (Sigma). 
100 µL splicing extract was incubated with 25 µL anti-FLAG beads equilibrated in TBS (50 mM Tris-Cl, 
150 mM NaCl, pH 7.4), and nutated at 4 °C. After 1 hour, the extract was separated from the beads, 
and the whole procedure was repeated twice with 25 µL beads each time. After every step, 3 µL 
extract were probed for remaining Prp16-3xFLAG with anti-FLAG AB by western blot.  
The depleted extract was tested for second step splicing defects in 20 µL splicing reactions. To res-
cue the phenotype, 2 µL of the splicing reaction were replaced by rPrp16-WT in buffer D ranging 
from 1.6 to 3.2 µg/mL final concentration in the reaction. In addition, controls supplemented with 
similar amounts of rPrp16-G378A or buffer D were tested for splicing.   
 
7.3.15 Micrococcal nuclease treatment 
100 µL splicing extract were incubated with 2 mM CaCl2 and 2.5 µL micrococcal nuclease (NEB) for 
30 min at 30 °C to remove endogenous RNA. The reaction was terminated by 8 mM EGTA and incu-
bation for 1 min at 30 °C followed by 10 min at 4 °C. Treated extracts were directly used in splicing 
reactions. 
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For optimisations as shown in subchapter 5.3.3, 20 µL splicing extract were supplemented with 
2 mM CaCl2. To monitor nuclease efficiency, Cy5-lablled RNA was added to a 2.5 nM final concen-
tration. To monitor the later inactivation, no RNA was added. The samples were incubated with 5, 
10 or 20 units micrococcal nuclease per µL splicing extract and incubated at 30 °C for 30 min. The 
reaction was adjusted to final concentration of 8 mM EGTA and incubated for 1 min at 30 °C, fol-
lowed by 10 min at 4 °C. Samples for ‘inactivation monitoring’ were supplemented with 2.5 nM Cy5-
labelled RNA at this point. All samples were incubated for a further 30 min at 30 °C. In addition, a 
control sample without nuclease was prepared.  
Samples were deproteinised with stop mix (Table 7-7) and the RNA was extracted by PCI before 
separation on a 10 % denaturing PAGE (1 x TBE, 7 M urea).  
 
7.4 iCLIP Methods 
Buffers and sequences for oligonucleotide used in in vitro spliceosomal iCLIP are listed in Table 7-9 
and Table 7-10, respectively.  
Table 7-9: Buffers and reagents for iCLIP experiments. Wash buffers were prepared with Milli Q water (Millipore) 
and filtered through 0.22 µm. Reaction buffers for enzymes were prepared with RNase free water (Ambion). 
Reaction mixes based on volumes give the final volume in brackets. *IR-L3 adapter was generated by Martina 
Hallegger.  
buffer composition 
K75 20 mM HEPES pH 7.9, 75 mM KCl, 0.05 % Igepal CA-630, 0.25 mM EDTA, 5 % 
glycerol 
debranching buffer 125 mM KCl, 10 % glycerol, 1 mM DTT, 20 mM HEPES pH 7.5 
RNase buffer 50 mM Tris-Cl pH 7.4, 150 mM NaCl, 2 mM EDTA 
RNase dilution buffer 10 mM Tris-Cl pH 8.0, 100 mM NaCl, 10 % glycerol 
high salt buffer 50 mM Tris-Cl pH 7.4, 1 M NaCl, 1 mM EDTA, 1 % Igepal CA-630, 0.1% SDS, 
0.5% sodium deoxycholate 
PNK wash buffer 20 mM Tris-Cl pH 7.4, 10 mM MgCl2, 0.2 % Tween-20 
PNK irCLIP mix 6 µL 5 x iCLIP PNK buffer, 6 µL PEG400 (Sigma), 1.2 µL T4 PNK, 1.2 µL fastAP, 
0.5 µL RNasin (Promega), 15.1 µL H20 (for 30 µL total) 
5 x iCLIP PNK buffer 350 mM Tris-Cl pH 6.5, 50 mM MgCl2, 5 mM DTT 
radiolabelling mix 0.6 µL T4 PNK, 1.5 µL γ-33P-ATP, 1.2 µL 10 x reaction buffer (NEB), 8.7 µL H20 
(for 12 µL total) 
ligation mix 3 µL 10 x ligation buffer, 0.8 µL DMSO, 2.5 µL T4 RNA ligase 1 (high concen-
tration, NEB), 0.4 µL RNasin, 0.5 µL T4 PNK, 2.5 µL 1 µM pre-adenylated 
IR-L3 adapter*, 9 µL PEG8,000, 6.3 µL H20 (for 25 µL total) 
10 x ligation buffer 500 mM Tris-Cl pH 7.5, 100 mM MgCl2 
adapter removal mix 2 µL buffer 2 (NEB), 0.5 5’deadenylase, 0.5 µL RecJf endonuclease, 0.5 µL 
RNasin, 4 µL PEG400, 12.5 µL H20 (for 20 µL total) 
20 x MOPS buffer 104.6 g MOPS, 60.6 g Tris base, 10.0 g SDS, 3.0 g EDTA in 500 mL total volume 
(LMB media kitchen) 
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WB transfer buffer 14.4 g glycine, 3.0 g Tris base, 100 mL methanol for 1 L total volume 
PK/SDS buffer 10 mM Tris-Cl pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.2 % SDS 
high stringency buffer 15 mM Tris-Cl pH 7.4, 120 mM NaCl, 25 mM KCl, 5 mM EDTA, 1 % Triton X-
100 (Sigma), 0.001% SDS, 1 % sodium deoxycholate 
1.25 x urea cracking buffer 66.6 mM Tris-Cl, pH 7.4, 8 M urea, 1.33 % SDS 
T20IP buffer 50 mM Tris-Cl pH7.4, 150 mM NaCl, 0.5% Tween 20, 0.1 mM EDTA, 1 µL 
RNasin per 920 µL 
crush-soak gel buffer 500mM NaCl, 1mM EDTA, 0.05% SDS 
 
Table 7-10: Oligonucleotides used for sequencing library preparation. The 39 available irCLIP_ddRT primers (## 
12-50) vary by the XXXXX unique barcode sequence. WWW is a random mix of A and T, N any nucleotide and 
iSP18 is an 18-atom hexa-ethylene glycol spacer. The IR-L3 adapter was pre-adenylated and conjugated to IR 
dye 800 via the internal azide modification by Martina Hallegger.  
oligonucleotide sequence 






P3 tall 5’-GCATTCCTGCTGAACCGCTCTTCCGATCT-3’ 
P3 Solexa 5’-CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGAT 
CT-3’ 
P5 Solexa 5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGAT   
CT-3’ 
 
7.4.1 Enzymatic tests for individual iCLIP steps  
To test digestion by RNase I, 1.7 pmol Cy5-labelled 3xMS2_UBC4_AC_short were incubated in 
200 µL RNase buffer with different amounts of RNase I for 3 min at 37 °C. The RNase was diluted 
previously in RNase dilution buffer, adding 2 µL volume per reaction. 50 µL stop mix and deprotein-
ization at 37 °C for 20 min terminated the reaction. 100 µL splice diluent were added before phenol 
extraction. The RNA was precipitated, dissolved in formamide loading dye and separated on an 8 % 
denaturing PAGE (1 x TBE, 7 M urea).  
 
To test ligation conditions of the pre-adenylated IR-L3 adapter, 6.75 pmol U5 snRNA A were incu-
bated with 0.5 pmol IR-L3 adapter in 1 x RNA ligase ligation buffer (NEB) with changing amounts of 
RNA ligase I for 14 hours at different temperatures. The 15 µL reaction was quenched by addition 
of 10 µL stop mix and incubated for 20 min at 37 °C. The reaction volume was increased by 100 µL 
splice sample diluent and the nucleic acids purified by phenol extraction. After precipitation, the 
pellet was dissolved in 10 µL formamide dye, and the nucleic acids separated on an 8 % denaturing 
PAGE (1 x TBE, 7 M urea). The IRDye 800-labelled species were visualised on an Odyssey CLx (Licor).  
 
Materials and methods 123 
To test RNase digestion, dephosphorylation and IR-L3 adapter ligation on the same RNA material, 
7.5 pmol Cy5-labelled 3xMS2_UBC4_short were either incubated with 0.0375 units RNase I (Am-
bion) in 50 µL RNase buffer for 3 min at 37 °C or with the same number of units S1 Nuclease (Thermo 
Scientific) in 50 µL S1 reaction buffer for 15 min at 30 °C. 25 µL stop mix were added to quench the 
reactions deproteinising the reaction for 20 min at 37 °C. 100 µL splice diluent were added before 
phenol extraction and precipitation. The pellet was dissolved in 7.5 µL PNK irCLIP mix for 30 min at 
37 °C (indicated samples only). After addition of 5 µL stop mix, the RNA was purified again as de-
scribed above. Pellets were dissolved in 5 µL ligation mix containing the IR-L3 adapter and ligation 
was performed at 23 °C for 14 h. Samples were purified again and separated on an 8 % denaturing 
PAGE (1x TBE, 7 M urea).  
 
Debranching was tested under two conditions (a and b). Splicing was performed in 20 µL reactions 
with 3xMS2_UBC4_AC_short pre-mRNA substrate for 30 min at 23 °C. (a) 0.8 µg Dbr1 (Abnova) 
were added to the reaction and incubated at 30 °C for 20 min. (b) The reaction was deproteinised 
by incubation with stop mix, followed by PCI extraction and precipitation. The RNA pellet was taken 
up in K75 buffer supplemented with 2.5 mM MgCl2 and incubated with Dbr1 amounts ranging from 
0.04 to 0.8 µg for 20 min at 30 °C. In further tests, K75 buffer was additionally supplemented with 
different amounts of urea. (a and b) Reactions were added to stop mix, PCI extracted, precipitated 
and analysed on 10 % denaturing PAGE (1 x TBE, 7 M urea).  
 
7.4.2 In vitro spliceosome iCLIP 
200 µL spliceosome eluate (compare 7.3.10, 7.3.11 and 7.3.12 for complex C, C* and P, respectively) 
were distributed into 40 µL per well of a 96-well plate, placed on an ice-cooled metal block and 
irradiated with 254 nm light (Stratalinker 2400). UV doses are indicated in the respective chapter. 
Control samples were kept on ice without irradiation. All subsequent steps were done at 4 °C with 
cooled buffers. Magnetic beads were shaken during all enzymatic steps.  
72 mg urea were added and dissolved for 30 min while shaking. The solution was diluted to 0.8 M 
urea with K75 buffer, before incubation with anti-FLAG M2 magnetic beads (pre-equilibrated in TPS, 
10 µL bead volume for Prp16 and Prp22, 20 µL for SmB and Brr2) for 3 hours. Samples which were 
subjected to debranching were washed thrice with debranching buffer, before incubation with 3 µL 
Dbr1 in 50 µL debranching buffer supplemented with 2.5 mM MgCl2 and 3 µL Dbr1 for 20 min at 
30 °C.  
Beads were washed thrice with RNase buffer. RNase I was diluted in RNase dilution buffer to the 
optimal concentration (given in the respective chapter), and the digestion was performed in 200 µL 
RNase buffer for 3 min at 37 °C. Samples were kept at 4 °C for 3 min before washing once with high 
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salt buffer, and thrice with PNK wash buffer. Beads were transferred to DNA LoBind tubes (Eppen-
dorf) and resuspended in PNK irCLIP mix for dephosphorylation at 37 °C for 40 min. Beads were 
washed twice with PNK wash buffer. For RNA radiolabelling beads were incubated in 12 µL radio-
labelling mix with γ-33P-ATP (Hartmann Analytics or PerkinElmer) for 5 min at 37 °C. Beads were 
washed once with high salt buffer and thrice with PNK wash buffer. Beads were resuspended in 
25 µL ligation mix containing the IR-L3 adapter and ligation was performed for 75 min at 23 °C. After 
washing once with high salt buffer and twice with PNK buffer, beads were incubated in 20 µL 
adapter removal reaction mix for 1 hour at 30 °C and 30 min at 37 °C. Early experiments lacked this 
adapter removal step. After washing twice with PNK buffer, 15 µL 2xNuPAGE™ LDS Sample buffer 
(Invitrogen) were added to the beads and bound proteins eluted by incubation for <5 min at 70 °C.  
Samples were loaded on 4-12 % NuPAGE Bis-Tris protein gels (Invitrogen) and run at 180 V with 
MOPS buffer. Transfer onto nitrocellulose (GE Healthcare Amersham) was performed at 30 V for 90 
min with WB transfer buffer. To visualise the radio-signal, the membrane was placed against a phos-
phor imaging plate for approximately 48 hours, which was then scanned with an Amersham Ty-
phoon (GE Healthcare). The membrane was additionally scanned on an Odyssey CLx (Licor) for de-
tection of the IR-L3 adapter emission signal.   
Regions of the target RNA-protein complex were excised from the membrane according to the pre-
viously generated images. The same region was extracted for control samples. Nitrocellulose pieces 
were incubated with 190 µL PK/SDS buffer and 10 µL proteinase K (Roche) for 60 min at 50 °C while 
shaking. The soluble part was mixed with 200 µL PCI (25:24:1, saturated with 10 mM Tris, pH 8.0, 
1mM EDTA, Sigma Aldrich) and the phases were separated by centrifugation in a phase lock gel 
heavy tube (Eppendorf). The soluble phase was mixed with 800 µL chloroform in the same tube 
before re-separation by centrifugation. In early experiments, samples were taken before and after 
PCI extraction, mixed with Ultima Gold liquid scintillation cocktail (PerkinElmer) and measured in a 
Tri-Carb 2910 liquid scintillation counter (PerkinElmer). Finally, the RNA was precipitated by addi-
tion of 0.75 µL GlycoBlue (Ambion), 20 µL 5 M NaCl and 500 µL absolute ethanol at -20 °C for at 
least 12 hours.  
 
In vitro spliceosome iCLIP experiments for UV and RNase titration were performed similarly. Mini-
mally 40 µL spliceosome eluate were irradiated with different amounts of UV, captured with the 
relative amount of beads and split afterwards to test different amounts of RNase I. Radiolabelling 
was performed after RNase digestion, followed by separation on 4-12 % NuPAGE Bis-Tris protein 
gels. RNase I units were back calculated to represent the equivalent from 200 µL starting volume. 
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To monitor protein amounts, the nitrocellulose membrane was blocked with milk powder, deco-
rated with anti-FLAG M2-Peroxidase antibody (Sigma Aldrich). Western blots were developed with 
ECL western blotting detection reagents (GE Healthcare) on film. 
 
7.4.3 Short-iCLIP 
Preparation for short-iCLIP samples were performed in the same way up to the IR-L3 adapter liga-
tion step. When this version of the protocol was used, the adapter removal step was not introduced 
yet. For elution, 80 µL 1.25 x urea cracking buffer was added to the beads and incubated for 3 min 
at 65 °C while shaking. The supernatant was collected and added to 920 µL T20IP buffer. 50 µL 
Dynabeads™ Protein G (Invitrogen) were used to preclean the eluate while nutating for 20 min. The 
supernatant was added to 10 µL anti-FLAG M2 magnetic beads for another 2 hours of capture. 
Beads were washed once with high salt buffer, and twice with PNK wash buffer. The protein-RNA 
complexes were directly eluted from the beads by incubation with 190 µL PK/SDS buffer and 10 µL 
proteinase K for 1 hour at 50 °C. In a second version of the short-iCLIP procedure, precleaning with 
protein G and the second capture with FLAG beads was omitted. The elution was monitored by 
scintillation counting of radiolabelled RNA.   
 
7.4.4 Gel-free iCLIP  
Preparation for gel-free iCLIP samples followed the same steps as the long protocol until elution 
from anti-FLAG magnetic beads. To compare on-bead ligation and in-solution ligation, only half of 
each sample was subjected to the adapter ligation step. Protein-RNA complexes were eluted from 
anti-FLAG beads by addition of 250 µL RTL buffer (RNEasy Plus Micro Kit supplemented to 40 mM 
DTT, Qiagen). After removal of the supernatant, the beads were incubated with further 250 µL 
RTL/DTT buffer and incubated at 37 °C for 2 min while shaking. The combined supernatant was 
supplemented with 500 µL 70 % EtOH. The RNEasy Plus Micro Kit instructions were followed from 
step 4 onwards.  
For gel-free iCLIP, samples were eluted by adding 20 µL EB (Qiagen) to the RNEasy column, incu-
bated for 2 min at 65 °C while shaking, and released by centrifugation. Samples were kept at -20 °C 
until transfer to the Francis Crick Institute for further processing. The protein fraction was bound 
to 2.5 µL SP3 beads (1:1 mix of hydrophilic and hydrophobic beads, GE Healthcare). 200 µL ACN 
(acetonitrile) were added and the supernatant removed. The beads were washed with another 
200 µL ACN. 190 µL PK/SDS buffer and 10 µL proteinase K were added to the beads to digest the 
protein and release crosslinked RNA during 60 min at 50 °C. The supernatant was cleaned up by PCI 
extraction, and the RNA was precipitated (as in 7.4.1). For the second half of the samples, which 
lacked the IR-L3 adapter, the pellet was resolved in ligation mix and incubated for 75 min at 23 °C. 
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Agencourt AMPure XP beads (Beckman Coulter) were used for buffer exchange as described in the 
manufacturer’s instructions before the adapter removal reaction. After a second buffer exchange 
by AMPure XP beads, RNA was eluted in 11 µL H2O. Reverse transcription reactions for in-solution 
ligated samples were set up in double volumes later (22 µL compare with 7.4.5). 
 
7.4.5 Sequencing library preparation 
Table 7-11: PCR conditions for cDNA library preparation. RCR conditions are listed with the amounts and com-
position of the reaction and the run PCR program.   
PCR composition program 
RT 5.5 µL  
1 µL          
0.5 µL     
 





primer irCLIP_ddRT_##  (1 pmol/µL) 
dNTP mix (10 mM) 
 
5 x SSIV buffer (Invitrogen)* 
0.1 M DTT* 
RNasin* 
SuperScript IV (Invitrogen)* 
65 °C     5 min 
25 °C     hold until components 
marked with * are added 
 
25 °C   5 min 
50 °C   5 min 
55 °C   5 min 






1 µM P3 tall 
50 mM MnCl2 
H2O 
95 °C     3 min 
95 C -> 60 C       
temperature ramp @ -0.1 C/sec 









primer mix P5 / P3 Solexa, 10 µM each 
Phusion High-Fidelity PCR Master Mix 
(Thermo Scientific) 
H2O 
98 C     40 sec 
 
15 – 30 cycles: 
98 °C    20 sec 
65 °C    30 sec 
72 °C    45 sec 
 
72 °C    3 min  
25 °C    hold 






primer mix P5 Solexa / P3 Solexa,  
10 µM each 
Phusion High-Fidelity PCR Master Mix 
H2O 
98 °C     40 sec 
 
Optimised number of cycles -2:  
98 °C    20 sec 
65 °C    30 sec 
72 °C    45 sec 
 
72 °C    3 min 
25 °C    hold 
 
All sequencing libraries were prepared in the Francis Crick Institute. Used primers and PCR condi-
tions are listed in Table 7-10 and Table 7-11, respectively. The precipitated RNA from in vitro 
spliceosome iCLIP was resolved in H2O and transcribed into cDNA using distinct irCLIP-RT primers 
and the SuperScript IV polymerase mix (Invitrogen). The RNA template was digested by addition of 
1 µL 1:1 mix of RNase H (NEB) and RNase A (Ambion) for 15 min 37 °C. Up to 3 samples from differ-
ent experiments were multiplexed at this point. The cDNA was purified by binding to 7.5 µL MyOne 
C1 SA-dynabeads for 30 min, washed twice with high stringency buffer and thrice with PBS (phos-
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phate-buffered saline; Invitrogen). Elution of the cDNA was performed by annealing of the oligonu-
cleotide ‘P3 tall’ during a temperature ramp from 95 °C to 60 °C, following circularisation by CircLig-
ase II (Epicentre) in CircLigase buffer II for 2 hours at 60 °C.  
After further incubation for 3 min at 95 °C, the circularised cDNA product was collected from the 
beads and precipitated with 0.75 µL GlucoBlue, 0.1 x volume of 3 M sodium acetate and 1.5 x vol-
umes of absolute ethanol at -20 °C. The cDNA pellet was resolved in 10 µL H2O. Test amplifications 
(Table 7-11) were run on 1 µL of the cDNA and analysed on a 6 % Novex TBE gels (Invitrogen) stained 
with SYBR green I (Thermo Fisher). This step was repeated with varying cycle numbers until samples 
were seen at sufficient intensity without over-amplification.  
A larger, preparative scale PCR was set up and amplified with the previously determined optimal 
cycle number minus two, and checked for quality on a 6 % Novex TBE gel. In most cases, the second 
half of cDNA template was amplified with the same number of PCR cycles. At this point, PCR prod-
ucts of different samples were multiplexed and purified with Agencourt AMPure XP beads, followed 
by gel extraction from 6 % Novex TBE gel. The amplified DNA was excised from the 145 – 400 nt 
region. The excised gel piece was crushed and incubated in 500 µL crush-soak gel buffer per gel lane 
for 2 hours at 65 °C. The liquid portion was cleaned up by centrifugation through two glass pre-
filters in a Costar SpinX column, followed by precipitation with 1 µL GlycoBlue, 50 µL 3 M sodium 
acetate pH 5.5 and 1.5 mL absolute ethanol at -20 °C. 
 
7.4.6 Quality control and next-generation sequencing 
cDNA pellets were resuspended in 10 – 20 µL H2O. The concentration was determined with the 
DeNovix dsDNA High Sensitivity kit according to the manufacturer’s instruction. For quality control, 
the sample was also analysed on the Agilent 2200 TapeStation system using the High Sensitivity 
D1000 ScreenTape (Agilent). 
Libraries were multiplexed with libraries generated from other scientists and analysed by qPCR 
prior to sequencing at the Illumina HiSeq 2500 platform. qPCR was performed by the scientist re-
sponsible for the respective sequencer. Libraries were sequenced with cycle lengths between 100 
and 250 nt in single-read mode at the Francis Crick Institute (London), the Gurdon Institute (Cam-
bridge) or the MRC Laboratory of Molecular Biology.  
 
7.4.7 Data Analysis 
Data processing was done by Charlotte Capitanchik. A novel Snakemake pipeline (Köster and 
Rahmann 2012) was written to process all the data in a reproducible manner, with accessory scripts 
written in R (R Core Team 2017) (the code is attached through a link in the Appendix). The first 9 nt 
of the sequenced read correspond to the barcode, which contains the experimental identifier and 
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the unique molecular identifier (UMI). Reads were demultiplexed and the 5’- and 3’-adaptor 
trimmed using iCount demultiplex, which moves the UMI to the fastq header. Reads were then 
trimmed using Trim Galore! (version 0.4.5, Babraham Bioinformatics) to remove bases from the 3’-
end of reads with a quality score of less than phred 20. Reads shorter than 11 nt were removed 
after the trimming step. To map in vitro spliceosome iCLIP data onto the substrate-ome, a novel 
reference-genome was created for the spliceosomal snRNAs and each transcript used for spliceo-
some assembly (compare Table 7-4). A custom annotation was generated to allow mapping of 
spliced reads to the canonical junction of each substrate.  
 
The processed reads were then mapped to the substrate-ome using STAR aligner (Dobin et al. 2013), 
with the following parameters. A maximum of 2 mismatches was allowed and multimappers were 
removed. The setting --seedSearchStartLmax 16 was used, meaning that the read is split 
into more seeds during alignment, resulting in a potentially more sensitive search, which is more 
suitable for shorter reads. --alignSJoverhangMin 1000 was used to prevent the generation 
of spurious splice junctions. Finally, --alignEndsType EndToEnd was used to prevent clip-
ping of bases from the 5’-end which could create false crosslink sites. Following mapping to the 
substrate-ome, reads which remained unmapped or mapped in the reverse orientation were 
aligned to the S. cerevisiae (SacCer3) genome using STAR, allowing for novel splice products, under 
the assumption that the S. cerevisiae annotations may be incomplete.  
 
The UMI was used to quantify numbers of uniquely mapped cDNAs by collapsing cDNAs with the 
same UMI and which mapped to the same starting position on the substrate-ome or the genome. 
The -1 position of the read was interpreted as the crosslinked position. Bedgraph-files, coding for 
the gene-location and number of crosslink-events, were visualised in Integrative Genomics Viewer 
(IGV) (Robinson et al. 2011), traces exported and figures prepared in Illustrator (Adobe).  
 
To determine the mutation rate introduced at the 5’SS and the brA during RT, the bam-files of ex-
periments conducted with 3xMS2_UBC4_(AC/WT)_long were loaded into IGV. The control experi-
ment (no_FLAGged_protein) was excluded. At the 5’SS the position x|GU (wherein | indicates the 
splice site) was analysed, and at the brA the read accuracy for the branch point adenosine. The base 
identity (in percent) was extracted from IGV directly. Determination of mean and median were de-
termined in Origin 8.0 (OriginLab, Northampton, MA) and illustrated in a box plot.  
 
To assess if the amount of truncation events between the downstream of the brA is pronounced in 
UV-irradiated samples, the sum of truncation events of position 234 to 279 nt was divided by the 
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number of truncation events at position 162 corresponding to the 5’SS. The respective numbers 
were extracted from the bedgraph-files using Python (Python Software Foundation) and plotted 
with Origin 8.0.  
 
Read coverage was calculated from bam-files using the depth command of SAMtools (version 
0.1.19) (Li et al. 2009). Coverage ratios were subsequently determined by dividing the coverage of 
the regions downstream of brA (nucleotide 232 in 3xMS2_UBC4_short) by the coverage of the re-
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The NGS data which is discussed in this thesis can be found under the link listed below. Bed-
graph-files (all discussed experiments) and bam-files (session_12 and 13) visualise the crosslink 
sites and the sequencing coverage, respectively, when opened in the IGV viewer. Therefore, the 
respective substrate-ome or the yeast genome (sacCer3) has to be loaded. Files named ‘IGV_ses-
sion_xxx’ in the respective folder list the respective genome; substrate-omes are kept in the 
‘substrate-omes’-folder. The pipeline written in Snakemake, which contains the processing code 
can equally be found in the linked folder.  
 
 Linked folder: https://cloud.mrc-lmb.cam.ac.uk/index.php/s/4xNtylyhtjeuJAE 
 Password: isCL2018 
 
 
The appendix contains additional statistical data on in vitro spliceosome iCLIP data, such as the 
mapping distribution between unmapped reads, genome and substrate-ome mapped reads 
(Figure 8-1 and Figure 8-2)  and the length distribution of cDNA reads (Figure 8-3). Additionally, 
the appendix contains two tables, which lists constructs for the protein expression described  in 




Figure 8-1: Read distribution for control experiments, Prp22 and SmB in vitro spliceosome iCLIP data. The 
proportion and number of reads, which remained unmapped (green), or map to the genome (blue) and 
substrate-ome (navy) are compared before PCR duplicates were removed. Grey bars show the proportion 
of PCR duplicates calculated based on reads which map the substrate-ome. Data indicated with a * derived 
from short-iCLIP experiments. The data was analysed and illustrated by Charlotte Capitanchik.  
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Figure 8-2: Read distribution for Prp16 in vitro spliceosome iCLIP data. The proportion and number of reads, 
which remained unmapped (green), or map to the genome (blue) and substrate-ome (navy) are compared 
before PCR duplicates were removed. Grey bars show the proportion of PCR duplicates calculated based 
on reads which map the substrate-ome. The data was analysed and illustrated by Charlotte Capitanchik. 
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Figure 8-3: cDNA length distribution of in vitro spliceosome iCLIP data. The read distribution of all reads (red) 
was determined by the length of all reads before mapping but removing PCR duplicates. For the distribution 
of reads mapping to the yeast genome (green) and substrate-ome (blue), read length were taken from the 
mapped bed-files and PCR duplicates removed. Reads spanning splice sites were excluded for genome-
mappers. Charlotte Capitanchik wrote an R script to produce the resented box plot. The median is indicated 





Table 8-1:  Overview of expression tests for Prp8-N. Constructs were either expressed in bacteria or yeast 
(column 1). The variation in tag/protease site and the amino acid fragment of the construct are given in 
column 2 and 3, respectively.  The last column indicates under which conditions the expression was suc-
cessful. Constructs indicated with a * are shown in purification in Figure 2-2.  
expression system 
(vector) 
tag / protease 
site 
amino acid fragment 
(add. TEV cleavage site) 
success 
Bacterial (pGEX-6P-I) N-GST-Pre-TEV 22-411, 69-411, 22-543, 
69-543, 412-770, 540-
770, 22-770, 69-770 
Expression low 
Bacterial (pET28a) N-His6-TEV 22-411, 69-411, 22-543, 
69-543, 412-770, 540-
770, 22-770, 69-770 
Expression low 
Bacterial (pETM-11) N-His6-TEV 22-411, 69-411, 22-543, 
69-543, 412-770, 540-




22-411, 69-411, 22-543, 
69-543, 412-770, 540-
770, 22-770, 69-770 
Expression low 
Bacterial (pETM-40) N-MBP-TEV 22-411, 69-411, 22-543, 
69-543, 412-770, 540-






1-770 Low protein yield 
Bacterial codon- 
optimised (pETM-40) 
N-MBP-His6  1-770 Low protein yield 
Yeast (pRS426) N-CBP-His8-TEV 1-770 Good co-expression with 
Snu114* 
Yeast (pRS426) N-CBP-His8 1-411 TEV(122) No expression 
Yeast (pRS426) N-CBP-His8 1-543 TEV(122) No expression 
Yeast (pRS426) N-CBP-His8 1-735 TEV(122) Bad expression 
Yeast (pRS426) N-CBP-His8 1-770 TEV(122) Good co-expression with Snu114, 
TEV accessible 
Yeast (pRS426) N-CBP-His8-TEV 1-770 TEV(328) Good co-expression with Snu114, 
TEV site inaccessible 
Yeast (pRS426) N-CBP-His8 1-770 TEV(328) Good co-expression with Snu114, 
TEV site inaccessible  
Yeast (pRS426) N-CBP-His8-TEV 1-770 TEV(380) Good co-expression with Snu114, 
TEV site inaccessible 
Yeast (pRS426) N-CBP-His8-TEV 1-770 TEV(318) Good co-expression with Snu114, 
cleaved fragment not released 
Yeast (pRS426) N-CBP-His8-TEV 1-770 spacer_TEV(328) Good co-expression with Snu114, 
cleaved fragment not released 
Yeast (pRS426) N-CBP-His8-TEV 1-770 spacer_TEV(380) Good co-expression with Snu114, 





Table 8-2: Overview of expression tests for Snu114. Constructs were either expressed in bacteria or yeast 
(column 1). The variation in tag/protease site and the amino acid fragment of the construct are given in 
column 2 and 3, respectively.  The last column indicates under which conditions the expression was suc-
cessful. Constructs indicated with a * are shown in purification in Figure 2-2. 
expression system 
(vector) 
tag / protease site amino acid fragment (add. 
TEV site) 
success 
Yeast (pRS424) TEV-His8-C Snu114 (full length) Incomplete cleavage 
Yeast (pRS424) - Snu114 (full length) Good expression* 
Yeast (pRS424) - Snu114 (full length) TEV(70) Good expression 
 
 
 
